{"PMC7343648": [["The Brighton Collaboration formed the Viral Vector Vaccines Safety Working Group (V3SWG) in October 2008 to improve the ability of key stakeholders to anticipate potential safety issues and meaningfully assess or interpret safety data, thereby facilitating greater public acceptance when viral vector vaccines are licensed [2].", [["the Viral Vector Vaccines", "TREATMENT", 34, 59], ["potential safety issues", "PROBLEM", 162, 185], ["viral vector vaccines", "TREATMENT", 288, 309]]], ["One of the tools developed by the V3SWG is a standardized template describing the key considerations for benefit-risk assessment of viral vector vaccines.", [["V3SWG", "DNA", 34, 39], ["a standardized template", "TREATMENT", 43, 66], ["risk assessment", "TEST", 113, 128], ["viral vector vaccines", "TREATMENT", 132, 153]]], ["The template has been used for the standardized risk-assessment of several new viral vector vaccines [3], [4], [5], including some targeting Ebola.", [["Ebola", "DISEASE", 141, 146], ["[4]", "SIMPLE_CHEMICAL", 106, 109], ["Ebola", "ORGANISM", 141, 146], ["The template", "TREATMENT", 0, 12], ["the standardized risk", "TEST", 31, 52], ["assessment", "TEST", 53, 63], ["several new viral vector vaccines", "TREATMENT", 67, 100], ["Ebola", "OBSERVATION", 141, 146]]], ["The WHO Global Advisory Committee on Vaccine Safety (GACVS) endorsed the use of the template for other new candidate Ebola vaccines \u201cas it is a structured approach to vaccine safety\u201d [6].IntroductionIn 2020, the development of vaccines for COVID-19 is occurring with unprecedented speed [7].", [["Ebola", "DISEASE", 117, 122], ["COVID-19", "CHEMICAL", 240, 248], ["Ebola", "ORGANISM", 117, 122], ["the template", "TREATMENT", 80, 92], ["Ebola vaccines", "TREATMENT", 117, 131], ["IntroductionIn", "TREATMENT", 187, 201], ["vaccines", "TREATMENT", 227, 235], ["COVID", "TEST", 240, 245]]], ["The pace and volume of vaccine development make a deliberate and systematic approach to safety that is accessible and understandable to a diversity of stakeholders of the utmost importance.", [["The pace", "TREATMENT", 0, 8], ["volume of vaccine", "TREATMENT", 13, 30]]], ["Several protein vaccine candidates (e.g., recombinant protein or synthetic peptide vaccines) are among the COVID-19 vaccines in development.", [["recombinant protein", "PROTEIN", 42, 61], ["Several protein vaccine candidates", "TREATMENT", 0, 34], ["recombinant protein", "TREATMENT", 42, 61], ["synthetic peptide vaccines", "TREATMENT", 65, 91], ["the COVID-19 vaccines", "TREATMENT", 103, 124]]], ["The Brighton Collaboration V3SWG has therefore developed a specific template for protein vaccines that the Coalition for Epidemic Preparedness Innovations (CEPI) and other key stakeholders could use to evaluate and communicate the benefit-risk assessment of using this platform.", [["protein vaccines", "TREATMENT", 81, 97], ["risk assessment", "TEST", 239, 254], ["this platform", "TREATMENT", 264, 277]]], ["See Supplementary Material for definitions and additional guidance for completing this template.IntroductionProtein vaccines generally comprise the viral surface antigen responsible for the stimulation of neutralizing antibodies (spike protein in the case of COVID-19) [8].", [["surface", "ANATOMY", 154, 161], ["viral surface antigen", "PROTEIN", 148, 169], ["neutralizing antibodies", "PROTEIN", 205, 228], ["spike protein", "PROTEIN", 230, 243], ["this template", "TREATMENT", 82, 95], ["IntroductionProtein vaccines", "TREATMENT", 96, 124], ["the viral surface antigen", "TEST", 144, 169], ["neutralizing antibodies", "TEST", 205, 228], ["spike protein", "TEST", 230, 243], ["COVID", "TEST", 259, 264]]], ["Peptides are also included in this category of vaccines and most of these are likely to be synthetic in nature.", [["vaccines", "TREATMENT", 47, 55], ["likely to be", "UNCERTAINTY", 78, 90], ["synthetic", "OBSERVATION", 91, 100]]], ["Examples of licensed protein vaccines include an influenza vaccine comprising highly purified recombinant hemagglutinin [9], and a herpes zoster vaccine with highly purified varicella zoster surface glycoprotein E antigen [10].", [["herpes zoster", "DISEASE", 131, 144], ["varicella zoster", "DISEASE", 174, 190], ["herpes zoster", "ORGANISM", 131, 144], ["varicella zoster", "ORGANISM", 174, 190], ["surface glycoprotein E antigen", "GENE_OR_GENE_PRODUCT", 191, 221], ["varicella zoster surface glycoprotein E antigen", "PROTEIN", 174, 221], ["herpes zoster vaccine", "SPECIES", 131, 152], ["varicella zoster", "SPECIES", 174, 190], ["licensed protein vaccines", "TREATMENT", 12, 37], ["an influenza vaccine", "TREATMENT", 46, 66], ["a herpes zoster vaccine", "TREATMENT", 129, 152], ["highly purified varicella zoster", "PROBLEM", 158, 190]]], ["Many other protein vaccines have undergone clinical testing for example HIV gp120 and gp140 vaccines, but are not yet licensed.", [["HIV", "ORGANISM", 72, 75], ["gp120", "ORGANISM", 76, 81], ["gp140", "ORGANISM", 86, 91], ["gp120", "PROTEIN", 76, 81], ["HIV", "SPECIES", 72, 75], ["HIV", "SPECIES", 72, 75], ["Many other protein vaccines", "TREATMENT", 0, 27], ["clinical testing", "TEST", 43, 59], ["HIV gp120", "TREATMENT", 72, 81], ["gp140 vaccines", "TREATMENT", 86, 100]]], ["Recombinant proteins have often been used in vector or DNA prime, and protein boost regimens, in particular for HIV vaccines [11].", [["DNA", "CELLULAR_COMPONENT", 55, 58], ["Recombinant proteins", "PROTEIN", 0, 20], ["HIV", "SPECIES", 112, 115], ["Recombinant proteins", "PROBLEM", 0, 20], ["DNA prime", "TREATMENT", 55, 64], ["protein boost regimens", "TREATMENT", 70, 92], ["HIV vaccines", "TREATMENT", 112, 124]]], ["Some recombinant viral antigens spontaneously assemble into virus-like particles (VLPs).", [["VLPs", "ORGANISM", 82, 86], ["recombinant viral antigens", "PROTEIN", 5, 31], ["Some recombinant viral antigens", "PROBLEM", 0, 31], ["recombinant", "OBSERVATION_MODIFIER", 5, 16], ["viral", "OBSERVATION", 17, 22], ["particles", "OBSERVATION_MODIFIER", 71, 80]]], ["These may be single or multi protein structures that are stable and more immunogenic compared to purified protein antigens.", [["purified protein antigens", "PROTEIN", 97, 122], ["single or multi protein structures", "PROBLEM", 13, 47], ["may be", "UNCERTAINTY", 6, 12], ["stable", "OBSERVATION_MODIFIER", 57, 63]]], ["Examples of licensed vaccines containing recombinant VLPs include hepatitis B and human papillomavirus vaccines [12].", [["hepatitis B", "DISEASE", 66, 77], ["human papillomavirus vaccines", "DISEASE", 82, 111], ["recombinant VLPs", "ORGANISM", 41, 57], ["hepatitis B", "ORGANISM", 66, 77], ["human papillomavirus", "ORGANISM", 82, 102], ["human", "SPECIES", 82, 87], ["papillomavirus", "SPECIES", 88, 102], ["hepatitis B", "SPECIES", 66, 77], ["human papillomavirus", "SPECIES", 82, 102], ["licensed vaccines", "TREATMENT", 12, 29], ["recombinant VLPs", "TREATMENT", 41, 57], ["hepatitis B", "TREATMENT", 66, 77], ["human papillomavirus vaccines", "TREATMENT", 82, 111]]], ["It should be highlighted that, in contrast to inactivated, live attenuated, and viral vectored vaccines, the manufacture of protein vaccines does not involve the cultivation of any live viruses and they do not contain any viral genomes, their production and quality control is simpler, they are generally considered safer in cases where viruses can establish a persistent infection or are oncogenic, and they are feasible to manufacture even if the virus cannot be cultivated.", [["infection", "DISEASE", 372, 381], ["viral vectored vaccines", "TREATMENT", 80, 103], ["the manufacture of protein vaccines", "TREATMENT", 105, 140], ["any live viruses", "PROBLEM", 177, 193], ["any viral genomes", "PROBLEM", 218, 235], ["viruses", "PROBLEM", 337, 344], ["a persistent infection", "PROBLEM", 359, 381], ["the virus", "PROBLEM", 445, 454], ["persistent", "OBSERVATION_MODIFIER", 361, 371], ["infection", "OBSERVATION", 372, 381]]], ["Commercialized recombinant protein vaccines have been shown to be safe and efficacious and their manufacture can be scaled-up with relative ease [13], [14], [15].", [["Commercialized recombinant protein vaccines", "TREATMENT", 0, 43]]], ["However, due to the limited immunogenicity of some protein-based vaccines in humans, their development has also focused on methods to enhance the immune response, for example through the use of adjuvants, optimizing the route or method of administration, and the use of a heterologous prime-boost strategies.IntroductionIn particular, protein vaccines are likely to require a potent adjuvant that will direct the immune response to a predominantly Th1-type response.", [["humans", "ORGANISM", 77, 83], ["humans", "SPECIES", 77, 83], ["humans", "SPECIES", 77, 83], ["some protein-based vaccines", "TREATMENT", 46, 73], ["adjuvants", "TREATMENT", 194, 203], ["method of administration", "TREATMENT", 229, 253], ["a heterologous prime-boost strategies", "TREATMENT", 270, 307], ["IntroductionIn", "TREATMENT", 308, 322], ["protein vaccines", "TREATMENT", 335, 351], ["a potent adjuvant", "TREATMENT", 374, 391]]], ["Adjuvants are not usually licensed per se and it is the adjuvanted vaccine that is granted marketing authorization.", [["Adjuvants", "TREATMENT", 0, 9], ["the adjuvanted vaccine", "TREATMENT", 52, 74]]], ["There are only a few different types of adjuvant used in commercial vaccines although many are under investigation and the availability of particular adjuvants may be limited.", [["adjuvant", "TREATMENT", 40, 48], ["commercial vaccines", "TREATMENT", 57, 76], ["particular adjuvants", "TREATMENT", 139, 159], ["few", "OBSERVATION_MODIFIER", 17, 20], ["different", "OBSERVATION_MODIFIER", 21, 30], ["types", "OBSERVATION_MODIFIER", 31, 36], ["adjuvant", "OBSERVATION", 40, 48]]], ["Whilst enhancing the immune response, adjuvants impart additional safety considerations to a vaccine that have to be carefully assessed [16].IntroductionThe V3SWG intends that this template focuses on key questions related to the essential safety and benefit-risk issues relevant for the intrinsic properties of the vaccine components.", [["V3SWG", "DNA", 157, 162], ["adjuvants", "TREATMENT", 38, 47], ["a vaccine", "TREATMENT", 91, 100], ["risk issues", "PROBLEM", 259, 270], ["the vaccine components", "TREATMENT", 312, 334], ["immune response", "OBSERVATION", 21, 36]]], ["Although we recognize that other aspects of manufacturing, quality, and implementation can play an important role in the safety of a vaccine and vaccination, we have chosen to keep some of those issues out of scope in order to summarize the most useful information for stakeholders.IntroductionThe latest version of the template can be accessed on https://brightoncollaboration.us/v3swg/.", [["a vaccine", "TREATMENT", 131, 140], ["vaccination", "TREATMENT", 145, 156], ["the template", "TREATMENT", 316, 328]]], ["Vaccine developers are encouraged to complete the relevant templates for their vaccine candidate platform or vaccine candidate and collaborate with the V3SWG.", [["V3SWG", "DNA", 152, 157]]], ["The draft templates would be shared for review by the V3SWG and submitted for publication.", [["V3SWG", "DNA", 54, 59], ["The draft templates", "TREATMENT", 0, 19]]], ["Similarly, updates to the templates by the vaccine developers should be submitted to the Brighton Collaboration website for V3SWG review.Specific instructions for completing the V3SWG template:", [["V3SWG template", "DNA", 178, 192]]]], "8cd979b81ad77c0fdc72290327cd5b7bdca885f1": [["F AN1 possesses 5 0 flap endonuclease and 5 0 -3 0 exonuclease activities and is involved in a DNA ICL damage repair pathway [1] [2] [3] [4] [5] [6] .", [["F AN1", "GENE_OR_GENE_PRODUCT", 0, 5], ["exonuclease", "GENE_OR_GENE_PRODUCT", 51, 62], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 125, 148], ["F AN1", "DNA", 0, 5], ["5 0 flap endonuclease", "DNA", 16, 37], ["flap endonuclease", "TREATMENT", 20, 37], ["a DNA ICL damage repair pathway", "TREATMENT", 93, 124]]], ["FAN1 is thought to be recruited to ICLs via its interaction with the monoubiquitinated form of the FANCI-FANCD2 complex, and, accordingly, disruption of the nuclease activity of FAN1 sensitizes cells to ICL inducing agents [1] [2] [3] [4] [5] [6] .", [["cells", "ANATOMY", 194, 199], ["FAN1", "GENE_OR_GENE_PRODUCT", 0, 4], ["ICLs", "CELLULAR_COMPONENT", 35, 39], ["FANCI", "GENE_OR_GENE_PRODUCT", 99, 104], ["FANCD2", "GENE_OR_GENE_PRODUCT", 105, 111], ["FAN1", "GENE_OR_GENE_PRODUCT", 178, 182], ["cells", "CELL", 194, 199], ["ICL", "SIMPLE_CHEMICAL", 203, 206], ["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 223, 246], ["FAN1", "PROTEIN", 0, 4], ["FANCI", "PROTEIN", 99, 104], ["FANCD2 complex", "PROTEIN", 105, 119], ["nuclease", "PROTEIN", 157, 165], ["FAN1", "PROTEIN", 178, 182], ["the nuclease activity of FAN1 sensitizes cells", "TREATMENT", 153, 199], ["ICL inducing agents", "TREATMENT", 203, 222], ["thought to be", "UNCERTAINTY", 8, 21]]], ["In ICL repair, FAN1 is thought to co-operate with other nucleases to introduce DNA incisions necessary for the efficient unhooking of the ICL 1-6 .", [["FAN1", "GENE_OR_GENE_PRODUCT", 15, 19], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["FAN1", "PROTEIN", 15, 19], ["ICL 1-6", "DNA", 138, 145], ["ICL repair", "TREATMENT", 3, 13], ["other nucleases", "TREATMENT", 50, 65], ["DNA incisions", "TREATMENT", 79, 92], ["the ICL", "TREATMENT", 134, 141], ["ICL repair", "OBSERVATION", 3, 13]]], ["Interestingly, FAN1 inactivation can lead to chronic kidney diseases 7 and autism/schizophrenia 8 , linking defective DNA lesion repair with ageing 9 and neurological disorders 8 .", [["kidney", "ANATOMY", 53, 59], ["lesion", "ANATOMY", 122, 128], ["neurological", "ANATOMY", 154, 166], ["chronic kidney diseases", "DISEASE", 45, 68], ["autism", "DISEASE", 75, 81], ["schizophrenia", "DISEASE", 82, 95], ["neurological disorders", "DISEASE", 154, 176], ["FAN1", "GENE_OR_GENE_PRODUCT", 15, 19], ["kidney", "ORGAN", 53, 59], ["DNA", "CELLULAR_COMPONENT", 118, 121], ["FAN1", "PROTEIN", 15, 19], ["chronic kidney diseases", "PROBLEM", 45, 68], ["autism/schizophrenia 8", "PROBLEM", 75, 97], ["defective DNA lesion repair", "TREATMENT", 108, 135], ["neurological disorders", "PROBLEM", 154, 176], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["kidney", "ANATOMY", 53, 59], ["diseases", "OBSERVATION", 60, 68], ["defective", "OBSERVATION_MODIFIER", 108, 117], ["DNA", "OBSERVATION_MODIFIER", 118, 121], ["lesion repair", "OBSERVATION", 122, 135]]], ["Besides its positive role in genome maintenance, FAN1 is also implicated in conferring chemo-resistance in several cancer subtypes 10, 11 , presenting itself as a promising drug target against chemotherapy resistance.", [["cancer", "ANATOMY", 115, 121], ["cancer", "DISEASE", 115, 121], ["genome", "CELLULAR_COMPONENT", 29, 35], ["FAN1", "GENE_OR_GENE_PRODUCT", 49, 53], ["cancer", "CANCER", 115, 121], ["FAN1", "PROTEIN", 49, 53], ["several cancer subtypes", "PROBLEM", 107, 130], ["chemotherapy resistance", "TREATMENT", 193, 216], ["positive", "OBSERVATION_MODIFIER", 12, 20], ["genome maintenance", "OBSERVATION", 29, 47], ["several", "OBSERVATION_MODIFIER", 107, 114], ["cancer", "OBSERVATION", 115, 121]]]], "PMC7228733": [], "909ed39ab9a30b31c05ccbadaeb7e153ee021179": [["a1111111111 a1111111111 a1111111111 a1111111111 a1111111111IntroductionSevere Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) and the disease it causes COVID-19 (henceforth known as COVID) is causing widespread disruption to normal healthcare services, as the number COVID-positive cases increases.", [["Acute Respiratory Syndrome", "DISEASE", 78, 104], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 121, 131], ["COVID", "GENE_OR_GENE_PRODUCT", 274, 279], ["COVID-19", "DNA", 159, 167], ["SARS-CoV", "SPECIES", 121, 129], ["Acute Respiratory Syndrome", "PROBLEM", 78, 104], ["Corona Virus", "TEST", 105, 117], ["SARS", "TEST", 121, 125], ["CoV", "TEST", 126, 129], ["the disease", "PROBLEM", 137, 148], ["COVID", "TEST", 159, 164], ["the number COVID", "TEST", 263, 279], ["Acute", "OBSERVATION_MODIFIER", 78, 83], ["Respiratory Syndrome", "OBSERVATION", 84, 104], ["disease", "OBSERVATION", 141, 148]]], ["In the UK a worst case scenario is that 80% of the population are infected over a three month period, if controls are not put in place [1] .", [["infected", "OBSERVATION", 66, 74]]], ["Although social distancing measures are in place both in the UK and internationally, patients with Chronic Kidney Disease who must visit dialysis units are limited in their ability to be fully isolated.", [["Kidney", "ANATOMY", 107, 113], ["Chronic Kidney Disease", "DISEASE", 99, 121], ["patients", "ORGANISM", 85, 93], ["Kidney", "ORGAN", 107, 113], ["patients", "SPECIES", 85, 93], ["social distancing measures", "TREATMENT", 9, 35], ["Chronic Kidney Disease", "PROBLEM", 99, 121], ["dialysis units", "TREATMENT", 137, 151], ["Kidney", "ANATOMY", 107, 113], ["Disease", "OBSERVATION", 114, 121]]], ["It is possible therefore that spread in the dialysis population will be faster than in the general population.IntroductionRapid guidelines for dialysis service delivery have been published [2] [3] [4] .", [["[2] [3] [4]", "SIMPLE_CHEMICAL", 189, 200], ["the dialysis population", "TREATMENT", 40, 63], ["IntroductionRapid guidelines", "TREATMENT", 110, 138], ["dialysis service delivery", "TREATMENT", 143, 168], ["spread", "OBSERVATION_MODIFIER", 30, 36]]], ["These include separation of COVID-positive and COVID-negative patients; dialysis units working with transport providers to minimise the risk of cross-infection; and continuing to treat patients as close to home as possible.", [["COVID", "GENE_OR_GENE_PRODUCT", 28, 33], ["COVID", "SIMPLE_CHEMICAL", 47, 52], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 185, 193], ["COVID", "TEST", 28, 33], ["COVID", "TEST", 47, 52], ["dialysis units", "TREATMENT", 72, 86], ["transport providers", "TREATMENT", 100, 119], ["cross-infection", "PROBLEM", 144, 159], ["cross-infection", "OBSERVATION", 144, 159]]], ["[2] .IntroductionPlanning service delivery that separates COVID-positive patients is complicated, due to the uncertainty of the spread of SARS-CoV-2, the variability seen in symptom onset, length of infectivity, and regional delivery of dialysis.IntroductionWe therefore sought to support decision making in the period prior to peak infection by developing mathematical models of dialysis service delivery and patient transport.", [["SARS", "DISEASE", 138, 142], ["infection", "DISEASE", 333, 342], ["COVID", "GENE_OR_GENE_PRODUCT", 58, 63], ["patients", "ORGANISM", 73, 81], ["SARS-CoV-2", "ORGANISM", 138, 148], ["patient", "ORGANISM", 410, 417], ["patients", "SPECIES", 73, 81], ["patient", "SPECIES", 410, 417], ["SARS-CoV", "SPECIES", 138, 146], ["SARS", "PROBLEM", 138, 142], ["CoV", "TEST", 143, 146], ["symptom onset", "PROBLEM", 174, 187], ["length of infectivity", "PROBLEM", 189, 210], ["dialysis", "TREATMENT", 237, 245], ["peak infection", "PROBLEM", 328, 342], ["dialysis service delivery", "TREATMENT", 380, 405], ["infection", "OBSERVATION", 333, 342]]], ["We aimed to provide reusable tools to provide rapid information under various scenarios including a worst case three month spread.Materials and methodsWe developed a discrete-event simulation (DES) model of service delivery in the dialysis network.", [["the dialysis network", "TREATMENT", 227, 247], ["discrete", "OBSERVATION_MODIFIER", 166, 174]]], ["DES is an appropriate method to capture the stochastic dynamics of a capacity constrained system and model patients individually [5] .", [["DES", "CHEMICAL", 0, 3], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115]]], ["DES has been applied extensively in health service delivery [6] [7] [8] [9] and previously to model dialysis demand [10] as well as networks of care facilities [11] .", [["DES", "CHEMICAL", 0, 3], ["DES", "TREATMENT", 0, 3], ["model dialysis demand", "TREATMENT", 94, 115]]], ["We also developed a Monte-Carlo vehicle routing model to model patient transport.", [["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70]]], ["The algorithm used, a combination of the Clarke-Wright Savings [12] method and Iterated Local Search [13] , finds good solutions grouping and ordering patient pickup.Study settingWe apply the service delivery modelling tools [14] in the South of England in the region of Wessex: a mixed urban/rural setting where the renal dialysis service cares for 644 patients.", [["renal", "ANATOMY", 317, 322], ["patient", "ORGANISM", 151, 158], ["renal", "ORGAN", 317, 322], ["patients", "ORGANISM", 354, 362], ["patient", "SPECIES", 151, 158], ["patients", "SPECIES", 354, 362], ["Study setting", "TEST", 166, 179], ["the renal dialysis service cares", "TREATMENT", 313, 345], ["renal", "ANATOMY", 317, 322]]], ["The largest of which is located at the Queen Alexandra (QA) Hospital, Portsmouth.", [["largest", "OBSERVATION_MODIFIER", 4, 11]]], ["To access dialysis services 75% of patients make use of patient transport services.", [["patients", "ORGANISM", 35, 43], ["patient", "ORGANISM", 56, 63], ["patients", "SPECIES", 35, 43], ["patient", "SPECIES", 56, 63], ["dialysis services", "TREATMENT", 10, 27]]], ["During the epidemic, COVID-positive patients will be treated separately from negative and recovered.", [["COVID", "GENE_OR_GENE_PRODUCT", 21, 26], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["COVID", "TEST", 21, 26]]], ["The Queen Alexandra will be used as the primary site for positive outpatients and inpatients with spillover to a second site (Basingstoke) when capacity is insufficient.", [["outpatients", "SPECIES", 66, 77]]], ["Patient transport services will provide COVID only ambulances with a policy of single patient transport.Study settingIn the analysis we excluded home patients (n = 80) and due to its separation from the mainland the Isle of Wight (n = 44).Study settingThe geography of units and patients is described in more detail in S1 Appendix.Outcome measuresWe estimated the the change in outpatient and inpatient workload during the epidemic in terms of COVID-positive negative and recovered, at each dialysis unit in the network.Outcome measuresEstimates were produced over periods three to six months.", [["patient", "ORGANISM", 86, 93], ["patients", "ORGANISM", 150, 158], ["patients", "ORGANISM", 279, 287], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 86, 93], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 279, 287], ["Study setting", "TEST", 104, 117], ["Study setting", "TEST", 239, 252], ["COVID", "TEST", 444, 449], ["S1 Appendix", "ANATOMY", 319, 330]]], ["We also estimated the number of patients who were required to travel to a different unit from normal and the change in travel time.Outcome measuresWe estimated the vehicle total travel implications for patient transport services given a range of COVID-positive scenarios across the region's geography.Data sourcesResearchers had no access to individual patient level data.", [["patients", "ORGANISM", 32, 40], ["patient", "ORGANISM", 202, 209], ["patient", "ORGANISM", 353, 360], ["patients", "SPECIES", 32, 40], ["patient", "SPECIES", 202, 209], ["patient", "SPECIES", 353, 360], ["patient transport services", "TREATMENT", 202, 228], ["normal", "OBSERVATION", 94, 100]]], ["To ensure confidentiality, patient geographic locations was provided at the UK postcode sector level (alternatives might be output areas or northings and eastings).", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34]]], ["Travel times between these sectors were estimated using Routino (routino.org) with data from OpenStreetMap (openstreetmap.org).Data sourcesThe worst case time of spread of COVID-positive was taken from Fergeson et al. [1] .", [["COVID", "CHEMICAL", 172, 177], ["COVID", "CANCER", 172, 177], ["COVID", "TEST", 172, 177]]], ["Mortality rate, time a patient was COVID-positive before admission and inpatient length of stay were local parameters.Analysis environmentAll models were written in Python 3.8.", [["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["Mortality rate", "TEST", 0, 14], ["local parameters", "TEST", 101, 117]]], ["We used SimPy 3 [15] to implement the DES model.", [["DES", "CHEMICAL", 38, 41], ["the DES model", "TREATMENT", 34, 47]]], ["We provide all code and data used in the study and follow the STRESS reporting guidelines for DES [19] .", [["DES", "CHEMICAL", 94, 97], ["DES", "CHEMICAL", 94, 97], ["the study", "TEST", 37, 46]]], ["The transport modelling results were run on an Intel i9-9900K CPU with 64GB RAM running the Pop!_OS 19.10 Linux.Verification and validationWe performed model testing (verification) as models were developed in line with simulation standards [20] .", [["model testing", "TEST", 152, 165]]], ["We also opted to model a range of likely scenarios including what is widely believed to be the worst case.Dialysis modelThe dialysis model runs through a defined period (e.g. one year) and simulates the progression of patients through phases of COVID infection: negative, positive (with some requiring inpatient care) and recovered or died.", [["infection", "DISEASE", 251, 260], ["patients", "ORGANISM", 218, 226], ["COVID", "GENE_OR_GENE_PRODUCT", 245, 250], ["patients", "SPECIES", 218, 226], ["Dialysis model", "TREATMENT", 106, 120], ["The dialysis model runs", "TREATMENT", 120, 143], ["COVID infection", "PROBLEM", 245, 260], ["progression", "OBSERVATION_MODIFIER", 203, 214], ["infection", "OBSERVATION", 251, 260]]], ["The speed of progression of infection through the population may be varied (typically 3-12 months).Dialysis modelAs patients change COVID state the model seeks to place them in the appropriate unit and session, opening up COVID-positive sessions in units that allow it.", [["infection", "DISEASE", 28, 37], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["infection", "PROBLEM", 28, 37], ["Dialysis modelAs", "TREATMENT", 99, 115], ["progression", "OBSERVATION_MODIFIER", 13, 24], ["infection", "OBSERVATION", 28, 37]]], ["COVID-positive patients do not mix with any other patients.", [["COVID", "GENE_OR_GENE_PRODUCT", 0, 5], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 50, 58], ["COVID", "PROTEIN", 0, 5], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 50, 58], ["positive", "OBSERVATION", 6, 14]]], ["Opening up COVID-positive sessions causes other patients to be displaced from that session, and the model seeks to reallocate them either to the same unit or, if there is no space left, to the closest alternative unit.Dialysis modelThe dialysis model is run 30 times to simulate 30 alternative years as, due to the randomness of infection, no two years will be exactly alike.", [["infection", "DISEASE", 329, 338], ["patients", "ORGANISM", 48, 56], ["COVID", "DNA", 11, 16], ["patients", "SPECIES", 48, 56], ["Dialysis model", "TREATMENT", 218, 232], ["The dialysis model", "TREATMENT", 232, 250], ["infection", "PROBLEM", 329, 338], ["displaced", "OBSERVATION", 63, 72], ["infection", "OBSERVATION", 329, 338]]], ["Results show typical (median) and extreme years.Patient progression model.A simplification used in this model is that all patients should receive dialysis three times weekly, with each patient allocated to a starting day for the week of either Monday or Tuesday.Patient progression model.A proportion of patients moves through phases of COVID state and care (Fig 1) .", [["patients", "ORGANISM", 122, 130], ["patient", "ORGANISM", 185, 192], ["patients", "ORGANISM", 304, 312], ["Patient", "SPECIES", 48, 55], ["patients", "SPECIES", 122, 130], ["patient", "SPECIES", 185, 192], ["Patient", "SPECIES", 262, 269], ["patients", "SPECIES", 304, 312], ["A simplification", "TREATMENT", 74, 90], ["dialysis", "TREATMENT", 146, 154]]], ["The proportions of patients and times in each phase is either fixed or sampled from stochastic distributions as given in Table 1 .", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27]]], ["We assume that COVID patients must be separated from uninfected patients, and that patients who have recovered from a COVID episode do not mix with those currently testing COVID positive.", [["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 83, 91], ["a COVID episode", "PROBLEM", 116, 131]]], ["We do not deal specifically with suspected COVID patients in the model, anticipating that rapid testing will soon be available to diagnose which group they belong to.Patient progression model.The baseline model takes a worst case progression of COVID, infecting 80% of the dialysis population over 3 months.Patient progression model.Unit search strategy.", [["COVID", "DISEASE", 43, 48], ["COVID", "DISEASE", 245, 250], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["Patient", "SPECIES", 166, 173], ["Patient", "SPECIES", 307, 314], ["rapid testing", "TEST", 90, 103], ["COVID", "PROBLEM", 245, 250], ["the dialysis population", "TREATMENT", 269, 292]]], ["When allocating patients to units, the following search strategy is employed.Patient progression model.\u2022 COVID negative: First look for place in current unit attended.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["Patient", "SPECIES", 77, 84]]], ["COVID session is required, the model will displace all COVID negative patients in that session, and seek to re-allocate them according to the rules for allocating COVID negative patients.Patient progression model.\u2022 COVID-positive inpatient: All inpatients are placed in Queen Alexandra Hospital, Portsmouth (though the model allows searching by travel time if another unit were to open to renal COVID-positive inpatients).Patient progression model.\u2022 COVID-recovered: Treat as COVID negative.Patient progression model.\u2022 Unallocated patients: If a patient cannot be allocated to any unit, the model attempts to allocate them each day.Patient progression model.Patients, in the model, may end up being cared for at a more distant unit than their starting unit.", [["renal", "ANATOMY", 389, 394], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 178, 186], ["COVID", "GENE_OR_GENE_PRODUCT", 215, 220], ["renal", "ORGAN", 389, 394], ["patients", "ORGANISM", 531, 539], ["patient", "ORGANISM", 546, 553], ["Patients", "ORGANISM", 658, 666], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 178, 186], ["Patient", "SPECIES", 187, 194], ["Patient", "SPECIES", 422, 429], ["Patient", "SPECIES", 491, 498], ["patients", "SPECIES", 531, 539], ["patient", "SPECIES", 546, 553], ["Patient", "SPECIES", 632, 639], ["Patients", "SPECIES", 658, 666], ["positive", "OBSERVATION", 221, 229], ["renal", "ANATOMY", 389, 394]]], ["Once every week, the model seeks to reallocate patients back to their starting unit, or closest available unit if room in their starting unit is not available.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["This will also compress COVIDpositive patients into as few units and sessions as possible.Patient progression model.COVID-positive sessions are converted back to COVID negative sessions when they are no longer needed.Patient transport modelThe transport model provides an estimate of the vehicle travel time needed to transport COVID-positive patients to (and from) an outpatient treatment facility.Patient transport modelTransport scenarios.", [["patients", "ORGANISM", 38, 46], ["COVID", "GENE_OR_GENE_PRODUCT", 328, 333], ["patients", "ORGANISM", 343, 351], ["patients", "SPECIES", 38, 46], ["Patient", "SPECIES", 90, 97], ["Patient", "SPECIES", 217, 224], ["patients", "SPECIES", 343, 351], ["Patient", "SPECIES", 399, 406], ["an outpatient treatment facility", "TREATMENT", 366, 398], ["positive", "OBSERVATION", 122, 130]]], ["The model can vary the capacity of transport vehicles (e.g. the number of seats per ambulance) and the number of COVID positive patients in the population who need COVID-positive capable transport at any time.Patient transport modelWe model the following daily scenarios:Patient transport model\u2022 A population of 20 patients are COVID-positive.Patient transport model\u2022 A population of 40 patients are COVID-positive.Patient transport model\u2022 A population of 60 patients are COVID-positive.Patient transport model\u2022 Ambulances are able to pick up between 1 and 4 COVID-positive patients on a single trip.Patient transport modelFor example, if COVID spreads through the population in three months, there may be 140 COVID-positive patients.", [["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 315, 323], ["COVID", "GENE_OR_GENE_PRODUCT", 328, 333], ["patients", "ORGANISM", 387, 395], ["COVID", "GENE_OR_GENE_PRODUCT", 400, 405], ["patients", "ORGANISM", 459, 467], ["COVID", "GENE_OR_GENE_PRODUCT", 472, 477], ["COVID", "GENE_OR_GENE_PRODUCT", 559, 564], ["patients", "ORGANISM", 574, 582], ["COVID", "GENE_OR_GENE_PRODUCT", 710, 715], ["patients", "ORGANISM", 725, 733], ["patients", "SPECIES", 128, 136], ["Patient", "SPECIES", 209, 216], ["patients", "SPECIES", 315, 323], ["Patient", "SPECIES", 343, 350], ["patients", "SPECIES", 387, 395], ["Patient", "SPECIES", 415, 422], ["patients", "SPECIES", 459, 467], ["Patient", "SPECIES", 487, 494], ["patients", "SPECIES", 574, 582], ["Patient", "SPECIES", 600, 607], ["patients", "SPECIES", 725, 733], ["COVID", "TEST", 328, 333], ["COVID", "TEST", 400, 405], ["A population", "TEST", 440, 452], ["COVID", "TEST", 472, 477], ["COVID", "TEST", 710, 715], ["capacity", "OBSERVATION_MODIFIER", 23, 31], ["transport vehicles", "OBSERVATION", 35, 53], ["positive", "OBSERVATION", 334, 342], ["positive", "OBSERVATION", 406, 414], ["positive", "OBSERVATION", 478, 486]]], ["If 40% are inpatients, and 75% require transport, there may be 60-70 patients requiring COVID-positive transport (30-35 on each day).Patient transport modelSimulation of pickup locations.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["Patient", "SPECIES", 133, 140]]], ["There is no robust way to estimate which patients will become infected and at what time.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["infected", "PROBLEM", 62, 70], ["no", "UNCERTAINTY", 9, 11], ["infected", "OBSERVATION", 62, 70]]], ["The model therefore uses a Monte-Carlo sampling approach to simulate different groups of patients becoming infected.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["a Monte-Carlo sampling approach", "TREATMENT", 25, 56], ["infected", "PROBLEM", 107, 115], ["infected", "OBSERVATION", 107, 115]]], ["The sampling uses the geographic distribution of patient home postcode sectors.", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["geographic", "OBSERVATION_MODIFIER", 22, 32], ["distribution", "OBSERVATION_MODIFIER", 33, 45]]], ["We firstly assume that all patients are equally likely to become infected.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["infected", "PROBLEM", 65, 73], ["equally likely", "UNCERTAINTY", 40, 54], ["infected", "OBSERVATION", 65, 73]]], ["We then weight the sample by the number of patients within each postcode sector.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51]]], ["I.e. areas with more patients are more likely to be sampled.Patient transport modelThe model works by performing multiple runs.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["Patient", "SPECIES", 60, 67]]], ["On each run a different cohort of patients is selected.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["This means that hundreds of combinations of COVID-positive patient locations can be explored.", [["COVID", "GENE_OR_GENE_PRODUCT", 44, 49], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["COVID", "TREATMENT", 44, 49]]], ["The transport routes group patients together and order them for transport to the hospital.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35]]], ["The grouping is based on travel time.Patient transport modelWe simplified the problem to consider a symmetric road network.", [["road network", "MULTI-TISSUE_STRUCTURE", 110, 122], ["Patient", "SPECIES", 37, 44]]], ["That is travel time outward to a patient is the same as inward travel time.", [["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40]]], ["In reality road networks are asymmetric, for example due to one way systems, and roadworks.", [["road networks", "MULTI-TISSUE_STRUCTURE", 11, 24], ["asymmetric", "OBSERVATION_MODIFIER", 29, 39]]], ["After a set of patient locations is chosen a set of routes are constructed.", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22]]], ["We have simplified the problem so that the ambulance is based at the Queen Alexandra (in reality it will start from an depot elsewhere, but this is only one leg of multiple journeys).", [["leg", "ORGANISM_SUBDIVISION", 157, 160]]], ["In each scenario, we also simplified the problem so that all ambulances have the same capacity (no. of seats).Patient transport modelWhen vehicle capacity is equal to one then the cost of all routes is equal to the travel time to and from all patients.", [["patients", "ORGANISM", 243, 251], ["Patient", "SPECIES", 110, 117], ["patients", "SPECIES", 243, 251]]], ["This is our baseline scenario and all other scenarios are compared to it.Patient transport modelWhen vehicles have capacity greater than one, we simplify the problem of patient transport to the deterministic Capacitated Vehicle Routing Problem (CVRP).", [["patient", "ORGANISM", 169, 176], ["Patient", "SPECIES", 73, 80], ["patient", "SPECIES", 169, 176]]], ["As we must solve medium to large CRVP instances thousands of times we do not make use of an industrial solver, such as Gurobi to solve to optimality, due to model runtime.", [["an industrial solver", "TREATMENT", 89, 109]]], ["Here we use a two-step heuristic approach.", [["a two-step heuristic approach", "TREATMENT", 12, 41]]], ["Details of the heuristics are provided in S2 Appendix.Dialysis networkCurrently the median travel time from home to dialysis unit (one way, with a single passenger) is 14 minutes.", [["Dialysis", "TREATMENT", 54, 62], ["Appendix", "ANATOMY", 45, 53]]], ["The minimum, lower quartile, upper quartile, and maximum travel times are 1, 9, 22, and 76 minutes.Dialysis networkCurrently there is sufficient capacity for 668 dialysis patients in the outpatient sessions which are currently open, with 583 patients currently receiving dialysis (87% capacity utilisation).", [["patients", "ORGANISM", 171, 179], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 171, 179], ["patients", "SPECIES", 242, 250], ["Dialysis", "TREATMENT", 99, 107], ["dialysis", "TREATMENT", 162, 170], ["dialysis", "TREATMENT", 271, 279], ["minimum", "OBSERVATION_MODIFIER", 4, 11], ["lower", "ANATOMY_MODIFIER", 13, 18], ["upper", "ANATOMY_MODIFIER", 29, 34], ["capacity", "OBSERVATION_MODIFIER", 145, 153]]], ["In the planned strategy of using half of one of the largest units (Queen Alexandra) for COVID-positive dialysis outpatients, and then using a second unit (Basingstoke, also providing up to half of its capacity for COVID-positive dialysis outpatient patients) for any excess, the dialysis system copes without any patients being unable to be allocated to a session (or without any need in dropping dialysis frequency).", [["outpatients", "ORGANISM", 112, 123], ["patients", "ORGANISM", 249, 257], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 249, 257], ["patients", "SPECIES", 313, 321], ["COVID-positive dialysis outpatients", "TREATMENT", 88, 123], ["a second unit (Basingstoke", "TREATMENT", 140, 166], ["COVID-positive dialysis", "TREATMENT", 214, 237], ["any excess", "PROBLEM", 263, 273], ["the dialysis system", "TREATMENT", 275, 294], ["dropping dialysis frequency", "TREATMENT", 388, 415]]], ["Workload in units that do not take COVIDpositive outpatients will fall during the outbreak (though some work will flow back to them if they need to care for COVID-negative patients displaced from the units caring for COVIDpositive patients).Dialysis networkOne unit (Queen Alexandra) takes all COVID-positive inpatients in the model.", [["outpatients", "ORGANISM", 49, 60], ["patients", "ORGANISM", 172, 180], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 231, 239], ["COVID", "TEST", 157, 162], ["Dialysis", "TREATMENT", 241, 249]]], ["The novel workload of treating COVID-positive patients who would otherwise not need inpatient care will likely stress inpatient care systems.Dialysis networkOutpatients may be displaced from their usual unit of care either because they need to travel to a COVID-positive session in another hospital, or because their unit has had to free up sessions for COVID-positive sessions.", [["COVID", "GENE_OR_GENE_PRODUCT", 31, 36], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["Dialysis", "TREATMENT", 141, 149]]], ["These patients typically require 20 minutes extra travel time to get to their temporary place of care (assuming they are travelling alone), with some requiring 50 minutes extra travel in each direction to/from dialysis.Patient transportFigs 5 and 6 illustrate the travel times distribution inbound, and inbound plus outbound (doubled inbound times), respectively, by transport capacity size of the COVID positive patient cohort.Patient transportA patient transport policy where a single patients are transported at a time has a median time substantially higher than all multi-occupancy policies.", [["patients", "ORGANISM", 6, 14], ["patient", "ORGANISM", 413, 420], ["patient", "ORGANISM", 447, 454], ["patients", "ORGANISM", 487, 495], ["transportFigs 5 and 6", "DNA", 227, 248], ["patients", "SPECIES", 6, 14], ["Patient", "SPECIES", 219, 226], ["patient", "SPECIES", 413, 420], ["Patient", "SPECIES", 428, 435], ["patient", "SPECIES", 447, 454], ["patients", "SPECIES", 487, 495], ["dialysis", "TREATMENT", 210, 218], ["size", "OBSERVATION_MODIFIER", 386, 390]]], ["In all COVID caseload scenarios the largest improvement is seen when a additional patient is transported in each trip.", [["patient", "ORGANISM", 82, 89], ["patient", "SPECIES", 82, 89], ["largest", "OBSERVATION_MODIFIER", 36, 43], ["improvement", "OBSERVATION_MODIFIER", 44, 55]]], ["Further improvement is seen if vehicle capacity is increased to three or four patients.Patient transportFor example, if 40 COVID-positive patients need inbound and outbound transport, then a a median of 80.0 hours (inter-quartile range = 12.5 hours) of ambulance driving time (not including fixed drop-off and clean times) is required per day.", [["patients", "ORGANISM", 78, 86], ["COVID", "GENE_OR_GENE_PRODUCT", 123, 128], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 78, 86], ["Patient", "SPECIES", 87, 94], ["patients", "SPECIES", 138, 146], ["vehicle capacity", "PROBLEM", 31, 47], ["improvement", "OBSERVATION_MODIFIER", 8, 19], ["increased", "OBSERVATION_MODIFIER", 51, 60]]], ["If the transport capacity of vehicles is increased to two, three or four patient seating capacity, the median travel time requirements are reduced to 48 hours (a 40% reduction relative to single occupancy vehicles), 38 hours (52% reduction) and 33 hours (60% reduction), respectively.DiscussionThe results indicate that, if current outpatient capacity is maintained, the dialysis units should be able to cope with the worst-case scenario of rapid (three month) spread of COVID, but that workloads will shift to the central hospital.", [["COVID", "DISEASE", 471, 476], ["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["a 40% reduction", "TREATMENT", 160, 175], ["the dialysis units", "TREATMENT", 367, 385]]], ["Coping with a rapid spread of COVID will require rapid reallocation of patients to different sessions and units, an effect likely to also impact on ambulance transfer services who will see journey times increase, and have reduced efficiency of having to split COVID positive and COVID-negative patients.DiscussionIt appears likely that there will be significant inpatient pressures, with current capacity likely to be breached.", [["COVID", "DISEASE", 30, 35], ["patients", "ORGANISM", 71, 79], ["COVID", "GENE_OR_GENE_PRODUCT", 260, 265], ["COVID", "GENE_OR_GENE_PRODUCT", 279, 284], ["patients", "ORGANISM", 294, 302], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 294, 302], ["COVID", "TEST", 279, 284], ["inpatient pressures", "TEST", 362, 381], ["appears likely", "UNCERTAINTY", 316, 330]]], ["It may be necessary to consider moving dialysis equipment during the peak COVID-positive workload when demand on units taking COVID-negative patients only will be reduced.PLOS ONEOrganising outpatient dialysis services during the COVID-19 pandemicPLOS ONEThe current practice of transporting COVID-positive patients individually appears unsustainable.", [["COVID", "CHEMICAL", 292, 297], ["COVID", "GENE_OR_GENE_PRODUCT", 126, 131], ["patients", "ORGANISM", 141, 149], ["COVID", "GENE_OR_GENE_PRODUCT", 292, 297], ["patients", "ORGANISM", 307, 315], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 307, 315], ["moving dialysis equipment", "TREATMENT", 32, 57], ["the peak COVID", "TEST", 65, 79], ["COVID", "TREATMENT", 126, 131], ["outpatient dialysis services", "TREATMENT", 190, 218], ["the COVID", "TEST", 226, 235], ["transporting COVID", "TEST", 279, 297], ["unsustainable", "OBSERVATION_MODIFIER", 337, 350]]], ["The results demonstrate that single seat ambulances face a challenge in transporting COVID-positive patients to and from the Queen Alexandra on a given day.", [["COVID", "GENE_OR_GENE_PRODUCT", 85, 90], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108]]], ["In each scenario, there is significant savings from using the additional ambulance capacity for more COVIDpositive patients.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["significant savings", "PROBLEM", 27, 46], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["savings", "OBSERVATION", 39, 46]]], ["In each scenario, the biggest relative improvement is seen when capacity is increased to 2 seats (e.g. reducing ambulance drive time from 75 to about 45 hours per day for 40 patient two-way journeys).", [["patient", "ORGANISM", 174, 181], ["patient", "SPECIES", 174, 181], ["biggest", "OBSERVATION_MODIFIER", 22, 29], ["relative", "OBSERVATION_MODIFIER", 30, 38], ["improvement", "OBSERVATION", 39, 50]]], ["Increasing to 2-4 seats has further benefit, but returns are diminishing.Strengths of the studyMuch of data science's initial COVID modelling effort has, rightly, been focused on epidemiology [1] and intensive care unit (ICU) capacity.", [["diminishing", "OBSERVATION_MODIFIER", 61, 72]]], ["Indeed a strength of our toolkit is its practical utility in supporting the continuous safe treatment of a vulnerable group during a national or regional outbreak of COVID infection.Strengths of the studyWe argue that more work like ours is needed to support health services and that the data science community must now focus on research translation.", [["infection", "DISEASE", 172, 181], ["COVID", "CANCER", 166, 171], ["the continuous safe treatment", "TREATMENT", 72, 101], ["COVID infection", "PROBLEM", 166, 181], ["the study", "TEST", 195, 204], ["infection", "OBSERVATION", 172, 181]]], ["While the world's population awaits the results of vaccine trials, the risk of a secondary wave of infections remains a reality.Strengths of the studyTo protect the public and support health services under these circumstances we urgently need more research and development of novel practical decision support tools.", [["infections", "DISEASE", 99, 109], ["vaccine trials", "TREATMENT", 51, 65], ["a secondary wave of infections", "PROBLEM", 79, 109], ["the study", "TEST", 141, 150], ["infections", "OBSERVATION", 99, 109]]], ["We encourage others to do the same.Limitations of the studyA general limitation to these types of models is the level of uncertainty about the spread of COVID.", [["COVID", "DISEASE", 153, 158], ["the study", "TEST", 50, 59]]], ["We have therefore sought to model worst-case scenarios to enable contingency planning.Limitations of the studyDialysis network model.Limitations of the study\u2022 The model assumes that patients can be re-allocated to units/sessions immediately.", [["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["the studyDialysis network model", "TREATMENT", 101, 132], ["the study", "TEST", 148, 157]]], ["In practice changes to session allocation (e.g. shifting from COVID-negative to COVID-positive are likely to be made a little in advance.Limitations of the study\u2022 The results reported here assume that current capacity is maintained throughout the COVID outbreak.", [["COVID", "TEST", 62, 67], ["the study", "TEST", 152, 161]]], ["We have not modelled the effect of reductions in capacity that may be caused by staff shortages.Limitations of the study\u2022 We have not modelled timing of sessions, but the model progressively allocates COVID-positive sessions as needed, and we would assume that these sessions would come later in the day, enabling cleaning at the end of the day, ready for any COVID-negative session the next morning.Limitations of the study\u2022 We have not included home dialysis patients, which may affect inpatient demand.", [["patients", "ORGANISM", 461, 469], ["patients", "SPECIES", 461, 469], ["reductions in capacity", "PROBLEM", 35, 57], ["the study", "TEST", 111, 120], ["the study", "TEST", 415, 424], ["home dialysis", "TREATMENT", 447, 460], ["may be caused", "UNCERTAINTY", 63, 76]]], ["A likely worst-case scenario (with home dialysis patients following the transmission spread, and need for inpatient care, of the dialysis units, is that inpatient demand may be increased 15%.Limitations of the studyTransport model.Limitations of the study\u2022 The results provide estimates of patient transport ambulances total travel time.", [["patients", "ORGANISM", 49, 57], ["patient", "ORGANISM", 290, 297], ["patients", "SPECIES", 49, 57], ["patient", "SPECIES", 290, 297], ["home dialysis", "TREATMENT", 35, 48], ["the dialysis units", "TREATMENT", 125, 143], ["the study", "TEST", 206, 215], ["the study", "TEST", 246, 255], ["likely", "UNCERTAINTY", 2, 8], ["worst", "OBSERVATION_MODIFIER", 9, 14]]], ["Dial-a-ride formulations explicitly take account of time windows for patient pickup and drop-off and maximum patient ride-time.", [["patient", "ORGANISM", 69, 76], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 69, 76], ["patient", "SPECIES", 109, 116], ["Dial-a-ride formulations", "TREATMENT", 0, 24], ["patient pickup", "TEST", 69, 83]]], ["Further dynamic complexity would be required in order to incorporate two-way patient journeys.Limitations of the study\u2022 The route optimisation uses two well known heuristics.", [["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["the study", "TEST", 109, 118]]], ["A heuristic algorithm offers a fast method to obtain a good solution, but it does not guarantee an optimal solution i.e the shortest possible travel time achieved by optimal assignment of patients to routes.", [["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["A heuristic algorithm", "TEST", 0, 21]]], ["It is possible to solve the CRVP with 100 nodes to 'optimality' using industrial solvers such Gurobi.", [["CRVP", "CANCER", 28, 32], ["the CRVP", "TREATMENT", 24, 32], ["nodes", "OBSERVATION", 42, 47]]], ["We chose a heuristic approach primarily for solution speed as we made no assumptions about the size of problem other networks could face internationally.", [["a heuristic approach", "TREATMENT", 9, 29]]], ["We note that a possible improvement to the approach could be to switch to the Parallel version of Clarke-Wright savings.Limitations of the study\u2022 Figures for inward and outwards journeys do not explore the potential efficiencies of dropping patients back at their homes (after dialysis) and picking up new patients up at the same time.ConclusionThe simulation tools we present in this article are free and open under an MIT permissive license [14] .", [["patients", "ORGANISM", 241, 249], ["patients", "ORGANISM", 306, 314], ["patients", "SPECIES", 241, 249], ["patients", "SPECIES", 306, 314], ["the study", "TEST", 135, 144], ["dialysis", "TREATMENT", 277, 285], ["The simulation tools", "TEST", 345, 365]]], ["Our intention was not to move the state-of-the-art in simulation or vehicle routing forward, but instead to develop tools that would support dialysis services during any pandemic.", [["dialysis services", "TREATMENT", 141, 158]]], ["The study we present applies these tools in the South of England where they were used to stress test capacity planning plans.", [["The study", "TEST", 0, 9]]], ["As the pandemic progresses internationally there are risks of regional outbreaks or secondary national spikes in cases.", [["regional outbreaks", "PROBLEM", 62, 80], ["secondary national spikes in cases", "PROBLEM", 84, 118]]], ["We have designed the tools to scale to large international dialysis planning situations and exploit parallelism and fast well known heuristics.", [["large international dialysis planning situations", "TREATMENT", 39, 87]]]], "3b8610cc1f1d487aec98cb4650216441b834eb7b": [["IntroductionCOVID-19, a new strain of coronavirus, originated in Wuhan, China in December 2019 (Huang et al., 2020) .", [["coronavirus", "ORGANISM", 38, 49], ["IntroductionCOVID", "TEST", 0, 17], ["coronavirus", "PROBLEM", 38, 49]]], ["On 11 th March 2020, the World Health Organization announced the COVID-19 outbreak as a pandemic.", [["the COVID", "TEST", 61, 70]]], ["This highly infectious COVID-19 has crossed boundaries in a speed anybody could have imagined turning the world upside down.", [["COVID-19", "DNA", 23, 31], ["infectious", "OBSERVATION", 12, 22]]], ["COVID-19 has already claimed more than 0.3 million lives, with around 6 million people infected in more than 200 countries or territories 1 up to May 31, 2020.IntroductionIt has shaken the global economic and social structure so badly, that resuming normal life is a thing to envision.", [["COVID-19", "CHEMICAL", 0, 8], ["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86], ["global", "OBSERVATION_MODIFIER", 189, 195], ["economic", "OBSERVATION_MODIFIER", 196, 204], ["social structure", "OBSERVATION", 209, 225]]], ["Since then much of the debate has been going on how the countries should ease the lockdown program.", [["the lockdown program", "TREATMENT", 78, 98]]], ["As lockdown is not the ultimate solution, easing the restrictions is the only way to minimize economic loss and keep the society functional.", [["economic loss", "PROBLEM", 94, 107]]], ["As the whole world is still not free from the deadly clutch of corona and continuing to claim human lives, reopen decisions from the government is a huge step to take.", [["human", "ORGANISM", 94, 99], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["corona", "OBSERVATION_MODIFIER", 63, 69]]], ["Public sentiment towards this reopen decision can help policymakers and general people to better understand the situation through classified information.IntroductionThis COVID-19 outbreak has not only caused economic breakdown (Fernandes, 2020) across the world but also left a great impact on human minds.", [["people", "ORGANISM", 80, 86], ["human", "ORGANISM", 294, 299], ["people", "SPECIES", 80, 86], ["human", "SPECIES", 294, 299], ["human", "SPECIES", 294, 299], ["IntroductionThis COVID", "TREATMENT", 153, 175], ["economic breakdown", "PROBLEM", 208, 226], ["economic", "OBSERVATION_MODIFIER", 208, 216], ["breakdown", "OBSERVATION", 217, 226], ["left", "ANATOMY_MODIFIER", 271, 275], ["great", "OBSERVATION_MODIFIER", 278, 283], ["impact", "OBSERVATION", 284, 290]]], ["To capture human emotions, social media websites work as one of the best possible sources (De Choudhury and Counts, 2012) .", [["human", "ORGANISM", 11, 16], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16]]], ["It is the fastest way for people to express themselves and thus the news feed is flooded with data reflecting thoughts dominating the peoples minds at this time.", [["people", "ORGANISM", 26, 32], ["people", "SPECIES", 26, 32]]], ["Apart from sharing their thoughts, people use these media to disseminate the information.", [["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41]]], ["During this lockdown, people have taken social networks to express their feelings and thus find a way to calm themselves down.IntroductionEmotions and sentiments are the driving force that people are sharing in social media.", [["people", "ORGANISM", 22, 28], ["people", "ORGANISM", 189, 195], ["people", "SPECIES", 22, 28], ["people", "SPECIES", 189, 195]]], ["From this kind of analysis, we may find what people like, what they want, and what are the main concerns of them.", [["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51]]], ["Twitter has a large number of daily active users all around the world where people share their thoughts and information regarding any topic of recent concern through this medium.", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82], ["large", "OBSERVATION_MODIFIER", 14, 19], ["number", "OBSERVATION_MODIFIER", 20, 26]]], ["It is a searchable archive of human thought.", [["human", "ORGANISM", 30, 35], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35]]], ["Researchers and practitioners are already giving useful information on issues related to this COVID-19 outbreak.", [["this COVID", "TEST", 89, 99]]], ["We have mainly contributed to the issue of the reopening phase giving an insight into people's reactions.", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92], ["the reopening phase", "PROBLEM", 43, 62]]], ["Coordination of responses from online and from the real-world is sure to reveal promising results to address the current crisis.", [["the current crisis", "PROBLEM", 109, 127]]], ["Our major finding is that during this reopen phase fear among people is less dominant compared to the previous times when the states made lockdown decisions.", [["people", "ORGANISM", 62, 68], ["people", "SPECIES", 62, 68], ["less dominant", "OBSERVATION_MODIFIER", 72, 85]]], ["Another finding is that as the reopen phase starts, the number of new cases is also increasing.", [["the reopen phase", "TEST", 27, 43], ["number", "OBSERVATION_MODIFIER", 56, 62], ["new", "OBSERVATION_MODIFIER", 66, 69], ["cases", "OBSERVATION", 70, 75], ["increasing", "OBSERVATION_MODIFIER", 84, 94]]], ["People are sharing their thoughts and opinions to combat this situation.IntroductionContributions.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["This paper makes the following contributions.Introduction\u2022 First, we generate the word cloud and N-gram representation of tweets to see the insights of twitter users during the reopening phase (more details in section 5.1). \u2022 Second, we conduct a shallow analysis to study the sentiment and the emotion in reopening related tweets (more details in section 5.2 and section 5.3). \u2022 Third, we analyze the actual effects of lockdown and reopening using real data (more details in section 5.4). \u2022 Finally, we have made our code publicly available for an extensible work in similar areas.IntroductionThe structure of this paper is organized as follows.", [["a shallow analysis", "TEST", 245, 263], ["lockdown", "TREATMENT", 420, 428]]], ["Section 5 provides an analysis of the results and findings.", [["an analysis", "TEST", 19, 30]]], ["Finally, Section 7 concludes the paper with future works.Related WorkResearchers all around the world are analyzing Twitter data to discover people's reactions to the corona virus related issues such as lockdown, safety measures.", [["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147], ["the corona virus", "PROBLEM", 163, 179]]], ["(Barkur et al., 2020) analyzed Twitter data and found that people of India were positive towards the lockdown decision of their government to flatten the curve.", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65]]], ["(Dubey, 2020) made a sentiment analysis on the tweets related to COVID19 in some or the other way from March 11 to March 31 on twelve different countries, USA, Italy, Spain, Germany, China, France, UK, Switzerland, Belgium, Netherland, and Australia.", [["a sentiment analysis", "TEST", 19, 39], ["COVID19", "TREATMENT", 65, 72]]], ["They found that while most of the countries are taking a positive attitude towards this situation, there is also negative emotion such as fear, sadness present among people.", [["people", "ORGANISM", 166, 172], ["people", "SPECIES", 166, 172], ["sadness", "PROBLEM", 144, 151]]], ["(Rajput et al., 2020) Made a statistical analysis of Twitter data posted during this Coronavirus outbreak.", [["this Coronavirus outbreak", "PROBLEM", 80, 105]]], ["The number of tweet ids tweeting about coronavirus rose rapidly making several peaks during February and March.", [["coronavirus", "ORGANISM", 39, 50], ["coronavirus", "PROBLEM", 39, 50]]], ["An empirical analysis of words in the messages showed that the most frequent words were Coronavirus, Covid19, and Wuhan.", [["An empirical analysis", "TEST", 0, 21], ["Coronavirus", "PROBLEM", 88, 99]]], ["The immense number of tweet messages within a period of 2-3 months and the frequency of these words clearly show the threats the global population is exposed to.", [["immense", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18]]], ["(Abd-Alrazaq et al., 2020) Aimed to identify the main topics posted by Twitter users related to the COVID-19 pandemic between February 2, 2020, and March 15, 2020.", [["Abd", "ANATOMY", 1, 4]]], ["Users on Twitter discussed 12 main topics related to COVID-19 that were grouped into four main themes, 1) the origin of the virus; 2) its sources; 3) its impact on people, countries, and the economy that were represented by six topics: deaths, fear, and stress, travel bans and warnings, economic losses, panic, increased racism, and 4) the last theme was ways of mitigating the risk of infection.", [["deaths", "DISEASE", 236, 242], ["panic", "DISEASE", 305, 310], ["infection", "DISEASE", 387, 396], ["people", "ORGANISM", 164, 170], ["people", "SPECIES", 164, 170], ["the virus", "PROBLEM", 120, 129], ["fear", "PROBLEM", 244, 248], ["stress", "PROBLEM", 254, 260], ["economic losses", "PROBLEM", 288, 303], ["panic", "PROBLEM", 305, 310], ["infection", "PROBLEM", 387, 396], ["virus", "OBSERVATION", 124, 129], ["infection", "OBSERVATION", 387, 396]]], ["(Cinelli et al., 2020 ) ran a comparative analysis of five different social media platforms Twitter, Instagram, YouTube, Reddit, and Gab about information diffusion about COVID-19.", [["a comparative analysis", "TEST", 28, 50], ["COVID", "TEST", 171, 176]]], ["Their analysis suggests that information spread depends on the interaction pattern of users engaged with the topic rather than how reliable the information is.", [["Their analysis", "TEST", 0, 14]]], ["(Samuel and Ali) Identified public sentiment using coronavirus specific tweets and provided insights on how fear sentiment evolved over time specially when COVID-19 hit the peak levels in the United States.", [["coronavirus", "ORGANISM", 51, 62], ["coronavirus", "PROBLEM", 51, 62], ["COVID", "TEST", 156, 161], ["Ali", "ANATOMY", 12, 15]]], ["As they classified tweets using sentiment analysis, the fear sentiment, which was the most dominant emotion across the entire tweets and by the end of march its seriousness became clearly evident as the fear curve showed a steep rise.DatasetWe used data from multiple sources.", [["sentiment analysis", "TEST", 32, 50], ["the fear curve", "TEST", 199, 213], ["a steep rise", "PROBLEM", 221, 233]]], ["The primary source of this analysis is the social platform Twitter.", [["this analysis", "TEST", 22, 35]]], ["We used the Python library Tweepy 2 (Roesslein, 2009 ) and Twitter developers API 3 for collecting the tweet data from Twitter.", [["the Python library Tweepy", "TREATMENT", 8, 33]]], ["We used a unique Twitter dataset, which is specifically collected for this study using a date range from May 3, 2020, to May 15, 2020.", [["Twitter dataset", "DNA", 17, 32], ["this study", "TEST", 70, 80]]], ["Tweets were extracted using the hashtags: #covid19, #covid, #corona, #coronaviras, #corona-virus, #covid19-virus, and #sarscov2.", [["#coronaviras", "ORGANISM", 69, 81], ["#corona-virus", "ORGANISM", 83, 96], ["#covid19-virus", "ORGANISM", 98, 112], ["covid19", "TREATMENT", 43, 50], ["covid", "TREATMENT", 53, 58], ["corona", "TREATMENT", 61, 67], ["coronaviras", "TEST", 70, 81], ["corona-virus", "TREATMENT", 84, 96], ["#covid19-virus", "TREATMENT", 98, 112], ["sarscov2", "TREATMENT", 119, 127]]], ["It contains country and statewise daily new cases, recovered and death data of COVID-19.MethodologyIn this section, we will describe the data preprocessing, and the experimental setup for sentiment and emotion analysis.Data PreprocessingThe data we used from the Twitter post between May 3-15, 2020 is noisy and unstructured text in nature.", [["death", "DISEASE", 65, 70], ["death data", "TEST", 65, 75], ["COVID", "TEST", 79, 84], ["the data preprocessing", "TEST", 133, 155], ["emotion analysis", "TEST", 202, 218]]], ["Therefore, we applied the following preprocessing steps to clean the raw tweet.Data Preprocessing\u2022 URL and Email: Removing URLs and emails from tweets using regular expression. \u2022 Mention and Tagging: Removing mentions (@ symbol and word after @ symbol) and hashtags (only # symbol) from tweets using regular expression. \u2022 Noisy Words: Removing irrelevant words (i.e.Data PreprocessingRT, &) after manual inspection, and stripping non-ASCII characters from the tweet. \u2022 Newline and Whitespace: Removing newlines and extra whitespaces from tweets.Data Preprocessing\u2022 US-reopen: In section 5.1 -5.3, we first filtered tweets by locations (States of US) and then selected tweets having word 'reopen'. \u2022 Stopwords and Gazetteers: In section 5.1 for most frequent words, we removed words from tweets that are found in the Python NLTK stopwords and gazetteers corpus 4 .", [["manual inspection", "TEST", 397, 414], ["newlines", "TREATMENT", 502, 510], ["US", "TEST", 565, 567]]], ["We also split the tweets into a list of words using the Python NLTK TweetTokenizer, and represent different forms of words to a single word using the Python NLTK WordNetLemmatizer (Loper and Bird, 2002) . \u2022 Multi-line Tweet: In section 5.2 for emotion analysis, we converted the multi-line tweet into a single-line tweet in order to use the corresponding APIs.Sentiment AnalysisWe used the Python library TextBlob (Loria, 2018) for finding the sentiments from tweets.", [["multi-line tweet", "CELL_LINE", 279, 295], ["emotion analysis", "TEST", 244, 260], ["the multi-line", "TREATMENT", 275, 289], ["a single-line tweet", "TREATMENT", 301, 320], ["the corresponding APIs", "TREATMENT", 337, 359]]], ["In TextBlob, sentiments of tweets are analyzed in two perspectives: (1) Polarity and (2) Subjectivity.Sentiment AnalysisBased on tweets, this library returns the polarity score and subjectivity score.", [["subjectivity score", "PROBLEM", 181, 199]]], ["Polarity score is float value within the range [-1 to 1] where 0 indicates Neutral sentiments, the positive score represents Positive sentiments and the negative score represents Negative sentiments.", [["Polarity score", "TEST", 0, 14], ["float value", "TEST", 18, 29], ["the positive score", "PROBLEM", 95, 113], ["Positive sentiments", "OBSERVATION", 125, 144], ["Negative sentiments", "OBSERVATION", 179, 198]]], ["Subjectivity score is also a float value within the range [0 to 1] where 0 indicates that it is a Fact and other values indicate the public opinions.Emotion AnalysisWe used the Python implementation of IBM Watson Tone Analyzer service 5 to detect emotional tones in tweets.", [["Subjectivity score", "TEST", 0, 18]]], ["The ToneAnalyses API uses the general-purpose endpoint to analyze the emotional tones of a tweet and reports the following seven tones: analytical, tentative, confident, joy, fear, sadness, and anger.", [["The ToneAnalyses API", "TEST", 0, 20], ["sadness", "PROBLEM", 181, 188]]], ["The emotion detection process is summarized as following steps:Emotion Analysis\u2022 Create a Tone Analyzer service in IBM Cloud for a specific region and API plan. \u2022 Get the API key, the service endpoint URL, and the version of API. \u2022 Authenticate to the API using IBM Cloud Identity and Access Management (IAM). \u2022 Request up to 100 sentences (no more than 128 KB size in total) for the sentence-level tone analysis. \u2022 Parse the JSON responses that provide the results for each sentence of the tweet.Emotion AnalysisHere for our analysis, the ToneAnalyses requires a tweet as a single sentence for detecting sentence-level emotional tones.Results and AnalysisIn this paper, we seek to answer the following research questions.Results and Analysis\u2022 RQ1: What are the most frequent words?Results and Analysis\u2022 RQ2: What are the trends of sentiment?Results and Analysis\u2022 RQ3: What are the trends of emotion?Results and Analysis\u2022 RQ4: What are the effects of reopening?Word Cloud RepresentationThe tweets were organized into word clouds to analyze which words have been frequently used by Twitter users around the world.", [["KB", "CANCER", 358, 360], ["ToneAnalyses", "DNA", 540, 552], ["Emotion Analysis", "TEST", 63, 79], ["the sentence", "TEST", 380, 392], ["level tone analysis", "TEST", 393, 412], ["Emotion Analysis", "TEST", 497, 513], ["our analysis", "TEST", 522, 534]]], ["As word cloud visualization consists of the size and visual emphasis of words being weighted by their frequency of occurrence in the textual corpus, we can get insights from the most frequent words occurring.", [["corpus", "ORGAN", 141, 147], ["word cloud visualization", "TEST", 3, 27], ["size", "OBSERVATION_MODIFIER", 44, 48]]], ["From figure 1a , we can see that along with the words 'COVID', 'corona', or 'virus', words like 'new', and 'cases' got a large number of mentions.", [["corona'", "ANATOMY", 64, 71], ["corona'", "CELLULAR_COMPONENT", 64, 71], ["large", "OBSERVATION_MODIFIER", 121, 126]]], ["No wonder the rising number of new cases everyday around the world contribute to the good number of mentions of these words.", [["rising", "OBSERVATION_MODIFIER", 14, 20], ["number", "OBSERVATION_MODIFIER", 21, 27], ["new", "OBSERVATION_MODIFIER", 31, 34]]], ["Our main goal is to see the effect of reopening in our analysis that's why we also investigate the most frequent words used in reopen related tweets.", [["reopening", "TREATMENT", 38, 47]]], ["Few tweets are 'Protesting to reopen the economy', 'reopen the economy against shelter in place which is a false choice', 'As schools make plans to reopen after #COVID19 shutdowns, how should we proceed?', 'Any rush to reopen without adequate testing and tracing will cause a resurgence.', 'As we reopen shuttered offices and buildings, there is a danger of an outbreak of Legionnaire disease'.", [["Legionnaire disease", "DISEASE", 373, 392], ["adequate testing", "TEST", 234, 250], ["Legionnaire disease", "PROBLEM", 373, 392], ["Legionnaire disease", "OBSERVATION", 373, 392]]], ["From these few tweets, we can see that few people are protesting to reopen, but most of the people are concerned about the reopening timing, aftermath of reopening, and thinking about the precaution measures needed after reopening.N-gram RepresentationWe searched for the most frequent words that appeared in twitter posts of our collected data.", [["people", "ORGANISM", 43, 49], ["people", "ORGANISM", 92, 98], ["people", "SPECIES", 43, 49], ["people", "SPECIES", 92, 98], ["the precaution measures", "TREATMENT", 184, 207], ["our collected data", "TEST", 326, 344], ["few", "OBSERVATION_MODIFIER", 11, 14], ["tweets", "OBSERVATION", 15, 21]]], ["The top 15 most frequent chunks, known as n-gram, are shown in Table 1 economic breakdown and necessity to overcome this situation through reopen.", [["Table 1 economic breakdown", "PROBLEM", 63, 89], ["economic", "OBSERVATION_MODIFIER", 71, 79], ["breakdown", "OBSERVATION", 80, 89]]], ["The 'plan', 'case', 'testing', and 'phase' surely emphasize the safety measures that need to be followed while reopening as a control measure.", [["the safety measures", "TREATMENT", 60, 79]]], ["The 'state' and 'people' surely stands for how all states beginning to reopen in some way.", [["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23]]], ["The 'testing site', 'public health', and 'task force' imply the safety measures people and policymakers should abide by to curb the spread during the reopen situation.", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86]]], ["The 'state begin', 'small business', 'back work', and 'business begin' indicate as people are going to resume their work after states are reopening.N-gram RepresentationFrom 3-grams, the economic breakdown, stockmarket fluctuation, business plan, and training course are the topic that draws our attention.", [["people", "ORGANISM", 83, 89], ["people", "SPECIES", 83, 89], ["the economic breakdown", "PROBLEM", 183, 205], ["economic", "OBSERVATION_MODIFIER", 187, 195], ["breakdown", "OBSERVATION_MODIFIER", 196, 205]]], ["This surely indicates there were numerous posts about how the loss due to this pandemic can be overcome through the strategy of the people who are in charge of the decisions.RQ2: Emotion AnalysisFrom figure 2a, we can see that the highest percentage of emotional tone is 'Analytical'(34.7%).", [["people", "ORGANISM", 132, 138], ["RQ2", "DNA", 174, 177], ["people", "SPECIES", 132, 138], ["the loss", "PROBLEM", 58, 66], ["Emotion Analysis", "TEST", 179, 195], ["numerous", "OBSERVATION_MODIFIER", 33, 41], ["posts", "OBSERVATION", 42, 47]]], ["'Anger' and 'Fear' had the lowest percentage in our data collection.RQ2: Emotion AnalysisThe 'Analytical' tone implies that people shared information and their constructive thoughts through their posts.", [["people", "ORGANISM", 124, 130], ["RQ2", "DNA", 68, 71], ["people", "SPECIES", 124, 130], ["Emotion Analysis", "TEST", 73, 89]]], ["'Joy' implies that people showed a positive attitude towards the situation.", [["people", "ORGANISM", 19, 25], ["people", "SPECIES", 19, 25]]], ["(Samuel and Ali) showed that towards the end of March the 'Fear' emotion was the most dominant among all emotions and hit a peak.", [["Ali", "ANATOMY", 12, 15]]], ["But after the announcement of the lockdown easement program people had less fear.RQ2: Emotion AnalysisFrom figure 2b, we can see that, during May 13-15, 'Anger', 'Sadness' and 'Analytical' had high peaks.", [["people", "ORGANISM", 60, 66], ["RQ2", "DNA", 81, 84], ["people", "SPECIES", 60, 66], ["Emotion Analysis", "TEST", 86, 102], ["high peaks", "PROBLEM", 193, 203]]], ["The rest emotional tones 'Confident', 'Joy', 'Tentative', and 'Fear' had a steady curve during the time period of our data collection.RQ3: Sentiment AnalysisSentiment analysis identies words contextual polarity and subjectivity.", [["RQ3", "DNA", 134, 137], ["a steady curve", "PROBLEM", 73, 87], ["Sentiment AnalysisSentiment analysis", "TEST", 139, 175]]], ["We used Python library TextBlob (Loria, 2018) for sentiment analysis.", [["sentiment analysis", "TEST", 50, 68]]], ["The details of TextBlob is available in section 4.", [["TextBlob", "DNA", 15, 23]]], ["Fig. 3a corresponds to the barplot of sentiment polarities of tweets and Fig. 3b corresponds to the daily counts of polarities.", [["Fig", "OBSERVATION_MODIFIER", 73, 76]]], ["So, people are taking the reopen decision positively.", [["people", "ORGANISM", 4, 10], ["people", "SPECIES", 4, 10]]], ["Fig. 3c indicates that people are mostly posting their own opinion and Fig. 3d shows an interesting point that day by day people are posting their own opinion rather than facts.RQ4: Effect of ReopenWe saw that many peoples are protesting for reopening states and countries.", [["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29], ["people", "SPECIES", 122, 128]]], ["We investigated the reopening effect in the United States.", [["reopening effect", "OBSERVATION", 20, 36]]], ["Fig. 4(a) and (b), shows that after reopening the new COVID19 cases are increasing.", [["new", "OBSERVATION_MODIFIER", 50, 53], ["increasing", "OBSERVATION_MODIFIER", 72, 82]]], ["On the other hand, Fig. 4(c) and (d), shows that lockdown helps to reduce the number of new COVID19 cases.", [["COVID19", "GENE_OR_GENE_PRODUCT", 92, 99]]], ["It would be better if the lockdown continues for few more days or if the states or country decide to reopen, then they can take proper precautions before the reopen and people need to strictly maintain the instructions from health organizations.Threats to ValidityThe followings are the main challenges and threats to the validity of our study.", [["people", "ORGANISM", 169, 175], ["people", "SPECIES", 169, 175], ["proper precautions", "TREATMENT", 128, 146], ["our study", "TEST", 334, 343], ["main", "OBSERVATION_MODIFIER", 287, 291]]], ["Therefore, our results may not reflect the actual effect.", [["may not reflect", "UNCERTAINTY", 23, 38]]], ["We leave the large scale evaluation as future work.Threats to ValidityNoisy Data.", [["the large scale evaluation", "TEST", 9, 35]]], ["The dataset contains posts from social media (i.e. Twitter) that are noisy and unstructured.Threats to ValidityHaving mis-spelling and unknown words are also common in the post.", [["mis-spelling", "PROBLEM", 118, 130]]], ["Additionally, the dataset contains other languages but written using the English alphabet that can negatively impact the analysis.", [["the analysis", "TEST", 117, 129]]], ["There are many posts whose length is very small (i.e. around 3 words).", [["many", "OBSERVATION_MODIFIER", 10, 14], ["posts", "OBSERVATION_MODIFIER", 15, 20], ["length", "OBSERVATION_MODIFIER", 27, 33], ["very", "OBSERVATION_MODIFIER", 37, 41], ["small", "OBSERVATION_MODIFIER", 42, 47]]], ["Therefore, dataset clean-ing is challenging and important as it has a direct impact on the analysis.", [["dataset clean", "TREATMENT", 11, 24], ["the analysis", "TEST", 87, 99], ["clean", "OBSERVATION", 19, 24]]], ["Internal Validity.", [["Validity", "OBSERVATION", 9, 17]]], ["We used some open source toolchains in this paper and some issues may exist in those APIs.", [["some open source toolchains", "TREATMENT", 8, 35]]], ["However, to reduce the issue in our implementation, other collaborators reviewed the code and manually inspected some results.ConclusionIn this work, we try to get insights into public reaction as the reopen phase starts.", [["public reaction", "PROBLEM", 178, 193]]], ["There has been Figure 4 : Effect of reopen.", [["reopen", "TREATMENT", 36, 42]]], ["We used two kinds of shaded regions to indicate the lockdown and reopen times: red shaded area represents the lockdown period, and the green shaded area represents the reopen period. some analysis from social media data about how people are reacting in the lockdown time.", [["people", "ORGANISM", 230, 236], ["people", "SPECIES", 230, 236], ["red shaded area", "PROBLEM", 79, 94], ["the green shaded area", "PROBLEM", 131, 152], ["some analysis", "PROBLEM", 183, 196], ["green shaded", "OBSERVATION_MODIFIER", 135, 147]]], ["We make an effort to understand whether there is a change in public sentiment from the lockdown phase to the reopen phase.", [["a change in public sentiment", "PROBLEM", 49, 77]]], ["We have made our analysis on Twitter data on reopening related issues during this COVID-19 outbreak.", [["our analysis", "TEST", 13, 25], ["reopening related issues", "PROBLEM", 45, 69], ["this COVID", "TEST", 77, 87]]], ["From our analysis, we have found that even though people are showing a positive attitude to reopen their areas to make the economy functional, they are also urging the authority in concern to make plans for avoiding the highly predictable second wave.", [["people", "ORGANISM", 50, 56], ["people", "SPECIES", 50, 56], ["our analysis", "TEST", 5, 17]]], ["From real data, we have seen that the new cases are increasing as the reopen phase starts.", [["new", "OBSERVATION_MODIFIER", 38, 41]]], ["Given this situation, the coordination of responses from online and from the real world is sure to reveal promising results to address the current crisis.", [["the current crisis", "PROBLEM", 135, 153]]], ["We want to put stress on the fact that along with traditional public health surveillance, infoveillance studies can play a vital role.", [["infoveillance studies", "TEST", 90, 111]]]], "d54daf4017c2d23a069f2379e74b286b645921d0": [["Introductionhas been associated with hyper-inflammation, coagulopathy and also a high thrombotic risk in critically unwell patients [1, 2] .", [["hyper-inflammation", "DISEASE", 37, 55], ["coagulopathy", "DISEASE", 57, 69], ["thrombotic", "DISEASE", 86, 96], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["hyper-inflammation", "PROBLEM", 37, 55], ["coagulopathy", "PROBLEM", 57, 69], ["a high thrombotic risk", "PROBLEM", 79, 101], ["inflammation", "OBSERVATION", 43, 55], ["coagulopathy", "OBSERVATION", 57, 69], ["high", "OBSERVATION_MODIFIER", 81, 85], ["thrombotic", "OBSERVATION_MODIFIER", 86, 96]]], ["Previously we have found a cumulative incidence of 30% for arterial and venous thrombosis on the intensive care unit (ICU) at our hospital for COVID-19 patients [3] .", [["arterial", "ANATOMY", 59, 67], ["venous", "ANATOMY", 72, 78], ["arterial and venous thrombosis", "DISEASE", 59, 89], ["arterial", "MULTI-TISSUE_STRUCTURE", 59, 67], ["venous", "MULTI-TISSUE_STRUCTURE", 72, 78], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["arterial and venous thrombosis", "PROBLEM", 59, 89], ["COVID", "TEST", 143, 148], ["arterial", "ANATOMY", 59, 67], ["venous", "ANATOMY", 72, 78], ["thrombosis", "OBSERVATION", 79, 89]]], ["This figure is comparable to other published series of critically unwell patients [4] [5] [6] [7] .", [["patients", "ORGANISM", 73, 81], ["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 82, 97], ["patients", "SPECIES", 73, 81]]], ["In an autopsy series pulmonary embolism and microvascular thrombosis was described in patients that had died from COVID-19 [8] .", [["pulmonary", "ANATOMY", 21, 30], ["microvascular", "ANATOMY", 44, 57], ["pulmonary embolism", "DISEASE", 21, 39], ["microvascular thrombosis", "DISEASE", 44, 68], ["COVID-19", "CHEMICAL", 114, 122], ["pulmonary", "ORGAN", 21, 30], ["microvascular", "MULTI-TISSUE_STRUCTURE", 44, 57], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["pulmonary embolism", "PROBLEM", 21, 39], ["microvascular thrombosis", "PROBLEM", 44, 68], ["COVID", "TEST", 114, 119], ["autopsy", "OBSERVATION", 6, 13], ["pulmonary", "ANATOMY", 21, 30], ["embolism", "OBSERVATION", 31, 39], ["microvascular", "ANATOMY", 44, 57], ["thrombosis", "OBSERVATION", 58, 68]]], ["There is a report from an intensive care unit (ICU) cohort of COVID-19 patients that has demonstrated that patients on a therapeutic dose of LMWH, as primary thromboprophylaxis, may develop thrombosis despite this escalated dose; the authors found a cumulative incidence for venous thromboembolism (VTE) of 56% in those patients [9] .", [["venous", "ANATOMY", 275, 281], ["LMWH", "CHEMICAL", 141, 145], ["thrombosis", "DISEASE", 190, 200], ["venous thromboembolism", "DISEASE", 275, 297], ["VTE", "DISEASE", 299, 302], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 107, 115], ["LMWH", "SIMPLE_CHEMICAL", 141, 145], ["venous", "PATHOLOGICAL_FORMATION", 275, 281], ["patients", "ORGANISM", 320, 328], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 320, 328], ["LMWH", "TREATMENT", 141, 145], ["primary thromboprophylaxis", "TREATMENT", 150, 176], ["thrombosis", "PROBLEM", 190, 200], ["this escalated dose", "TREATMENT", 209, 228], ["venous thromboembolism", "PROBLEM", 275, 297], ["VTE", "TEST", 299, 302], ["LMWH", "OBSERVATION", 141, 145], ["thrombosis", "OBSERVATION", 190, 200], ["venous", "ANATOMY", 275, 281], ["thromboembolism", "OBSERVATION", 282, 297]]], ["There is therefore concern that thrombosis is a significant pathological mechanism of COVID- 19 .", [["thrombosis", "DISEASE", 32, 42], ["COVID- 19", "CHEMICAL", 86, 95], ["thrombosis", "PROBLEM", 32, 42], ["COVID", "TEST", 86, 91], ["thrombosis", "OBSERVATION", 32, 42], ["significant", "OBSERVATION_MODIFIER", 48, 59]]], ["In light of this we aimed to review the clinical and laboratory evidence for heparin resistance in patients with COVID-19 at our intensive care unit.MethodsThis was a retrospective study of patients with COVID-19 admitted to the ICU at Addenbrooke's Hospital from 1st March 2020 until 21st April 2020 with COVID-19 confirmed by polymerase chain reaction swab of the respiratory tract.", [["respiratory tract", "ANATOMY", 366, 383], ["heparin", "CHEMICAL", 77, 84], ["COVID-19", "CHEMICAL", 113, 121], ["heparin", "SIMPLE_CHEMICAL", 77, 84], ["patients", "ORGANISM", 99, 107], ["patients", "ORGANISM", 190, 198], ["respiratory tract", "ORGANISM_SUBDIVISION", 366, 383], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 190, 198], ["heparin resistance", "TREATMENT", 77, 95], ["COVID", "TEST", 113, 118], ["a retrospective study", "TEST", 165, 186], ["COVID", "TEST", 306, 311], ["heparin resistance", "OBSERVATION", 77, 95], ["respiratory tract", "ANATOMY", 366, 383]]], ["This study had full institutional approval from the Trust research and development department.", [["This study", "TEST", 0, 10]]], ["The medical notes (Epic, WI, USA) were interrogated and statistical analysis was performed using Microsoft Excel 2010 (Microsoft, Redmond, WA, USA).", [["statistical analysis", "TEST", 56, 76]]], ["A p-value of 0.05 was considered significant.", [["A p-value", "TEST", 0, 9]]], ["Patient records were identified that had therapeutic anticoagulation with either subcutaneous LMWH (dalteparin, Pfizer, UK, was the only LMWH used) or intravenous unfractionated heparin (UFH) (Wockhardt UK, UK).", [["subcutaneous", "ANATOMY", 81, 93], ["intravenous", "ANATOMY", 151, 162], ["LMWH", "CHEMICAL", 94, 98], ["dalteparin", "CHEMICAL", 100, 110], ["heparin", "CHEMICAL", 178, 185], ["UFH", "CHEMICAL", 187, 190], ["dalteparin", "CHEMICAL", 100, 110], ["LMWH", "SIMPLE_CHEMICAL", 94, 98], ["dalteparin", "SIMPLE_CHEMICAL", 100, 110], ["Pfizer", "SIMPLE_CHEMICAL", 112, 118], ["intravenous unfractionated heparin", "SIMPLE_CHEMICAL", 151, 185], ["UFH", "SIMPLE_CHEMICAL", 187, 190], ["Patient", "SPECIES", 0, 7], ["therapeutic anticoagulation", "TREATMENT", 41, 68], ["subcutaneous LMWH (dalteparin", "TREATMENT", 81, 110], ["LMWH", "TREATMENT", 137, 141], ["intravenous unfractionated heparin", "TREATMENT", 151, 185]]], ["Indications for anticoagulation included either radiologically proven venous thromboembolism or prophylaxis of filter thrombosis for patients receiving continuous haemodiafiltration.", [["venous", "ANATOMY", 70, 76], ["venous thromboembolism", "DISEASE", 70, 92], ["thrombosis", "DISEASE", 118, 128], ["venous", "MULTI-TISSUE_STRUCTURE", 70, 76], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["anticoagulation", "TREATMENT", 16, 31], ["radiologically proven venous thromboembolism", "PROBLEM", 48, 92], ["filter thrombosis", "PROBLEM", 111, 128], ["continuous haemodiafiltration", "TREATMENT", 152, 181], ["venous", "ANATOMY", 70, 76], ["thromboembolism", "OBSERVATION", 77, 92], ["filter thrombosis", "OBSERVATION", 111, 128]]], ["Heparin resistance was defined as requiring > 35,000 units of heparin per day for those on UFH [10] .", [["Heparin", "CHEMICAL", 0, 7], ["heparin", "CHEMICAL", 62, 69], ["UFH", "CHEMICAL", 91, 94], ["Heparin", "SIMPLE_CHEMICAL", 0, 7], ["heparin", "SIMPLE_CHEMICAL", 62, 69], ["Heparin resistance", "TREATMENT", 0, 18], ["heparin", "TREATMENT", 62, 69], ["UFH", "TREATMENT", 91, 94]]], ["For patients on LMWH expected anti-Xa was defined as a 2-4 h peak anti-Xa activity of 0.6-1.0 IU/mL for those on twice daily dosing and > 1.0 IU/mL for those on once daily dosing [11] .", [["patients", "ORGANISM", 4, 12], ["LMWH", "SIMPLE_CHEMICAL", 16, 20], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 30, 37], ["Xa", "GENE_OR_GENE_PRODUCT", 71, 73], ["anti-Xa", "PROTEIN", 30, 37], ["Xa", "PROTEIN", 71, 73], ["patients", "SPECIES", 4, 12], ["LMWH", "TREATMENT", 16, 20], ["anti-Xa", "TREATMENT", 30, 37], ["a 2-4 h peak anti-Xa activity", "TREATMENT", 53, 82]]], ["At our hospital an activated partial thromboplastin ratio (APTR, defined as the activated partial thromboplastin time (APTT) divided by the mean of the reference range) of 1.5-2.5 is used as a target for therapeutic UFH.", [["UFH", "CHEMICAL", 216, 219], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 37, 51], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 98, 112], ["UFH", "SIMPLE_CHEMICAL", 216, 219], ["APTT", "PROTEIN", 119, 123], ["an activated partial thromboplastin ratio (APTR", "TREATMENT", 16, 63], ["the activated partial thromboplastin time", "TREATMENT", 76, 117], ["APTT", "TEST", 119, 123], ["therapeutic UFH", "TREATMENT", 204, 219]]], ["Concordance of the APTR/anti-Xa (performed on the same sample) was defined as: (i) APTR 1.5-2.5 and paired anti-Xa 0.3-0.7 IU/mL (ii) APTR < 1.5 and anti-Xa < 0.3 IU/mL or (iii) APTR > 2.5 and anti-Xa > 0.7 IU/mL.", [["APTR", "GENE_OR_GENE_PRODUCT", 19, 23], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 24, 31], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 107, 114], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 149, 156], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 193, 200], ["APTR", "PROTEIN", 19, 23], ["anti-Xa", "PROTEIN", 24, 31], ["Xa", "PROTEIN", 112, 114], ["Xa", "PROTEIN", 154, 156], ["Xa", "PROTEIN", 198, 200], ["the APTR/anti-Xa", "TREATMENT", 15, 31], ["APTR", "TEST", 83, 87], ["Xa", "TEST", 112, 114], ["APTR", "TEST", 134, 138], ["anti-Xa", "TEST", 149, 156], ["APTR", "TEST", 178, 182], ["anti-Xa", "TEST", 193, 200]]], ["An in-vitro LMWH spiking study was conducted on a convenience sample of ICU COVID-19 confirmed patients, sampled from the patients on ICU that 1 day, by spiking citrated plasma with 0.70 IU/mL dalteparin.", [["plasma", "ANATOMY", 170, 176], ["dalteparin", "CHEMICAL", 193, 203], ["dalteparin", "CHEMICAL", 193, 203], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 122, 130], ["citrated", "ORGANISM_SUBSTANCE", 161, 169], ["plasma", "ORGANISM_SUBSTANCE", 170, 176], ["dalteparin", "SIMPLE_CHEMICAL", 193, 203], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 122, 130], ["vitro LMWH spiking study", "TEST", 6, 30], ["ICU COVID", "TEST", 72, 81], ["spiking citrated plasma", "TREATMENT", 153, 176], ["dalteparin", "TREATMENT", 193, 203]]], ["Baseline antithrombin (Stago, France), One-stage factor VIII (FVIII:C1), Clauss fibrinogen and anti-Xa (Werfen, UK) were assessed using the ACL TOP 750 (Werfen, UK) prior to spiking.", [["antithrombin", "GENE_OR_GENE_PRODUCT", 9, 21], ["One-stage factor VIII", "GENE_OR_GENE_PRODUCT", 39, 60], ["FVIII:C1", "GENE_OR_GENE_PRODUCT", 62, 70], ["Clauss fibrinogen", "GENE_OR_GENE_PRODUCT", 73, 90], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 95, 102], ["antithrombin", "PROTEIN", 9, 21], ["One-stage factor VIII", "PROTEIN", 39, 60], ["FVIII", "PROTEIN", 62, 67], ["C1", "PROTEIN", 68, 70], ["Clauss fibrinogen", "PROTEIN", 73, 90], ["anti-Xa", "PROTEIN", 95, 102], ["Baseline antithrombin (Stago", "PROBLEM", 0, 28], ["One-stage factor VIII", "TEST", 39, 60], ["Clauss fibrinogen", "TEST", 73, 90], ["anti-Xa", "TREATMENT", 95, 102], ["the ACL TOP", "TREATMENT", 136, 147], ["antithrombin", "OBSERVATION", 9, 21]]], ["Exogenous antithrombin is not added to this anti-Xa assay.", [["antithrombin", "GENE_OR_GENE_PRODUCT", 10, 22], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 44, 51], ["antithrombin", "PROTEIN", 10, 22], ["anti-Xa", "PROTEIN", 44, 51], ["Exogenous antithrombin", "TREATMENT", 0, 22], ["this anti-Xa assay", "TEST", 39, 57], ["antithrombin", "OBSERVATION", 10, 22]]], ["Once spiked, the anti-Xa was reassessed immediately post spiking then at hourly intervals for 3 h.", [["anti-Xa", "GENE_OR_GENE_PRODUCT", 17, 24], ["anti-Xa", "PROTEIN", 17, 24], ["the anti-Xa", "TREATMENT", 13, 24]]], ["In-vitro recovery of the anti-Xa was determined by spiking a commercial pool of normal pooled plasma (Cryocheck, Precision Biologic, USA) to a target concentration of 0.70 IU/mL with dalteparin.", [["plasma", "ANATOMY", 94, 100], ["dalteparin", "CHEMICAL", 183, 193], ["dalteparin", "CHEMICAL", 183, 193], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 25, 32], ["plasma", "ORGANISM_SUBSTANCE", 94, 100], ["dalteparin", "SIMPLE_CHEMICAL", 183, 193], ["anti-Xa", "PROTEIN", 25, 32], ["the anti-Xa", "TREATMENT", 21, 32], ["dalteparin", "TREATMENT", 183, 193]]], ["The normal pooled plasma anti-Xa after spiking, with the deduction of the baseline anti-Xa, was defined as a 100% recovery of anti-Xa activity.", [["plasma", "ANATOMY", 18, 24], ["plasma", "ORGANISM_SUBSTANCE", 18, 24], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 25, 32], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 83, 90], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 126, 133], ["Xa", "PROTEIN", 30, 32], ["Xa", "PROTEIN", 88, 90], ["anti-Xa", "PROTEIN", 126, 133], ["anti-Xa activity", "TREATMENT", 126, 142], ["normal", "OBSERVATION", 4, 10]]], ["The process was repeated with 12 ICU COVID-19 positive patient samples.", [["samples", "ANATOMY", 63, 70], ["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62]]], ["Patient recovery was reported relative to that of the reference recovery from the normal pooled plasma.", [["plasma", "ANATOMY", 96, 102], ["Patient", "ORGANISM", 0, 7], ["plasma", "ORGANISM_SUBSTANCE", 96, 102], ["Patient", "SPECIES", 0, 7]]], ["In-vitro recovery = (observed increase in anti-Xa activity of patient sample from baseline/observed increased in anti-Xa activity of normal pooled plasma from baseline) \u00d7 100.Clinical evaluation of ICU patientsIn total 69 patients have been admitted with COVID-19 to the ICU in the study period and 15 patients were identified that had received therapeutic anticoagulation with either LMWH or UFH.", [["plasma", "ANATOMY", 147, 153], ["LMWH", "CHEMICAL", 385, 389], ["UFH", "CHEMICAL", 393, 396], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 42, 49], ["patient", "ORGANISM", 62, 69], ["Xa", "GENE_OR_GENE_PRODUCT", 118, 120], ["plasma", "ORGANISM_SUBSTANCE", 147, 153], ["patients", "ORGANISM", 202, 210], ["patients", "ORGANISM", 222, 230], ["patients", "ORGANISM", 302, 310], ["LMWH", "SIMPLE_CHEMICAL", 385, 389], ["UFH", "SIMPLE_CHEMICAL", 393, 396], ["Xa", "PROTEIN", 47, 49], ["Xa", "PROTEIN", 118, 120], ["patient", "SPECIES", 62, 69], ["patients", "SPECIES", 202, 210], ["patients", "SPECIES", 222, 230], ["patients", "SPECIES", 302, 310], ["anti-Xa activity", "TREATMENT", 42, 58], ["anti-Xa activity", "TREATMENT", 113, 129], ["Clinical evaluation", "TEST", 175, 194], ["COVID", "TEST", 255, 260], ["therapeutic anticoagulation", "TREATMENT", 345, 372], ["LMWH", "TREATMENT", 385, 389], ["UFH", "TREATMENT", 393, 396], ["UFH", "OBSERVATION", 393, 396]]], ["The characteristics of these 15 patients are summarised in Table 1 ; one patient in the group received LMWH (and no UFH) and did not have peak anti-Xa levels performed.", [["LMWH", "CHEMICAL", 103, 107], ["patients", "ORGANISM", 32, 40], ["patient", "ORGANISM", 73, 80], ["LMWH", "SIMPLE_CHEMICAL", 103, 107], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 143, 150], ["Xa", "PROTEIN", 148, 150], ["patients", "SPECIES", 32, 40], ["patient", "SPECIES", 73, 80], ["LMWH", "TREATMENT", 103, 107], ["UFH", "TREATMENT", 116, 119], ["peak anti-Xa levels", "TEST", 138, 157]]], ["Of the 10 infusions of UFH, 8 (80%) patients had heparin resistance (> 35,000 units/day) and of these 8 patients, 3 required > 50,000 units heparin per day to maintain the target APTR (not including the 5000 unit loading dose).", [["UFH", "CHEMICAL", 23, 26], ["heparin", "CHEMICAL", 49, 56], ["heparin", "CHEMICAL", 140, 147], ["UFH", "SIMPLE_CHEMICAL", 23, 26], ["patients", "ORGANISM", 36, 44], ["heparin", "SIMPLE_CHEMICAL", 49, 56], ["patients", "ORGANISM", 104, 112], ["heparin", "SIMPLE_CHEMICAL", 140, 147], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 104, 112], ["UFH", "TREATMENT", 23, 26], ["heparin resistance", "TREATMENT", 49, 67], ["heparin", "TREATMENT", 140, 147], ["the 5000 unit loading dose", "TREATMENT", 199, 225]]], ["In total 17 anti-Xa assays were performed as a pair with an APTR and the results from this are demonstrated in Fig. 1 .", [["anti-Xa", "GENE_OR_GENE_PRODUCT", 12, 19], ["Xa assays", "TEST", 17, 26], ["an APTR", "TEST", 57, 64]]], ["All patients on UFH had the APTR prolonged to > 1.5 in the first 24 h of starting the infusion.", [["UFH", "CHEMICAL", 16, 19], ["patients", "ORGANISM", 4, 12], ["UFH", "SIMPLE_CHEMICAL", 16, 19], ["patients", "SPECIES", 4, 12], ["UFH", "TREATMENT", 16, 19], ["the infusion", "TREATMENT", 82, 94]]], ["The APTR was concordant with the anti-Xa in 11/17 (73%) results.", [["APTR", "GENE_OR_GENE_PRODUCT", 4, 8], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 33, 40], ["APTR", "PROTEIN", 4, 8], ["anti-Xa", "PROTEIN", 33, 40]]], ["In total 7 patients received therapeutic LMWH (dalteparin) for management of venous thromboembolism, of which 5 patients had peak anti-Xa performed (after at least 3 doses and whilst still on ICU).", [["venous", "ANATOMY", 77, 83], ["LMWH", "CHEMICAL", 41, 45], ["dalteparin", "CHEMICAL", 47, 57], ["venous thromboembolism", "DISEASE", 77, 99], ["patients", "ORGANISM", 11, 19], ["LMWH", "SIMPLE_CHEMICAL", 41, 45], ["dalteparin", "SIMPLE_CHEMICAL", 47, 57], ["venous", "PATHOLOGICAL_FORMATION", 77, 83], ["patients", "ORGANISM", 112, 120], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 130, 137], ["Xa", "PROTEIN", 135, 137], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 112, 120], ["therapeutic LMWH", "TREATMENT", 29, 45], ["dalteparin", "TREATMENT", 47, 57], ["management", "TREATMENT", 63, 73], ["venous thromboembolism", "PROBLEM", 77, 99], ["peak anti-Xa", "TEST", 125, 137], ["venous", "ANATOMY", 77, 83], ["thromboembolism", "OBSERVATION", 84, 99]]], ["For the 3 patients on twice daily therapeutic LMWH regimens the peak was < 0.5 IU/mL in all cases and for the 2 patients on once daily LMWH regimens the peak levels were 0.82 and 0.46 IU/mL.", [["LMWH", "CHEMICAL", 46, 50], ["LMWH", "CHEMICAL", 135, 139], ["patients", "ORGANISM", 10, 18], ["LMWH", "SIMPLE_CHEMICAL", 46, 50], ["patients", "ORGANISM", 112, 120], ["LMWH", "SIMPLE_CHEMICAL", 135, 139], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 112, 120], ["therapeutic LMWH regimens", "TREATMENT", 34, 59], ["daily LMWH regimens", "TREATMENT", 129, 148], ["the peak levels", "TEST", 149, 164]]], ["There was no association of heparin resistance with smoking (p = 1.00, Fisher exact test) and no patients had COPD; both previously identified risk factors for heparin resistance [12] .", [["heparin", "CHEMICAL", 28, 35], ["smoking", "CHEMICAL", 52, 59], ["COPD", "DISEASE", 110, 114], ["heparin", "CHEMICAL", 160, 167], ["heparin", "SIMPLE_CHEMICAL", 28, 35], ["patients", "ORGANISM", 97, 105], ["heparin", "SIMPLE_CHEMICAL", 160, 167], ["patients", "SPECIES", 97, 105], ["heparin resistance", "PROBLEM", 28, 46], ["Fisher exact test", "TEST", 71, 88], ["COPD", "PROBLEM", 110, 114], ["heparin resistance", "TREATMENT", 160, 178], ["no association of", "UNCERTAINTY", 10, 27], ["heparin resistance", "OBSERVATION", 28, 46], ["COPD", "OBSERVATION", 110, 114]]], ["We are not aware of any of these patients having had a further thrombosis on therapeutic anticoagulation however systematic investigation for this has not occurred.Laboratory testing for heparin resistanceIn-vitro spiking, of 12 plasma ICU samples (3 of which came from patients in the cohort that had received therapeutic anticoagulation described above) from 1 day, showed a statistically significant decreased recovery of anti-Xa within 12/12 of the COVID19 patients assessed, p < 0.05 (t test), with the maximum recovery being 82% and the minimum recovery being 58% when compared with a calculated expected recovery.", [["plasma ICU samples", "ANATOMY", 229, 247], ["thrombosis", "DISEASE", 63, 73], ["heparin", "CHEMICAL", 187, 194], ["patients", "ORGANISM", 33, 41], ["heparin", "SIMPLE_CHEMICAL", 187, 194], ["plasma", "ORGANISM_SUBSTANCE", 229, 235], ["patients", "ORGANISM", 270, 278], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 425, 432], ["patients", "ORGANISM", 461, 469], ["Xa", "PROTEIN", 430, 432], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 270, 278], ["patients", "SPECIES", 461, 469], ["a further thrombosis", "PROBLEM", 53, 73], ["therapeutic anticoagulation", "TREATMENT", 77, 104], ["systematic investigation", "TEST", 113, 137], ["Laboratory testing", "TEST", 164, 182], ["heparin resistanceIn", "TREATMENT", 187, 207], ["plasma ICU samples", "TEST", 229, 247], ["therapeutic anticoagulation", "TREATMENT", 311, 338], ["anti-Xa", "TREATMENT", 425, 432], ["thrombosis", "OBSERVATION", 63, 73], ["significant", "OBSERVATION_MODIFIER", 391, 402], ["decreased", "OBSERVATION_MODIFIER", 403, 412], ["recovery", "OBSERVATION_MODIFIER", 413, 421]]], ["The anti-Xa remained stable in these patients post spiking for at least 3 h (data not shown).", [["anti-Xa", "GENE_OR_GENE_PRODUCT", 4, 11], ["patients", "ORGANISM", 37, 45], ["anti-Xa", "PROTEIN", 4, 11], ["patients", "SPECIES", 37, 45], ["The anti-Xa", "TREATMENT", 0, 11], ["stable", "OBSERVATION_MODIFIER", 21, 27]]], ["No correlation was observed between baseline factor VIII, antithrombin or Clauss fibrinogen with the anti-Xa recovery (data not shown).", [["factor VIII", "GENE_OR_GENE_PRODUCT", 45, 56], ["antithrombin", "GENE_OR_GENE_PRODUCT", 58, 70], ["Clauss fibrinogen", "GENE_OR_GENE_PRODUCT", 74, 91], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 101, 108], ["factor VIII", "PROTEIN", 45, 56], ["antithrombin", "PROTEIN", 58, 70], ["Clauss fibrinogen", "PROTEIN", 74, 91], ["Xa", "PROTEIN", 106, 108], ["antithrombin", "TREATMENT", 58, 70], ["Clauss fibrinogen", "TREATMENT", 74, 91]]], ["It is notable that these patients have grossly raised fibrinogen and factor VIII levels with mild decreases in the antithrombin ( Table 2 ).DiscussionThe rates of heparin resistance with intravenous UFH are high (80%) and are likely due to the effects of increased fibrinogen and factor VIII on the APTT, which has been described previously and acts to lower the APTT and as a risk factor for heparin resistance [12, 13] .", [["intravenous", "ANATOMY", 187, 198], ["heparin", "CHEMICAL", 163, 170], ["UFH", "CHEMICAL", 199, 202], ["heparin", "CHEMICAL", 393, 400], ["patients", "ORGANISM", 25, 33], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 54, 64], ["factor VIII", "GENE_OR_GENE_PRODUCT", 69, 80], ["antithrombin", "GENE_OR_GENE_PRODUCT", 115, 127], ["heparin", "SIMPLE_CHEMICAL", 163, 170], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 187, 198], ["UFH", "SIMPLE_CHEMICAL", 199, 202], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 265, 275], ["factor VIII", "GENE_OR_GENE_PRODUCT", 280, 291], ["APTT", "GENE_OR_GENE_PRODUCT", 299, 303], ["APTT", "GENE_OR_GENE_PRODUCT", 363, 367], ["heparin", "SIMPLE_CHEMICAL", 393, 400], ["fibrinogen", "PROTEIN", 54, 64], ["factor VIII", "PROTEIN", 69, 80], ["antithrombin", "PROTEIN", 115, 127], ["fibrinogen", "PROTEIN", 265, 275], ["factor VIII", "PROTEIN", 280, 291], ["APTT", "PROTEIN", 299, 303], ["APTT", "PROTEIN", 363, 367], ["patients", "SPECIES", 25, 33], ["grossly raised fibrinogen", "PROBLEM", 39, 64], ["factor VIII levels", "TEST", 69, 87], ["mild decreases", "PROBLEM", 93, 107], ["the antithrombin", "TREATMENT", 111, 127], ["heparin resistance", "TREATMENT", 163, 181], ["intravenous UFH", "TREATMENT", 187, 202], ["increased fibrinogen", "PROBLEM", 255, 275], ["factor VIII", "TREATMENT", 280, 291], ["the APTT", "TEST", 295, 303], ["the APTT", "TEST", 359, 367], ["heparin resistance", "TREATMENT", 393, 411], ["grossly", "OBSERVATION_MODIFIER", 39, 46], ["raised", "OBSERVATION_MODIFIER", 47, 53], ["fibrinogen", "OBSERVATION", 54, 64], ["mild", "OBSERVATION_MODIFIER", 93, 97], ["decreases", "OBSERVATION_MODIFIER", 98, 107], ["heparin resistance", "OBSERVATION", 163, 181], ["likely due to", "UNCERTAINTY", 226, 239], ["increased", "OBSERVATION_MODIFIER", 255, 264], ["fibrinogen", "OBSERVATION", 265, 275]]], ["Previously it has been recommended that the anti-Xa should be used for UFH monitoring and dosing however this was not proved to be beneficial over APTT monitoring when examined in a randomised control trial, though potentially lower doses of heparin would be needed [10, 14] .", [["UFH", "CHEMICAL", 71, 74], ["heparin", "CHEMICAL", 242, 249], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 44, 51], ["UFH", "SIMPLE_CHEMICAL", 71, 74], ["heparin", "SIMPLE_CHEMICAL", 242, 249], ["anti-Xa", "PROTEIN", 44, 51], ["APTT", "PROTEIN", 147, 151], ["the anti-Xa", "TREATMENT", 40, 51], ["UFH monitoring", "TEST", 71, 85], ["APTT monitoring", "TEST", 147, 162], ["a randomised control trial", "TREATMENT", 180, 206], ["heparin", "TREATMENT", 242, 249]]], ["In this study monitoring the heparin effect with anti-Xa for patients on UFH did not appear to add benefit to monitoring via the APTR, which is not unexpected as both measure the effects of heparin in plasma.", [["plasma", "ANATOMY", 201, 207], ["heparin", "CHEMICAL", 29, 36], ["UFH", "CHEMICAL", 73, 76], ["heparin", "CHEMICAL", 190, 197], ["heparin", "SIMPLE_CHEMICAL", 29, 36], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 49, 56], ["patients", "ORGANISM", 61, 69], ["UFH", "SIMPLE_CHEMICAL", 73, 76], ["heparin", "SIMPLE_CHEMICAL", 190, 197], ["plasma", "ORGANISM_SUBSTANCE", 201, 207], ["anti-Xa", "PROTEIN", 49, 56], ["patients", "SPECIES", 61, 69], ["this study", "TEST", 3, 13], ["the heparin effect", "TREATMENT", 25, 43], ["anti-Xa", "TREATMENT", 49, 56], ["UFH", "TREATMENT", 73, 76], ["the APTR", "TEST", 125, 133], ["heparin in plasma", "TREATMENT", 190, 207]]], ["Given the reasonable performance of the APTR against the anti-Xa assay and concordance in 73% of the paired samples then this could also suggest that higher heparin doses are required to ensure the anti-Xa is 0.3-0.7 IU/ mL.", [["samples", "ANATOMY", 108, 115], ["heparin", "CHEMICAL", 157, 164], ["APTR", "SIMPLE_CHEMICAL", 40, 44], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 57, 64], ["heparin", "SIMPLE_CHEMICAL", 157, 164], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 198, 205], ["APTR", "PROTEIN", 40, 44], ["Xa", "PROTEIN", 62, 64], ["Xa", "PROTEIN", 203, 205], ["the APTR", "TREATMENT", 36, 44], ["Xa assay", "TEST", 62, 70], ["concordance", "TEST", 75, 86], ["higher heparin doses", "TREATMENT", 150, 170], ["Xa", "TEST", 203, 205]]], ["In the small cohort of critically ill patients on LMWH with dose based on weight the anti-Xa levels indicate subtherapeutic levels per Garcia et al., 2012 [11] .", [["critically ill", "DISEASE", 23, 37], ["LMWH", "CHEMICAL", 50, 54], ["patients", "ORGANISM", 38, 46], ["LMWH", "SIMPLE_CHEMICAL", 50, 54], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 85, 92], ["Xa", "PROTEIN", 90, 92], ["patients", "SPECIES", 38, 46], ["LMWH", "TREATMENT", 50, 54], ["dose", "TREATMENT", 60, 64], ["weight", "TEST", 74, 80], ["the anti-Xa levels", "TEST", 81, 99], ["subtherapeutic levels", "PROBLEM", 109, 130], ["small", "OBSERVATION_MODIFIER", 7, 12], ["critically ill", "OBSERVATION_MODIFIER", 23, 37]]], ["We have demonstrated that ICU patients with COVID-19 have a decreased in-vitro recovery of anti-Xa activity compared to normal control plasma when spiked to therapeutic concentrations of LMWH; this did not correlate to either factor VIII, fibrinogen or antithrombin levels (data not shown).", [["plasma", "ANATOMY", 135, 141], ["LMWH", "CHEMICAL", 187, 191], ["COVID-19", "CHEMICAL", 44, 52], ["patients", "ORGANISM", 30, 38], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 91, 98], ["plasma", "ORGANISM_SUBSTANCE", 135, 141], ["LMWH", "SIMPLE_CHEMICAL", 187, 191], ["factor VIII", "GENE_OR_GENE_PRODUCT", 226, 237], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 239, 249], ["antithrombin", "GENE_OR_GENE_PRODUCT", 253, 265], ["Xa", "PROTEIN", 96, 98], ["factor VIII", "PROTEIN", 226, 237], ["fibrinogen", "PROTEIN", 239, 249], ["antithrombin", "PROTEIN", 253, 265], ["patients", "SPECIES", 30, 38], ["COVID", "TEST", 44, 49], ["anti-Xa activity", "TREATMENT", 91, 107], ["therapeutic concentrations of LMWH", "PROBLEM", 157, 191], ["factor VIII", "TEST", 226, 237], ["fibrinogen", "TEST", 239, 249], ["antithrombin levels", "TEST", 253, 272], ["decreased", "OBSERVATION_MODIFIER", 60, 69]]], ["Previously it has been shown that after 2500 units of dalteparin the anti-Xa activity is in ICU patients is approximately half of the value of that in healthy volunteers, and our findings are in accordance with that data [15] .DiscussionIn-vitro spiking of COVID patients with LMWH demonstrate a decreased recovery of anti-Xa; this further demonstrates heparin resistance within this subset of patients.", [["dalteparin", "CHEMICAL", 54, 64], ["LMWH", "CHEMICAL", 277, 281], ["heparin", "CHEMICAL", 353, 360], ["dalteparin", "CHEMICAL", 54, 64], ["dalteparin", "SIMPLE_CHEMICAL", 54, 64], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 69, 76], ["patients", "ORGANISM", 96, 104], ["volunteers", "ORGANISM", 159, 169], ["COVID", "ORGANISM", 257, 262], ["patients", "ORGANISM", 263, 271], ["LMWH", "SIMPLE_CHEMICAL", 277, 281], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 318, 325], ["heparin", "SIMPLE_CHEMICAL", 353, 360], ["patients", "ORGANISM", 394, 402], ["Xa", "PROTEIN", 74, 76], ["anti-Xa", "PROTEIN", 318, 325], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 263, 271], ["patients", "SPECIES", 394, 402], ["dalteparin", "TREATMENT", 54, 64], ["LMWH", "TREATMENT", 277, 281], ["anti-Xa", "TREATMENT", 318, 325], ["heparin resistance", "TREATMENT", 353, 371], ["decreased", "OBSERVATION_MODIFIER", 296, 305], ["heparin resistance", "OBSERVATION", 353, 371]]], ["The difference in recovery by patients suggests there is not a linear response to dosing of LMWH in these patients, when LMWH is known to have a linear dose-dependent response [16] .", [["LMWH", "CHEMICAL", 92, 96], ["LMWH", "CHEMICAL", 121, 125], ["patients", "ORGANISM", 30, 38], ["LMWH", "SIMPLE_CHEMICAL", 92, 96], ["patients", "ORGANISM", 106, 114], ["LMWH", "SIMPLE_CHEMICAL", 121, 125], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 106, 114], ["LMWH", "TREATMENT", 92, 96], ["LMWH", "TREATMENT", 121, 125], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["LMWH", "OBSERVATION", 92, 96]]], ["No correlation was found between the anti-Xa in-vitro recovery and antithrombin, factor VIII and fibrinogen levels however a combination of these factors may contribute to heparin resistance [17] .DiscussionSpiking of plasma was used to assess recovery of anti-Xa within COVID19 patients in comparison to a normal pool, to ensure commutability of the in-vitro spiking assessment.", [["plasma", "ANATOMY", 218, 224], ["heparin", "CHEMICAL", 172, 179], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 37, 44], ["antithrombin", "GENE_OR_GENE_PRODUCT", 67, 79], ["factor VIII", "GENE_OR_GENE_PRODUCT", 81, 92], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 97, 107], ["heparin", "SIMPLE_CHEMICAL", 172, 179], ["plasma", "ORGANISM_SUBSTANCE", 218, 224], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 256, 263], ["patients", "ORGANISM", 279, 287], ["Xa", "PROTEIN", 42, 44], ["antithrombin", "PROTEIN", 67, 79], ["factor VIII", "PROTEIN", 81, 92], ["fibrinogen", "PROTEIN", 97, 107], ["anti-Xa", "PROTEIN", 256, 263], ["patients", "SPECIES", 279, 287], ["antithrombin", "TREATMENT", 67, 79], ["factor VIII", "TEST", 81, 92], ["fibrinogen levels", "TEST", 97, 114], ["these factors", "PROBLEM", 140, 153], ["heparin resistance", "TREATMENT", 172, 190], ["anti-Xa", "TREATMENT", 256, 263]]], ["Dalteparin was used as it has been shown to be commutable to patient samples on comparison to UFH [18] .", [["samples", "ANATOMY", 69, 76], ["Dalteparin", "CHEMICAL", 0, 10], ["UFH", "CHEMICAL", 94, 97], ["Dalteparin", "CHEMICAL", 0, 10], ["Dalteparin", "SIMPLE_CHEMICAL", 0, 10], ["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["Dalteparin", "TREATMENT", 0, 10], ["UFH", "TEST", 94, 97]]], ["The ICU patients that had plasma samples spiked with heparin had elevated baseline anti-Xa as many are on UFH in haemodiafiltration circuits and because we are using escalated doses of prophylactic LMWH [3] .DiscussionThis study has limitations.", [["plasma samples", "ANATOMY", 26, 40], ["heparin", "CHEMICAL", 53, 60], ["UFH", "CHEMICAL", 106, 109], ["LMWH", "CHEMICAL", 198, 202], ["patients", "ORGANISM", 8, 16], ["plasma samples", "ORGANISM_SUBSTANCE", 26, 40], ["heparin", "SIMPLE_CHEMICAL", 53, 60], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 83, 90], ["UFH", "SIMPLE_CHEMICAL", 106, 109], ["anti-Xa", "PROTEIN", 83, 90], ["patients", "SPECIES", 8, 16], ["plasma samples", "TEST", 26, 40], ["heparin", "TREATMENT", 53, 60], ["Xa", "TREATMENT", 88, 90], ["UFH in haemodiafiltration circuits", "TREATMENT", 106, 140], ["prophylactic LMWH", "TREATMENT", 185, 202], ["This study", "TEST", 218, 228]]], ["It is a single centre study on a relatively small collection of heterogeneous patients and clinical end points were not examined and laboratory results were not available for all patients.", [["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 179, 187], ["a single centre study", "TEST", 6, 27], ["small", "OBSERVATION_MODIFIER", 44, 49], ["collection", "OBSERVATION", 50, 60], ["heterogeneous", "OBSERVATION_MODIFIER", 64, 77]]], ["In addition, we have not systematically collected data for every day of a patient's admission and there is a relatively limited number of laboratory data available.", [["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["laboratory data", "TEST", 138, 153]]], ["We also have not been able to as of yet define an exact mechanism of heparin resistance however as we did not observe a fall in anti-Xa activity over time this suggests there is not time dependant degradation of heparin.", [["heparin", "CHEMICAL", 69, 76], ["heparin", "CHEMICAL", 212, 219], ["heparin", "SIMPLE_CHEMICAL", 69, 76], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 128, 135], ["heparin", "SIMPLE_CHEMICAL", 212, 219], ["Xa", "PROTEIN", 133, 135], ["heparin resistance", "TREATMENT", 69, 87], ["a fall", "PROBLEM", 118, 124], ["anti-Xa activity", "TREATMENT", 128, 144], ["heparin", "TREATMENT", 212, 219], ["heparin resistance", "OBSERVATION", 69, 87]]], ["Some patients may also be on UFH however we performed experiments on LMWH which may have differing properties in plasma.", [["plasma", "ANATOMY", 113, 119], ["UFH", "CHEMICAL", 29, 32], ["LMWH", "CHEMICAL", 69, 73], ["patients", "ORGANISM", 5, 13], ["UFH", "SIMPLE_CHEMICAL", 29, 32], ["LMWH", "SIMPLE_CHEMICAL", 69, 73], ["plasma", "ORGANISM_SUBSTANCE", 113, 119], ["patients", "SPECIES", 5, 13], ["UFH", "TREATMENT", 29, 32], ["LMWH", "TREATMENT", 69, 73], ["may also be", "UNCERTAINTY", 14, 25]]], ["In addition the definition of UFH resistance as > 35,000 units per day is arbitrary though is widely quoted in the medical literature, and the evidence for the use of the anti-Xa to guide LMWH dosing limited.", [["UFH", "CHEMICAL", 30, 33], ["LMWH", "CHEMICAL", 188, 192], ["UFH", "SIMPLE_CHEMICAL", 30, 33], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 171, 178], ["LMWH", "SIMPLE_CHEMICAL", 188, 192], ["anti-Xa", "PROTEIN", 171, 178], ["UFH resistance", "TREATMENT", 30, 44], ["the anti-Xa", "TREATMENT", 167, 178], ["LMWH dosing", "TREATMENT", 188, 199]]], ["Whilst we cannot exclude an effect of the haemodiafiltration on removing heparin, this has not been previously described as a significant effect with negligible amounts of heparin found in ultrafiltrate [19] .ConclusionOur data demonstrates that patients with COVID-19 in the ICU are heparin resistant that receive therapeutic anticoagulation with UFH and may have decreased peak anti-Xa levels with therapeutic LMWH.", [["heparin", "CHEMICAL", 73, 80], ["heparin", "CHEMICAL", 172, 179], ["heparin", "CHEMICAL", 284, 291], ["UFH", "CHEMICAL", 348, 351], ["LMWH", "CHEMICAL", 412, 416], ["heparin", "SIMPLE_CHEMICAL", 73, 80], ["heparin", "SIMPLE_CHEMICAL", 172, 179], ["patients", "ORGANISM", 246, 254], ["UFH", "SIMPLE_CHEMICAL", 348, 351], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 380, 387], ["LMWH", "SIMPLE_CHEMICAL", 412, 416], ["Xa", "PROTEIN", 385, 387], ["patients", "SPECIES", 246, 254], ["the haemodiafiltration", "TREATMENT", 38, 60], ["heparin", "TREATMENT", 73, 80], ["heparin", "TREATMENT", 172, 179], ["ultrafiltrate", "TREATMENT", 189, 202], ["ConclusionOur data", "TEST", 209, 227], ["COVID", "TEST", 260, 265], ["heparin", "TREATMENT", 284, 291], ["therapeutic anticoagulation", "TREATMENT", 315, 342], ["UFH", "TREATMENT", 348, 351], ["decreased peak anti-Xa levels", "PROBLEM", 365, 394], ["therapeutic LMWH", "TREATMENT", 400, 416], ["haemodiafiltration", "OBSERVATION", 42, 60], ["LMWH", "OBSERVATION", 412, 416]]], ["The clinical significance of this requires further study, as do the biological mechanisms.", [["further study", "TEST", 43, 56]]], ["Given the resistance to heparin seen then this could Anti-Xa assay APTR offer some insights into why high rates of thromboprophylaxis failure have been seen in COVID-19 when standard thromboprophylactic LMWH doses are used [3, 4, [6] [7] [8] .ConclusionOn the basis of our work we will measure anti-Xa levels for patients on therapeutic LMWH in the ICU to ensure adequate dosing and continue with careful monitoring for those on UFH.", [["heparin", "CHEMICAL", 24, 31], ["LMWH", "CHEMICAL", 203, 207], ["LMWH", "CHEMICAL", 337, 341], ["UFH", "CHEMICAL", 429, 432], ["heparin", "SIMPLE_CHEMICAL", 24, 31], ["Anti-Xa", "GENE_OR_GENE_PRODUCT", 53, 60], ["LMWH", "SIMPLE_CHEMICAL", 203, 207], ["[6] [7] [8]", "SIMPLE_CHEMICAL", 230, 241], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 294, 301], ["patients", "ORGANISM", 313, 321], ["LMWH", "SIMPLE_CHEMICAL", 337, 341], ["UFH", "SIMPLE_CHEMICAL", 429, 432], ["Xa", "PROTEIN", 299, 301], ["patients", "SPECIES", 313, 321], ["heparin", "TREATMENT", 24, 31], ["Anti-Xa assay APTR", "TREATMENT", 53, 71], ["thromboprophylaxis failure", "PROBLEM", 115, 141], ["COVID", "TEST", 160, 165], ["standard thromboprophylactic LMWH doses", "TREATMENT", 174, 213], ["anti-Xa levels", "TEST", 294, 308], ["therapeutic LMWH", "TREATMENT", 325, 341], ["careful monitoring", "TEST", 397, 415], ["UFH", "TREATMENT", 429, 432], ["thromboprophylaxis failure", "OBSERVATION", 115, 141]]], ["In the acute phase UFH may be desirable for thrombosis in the ICU in COVID-19 to ensure therapeutic anticoagulation, which can be closely monitored in this setting, however this could be inconvenient and resource intensive.", [["UFH", "CHEMICAL", 19, 22], ["thrombosis", "DISEASE", 44, 54], ["the acute phase UFH", "TREATMENT", 3, 22], ["thrombosis", "PROBLEM", 44, 54], ["COVID", "TEST", 69, 74], ["therapeutic anticoagulation", "TREATMENT", 88, 115], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["thrombosis", "OBSERVATION", 44, 54]]], ["Further clinical and laboratory studies are required to determine the optimal thromboprophylaxis and management of venous/arterial thrombosis in patients with COVID-19 as well as mechanism of heparin resistance.ConclusionAuthor contributions WT and DW-designed the study, performed the data collection and wrote the manuscript.", [["venous", "ANATOMY", 115, 121], ["arterial", "ANATOMY", 122, 130], ["venous/arterial thrombosis", "DISEASE", 115, 141], ["COVID-19", "CHEMICAL", 159, 167], ["heparin", "CHEMICAL", 192, 199], ["venous", "MULTI-TISSUE_STRUCTURE", 115, 121], ["arterial", "MULTI-TISSUE_STRUCTURE", 122, 130], ["patients", "ORGANISM", 145, 153], ["heparin", "SIMPLE_CHEMICAL", 192, 199], ["patients", "SPECIES", 145, 153], ["laboratory studies", "TEST", 21, 39], ["the optimal thromboprophylaxis", "TREATMENT", 66, 96], ["management", "TREATMENT", 101, 111], ["venous/arterial thrombosis", "PROBLEM", 115, 141], ["COVID", "TEST", 159, 164], ["heparin resistance", "TREATMENT", 192, 210], ["the study", "TEST", 261, 270], ["the data collection", "TEST", 282, 301], ["venous", "ANATOMY", 115, 121], ["arterial", "ANATOMY", 122, 130], ["thrombosis", "OBSERVATION", 131, 141], ["heparin resistance", "OBSERVATION", 192, 210]]], ["TB, SM, MB, DdM-R, AJ, AL, JV, DS-provided intellectual input.ConclusionFunding None received.ConclusionAvailability of data and material The dataset will not be published.Compliance with ethical standardsConflicts of interest MB-speakers fee STAGO, Advisory board Novartis, Cosmopharma, Werfen.", [["TB", "DISEASE", 0, 2], ["TB", "PROBLEM", 0, 2], ["ethical standards", "TREATMENT", 188, 205], ["SM", "ANATOMY", 4, 6], ["MB", "ANATOMY", 8, 10]]], ["WT-speakers fees from Pfizer, Bayer, Takeda and advisory boards for Daiichi-Sankyo, Sanofi and Ablynx.", [["WT", "TEST", 0, 2]]], ["No other authors declared relevant conflicts of interest.Compliance with ethical standardsEthical approval This study had institutional research and ethics approval.", [["ethical standards", "TREATMENT", 73, 90], ["Ethical approval", "TREATMENT", 90, 106], ["This study", "TEST", 107, 117]]], ["As this was a retrospective study patient consent was not deemed necessary.", [["patient", "ORGANISM", 34, 41], ["patient", "SPECIES", 34, 41], ["a retrospective study", "TEST", 12, 33]]]], "a3abdd1c1c8d9c5aec0c3f3447c0c11f0adf16a6": [["IntroductionHepatitis B virus (HBV) chronically infects about 350 million people worldwide and 93 million people in China, with high risk of evolution to liver cirrhosis (LC) and hepatocellular carcinoma (HCC) [1, 2] .", [["liver cirrhosis", "ANATOMY", 154, 169], ["LC", "ANATOMY", 171, 173], ["hepatocellular carcinoma", "ANATOMY", 179, 203], ["HCC", "ANATOMY", 205, 208], ["IntroductionHepatitis B", "DISEASE", 0, 23], ["liver cirrhosis", "DISEASE", 154, 169], ["hepatocellular carcinoma", "DISEASE", 179, 203], ["HCC", "DISEASE", 205, 208], ["IntroductionHepatitis B virus", "ORGANISM", 0, 29], ["HBV", "ORGANISM", 31, 34], ["people", "ORGANISM", 74, 80], ["people", "ORGANISM", 106, 112], ["liver cirrhosis", "CANCER", 154, 169], ["LC", "CANCER", 171, 173], ["hepatocellular carcinoma", "CANCER", 179, 203], ["HCC", "CANCER", 205, 208], ["B virus", "SPECIES", 22, 29], ["people", "SPECIES", 74, 80], ["people", "SPECIES", 106, 112], ["IntroductionHepatitis B virus", "SPECIES", 0, 29], ["HBV", "SPECIES", 31, 34], ["IntroductionHepatitis B virus (HBV) chronically infects", "PROBLEM", 0, 55], ["liver cirrhosis", "PROBLEM", 154, 169], ["hepatocellular carcinoma (HCC)", "PROBLEM", 179, 209], ["virus", "OBSERVATION", 24, 29], ["liver", "ANATOMY", 154, 159], ["cirrhosis", "OBSERVATION", 160, 169], ["hepatocellular", "ANATOMY", 179, 193], ["carcinoma", "OBSERVATION", 194, 203]]], ["Chronic HBV infection leads to a wide spectrum of clinical presentations, including the asymptomatic carrier state, mild and severe chronic hepatitis B (CHB-M, CHB-S), and acute-onchronic liver failure (ACLF).", [["liver", "ANATOMY", 188, 193], ["HBV infection", "DISEASE", 8, 21], ["chronic hepatitis B", "DISEASE", 132, 151], ["CHB", "DISEASE", 153, 156], ["CHB", "DISEASE", 160, 163], ["acute-onchronic liver failure", "DISEASE", 172, 201], ["ACLF", "DISEASE", 203, 207], ["HBV", "ORGANISM", 8, 11], ["liver", "ORGAN", 188, 193], ["HBV", "SPECIES", 8, 11], ["Chronic HBV infection", "PROBLEM", 0, 21], ["the asymptomatic carrier state", "PROBLEM", 84, 114], ["mild and severe chronic hepatitis B", "PROBLEM", 116, 151], ["CHB", "PROBLEM", 160, 163], ["acute-onchronic liver failure", "PROBLEM", 172, 201], ["ACLF)", "PROBLEM", 203, 208], ["HBV", "OBSERVATION", 8, 11], ["infection", "OBSERVATION", 12, 21], ["wide spectrum", "OBSERVATION_MODIFIER", 33, 46], ["mild", "OBSERVATION_MODIFIER", 116, 120], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["hepatitis", "OBSERVATION", 140, 149], ["acute", "OBSERVATION_MODIFIER", 172, 177], ["liver", "ANATOMY", 188, 193], ["failure", "OBSERVATION", 194, 201], ["ACLF", "OBSERVATION", 203, 207]]], ["In China, patients with hepatitis B-related ACLF account for more than 80% of total ACLF cases due to the high prevalence of chronic HBV infection.", [["ACLF", "ANATOMY", 44, 48], ["hepatitis B", "DISEASE", 24, 35], ["ACLF", "DISEASE", 44, 48], ["ACLF", "DISEASE", 84, 88], ["HBV infection", "DISEASE", 133, 146], ["patients", "ORGANISM", 10, 18], ["hepatitis B", "ORGANISM", 24, 35], ["ACLF", "CANCER", 44, 48], ["ACLF", "CANCER", 84, 88], ["HBV", "ORGANISM", 133, 136], ["patients", "SPECIES", 10, 18], ["HBV", "SPECIES", 133, 136], ["hepatitis B", "PROBLEM", 24, 35], ["ACLF", "PROBLEM", 44, 48], ["total ACLF cases", "TREATMENT", 78, 94], ["chronic HBV infection", "PROBLEM", 125, 146], ["hepatitis", "OBSERVATION", 24, 33], ["chronic", "OBSERVATION_MODIFIER", 125, 132], ["HBV", "OBSERVATION", 133, 136], ["infection", "OBSERVATION", 137, 146]]], ["Without transplantation, such patients have a high mortality rate (60-80%), resulting in 22,600 deaths annually [3] .IntroductionThe pathogenesis of the severity of chronic HBV infection remains largely unclear.", [["deaths", "DISEASE", 96, 102], ["HBV infection", "DISEASE", 173, 186], ["patients", "ORGANISM", 30, 38], ["HBV", "ORGANISM", 173, 176], ["patients", "SPECIES", 30, 38], ["HBV", "SPECIES", 173, 176], ["transplantation", "TREATMENT", 8, 23], ["a high mortality rate", "PROBLEM", 44, 65], ["chronic HBV infection", "PROBLEM", 165, 186], ["transplantation", "OBSERVATION", 8, 23], ["severity", "OBSERVATION_MODIFIER", 153, 161], ["chronic", "OBSERVATION_MODIFIER", 165, 172], ["HBV", "OBSERVATION", 173, 176], ["infection", "OBSERVATION", 177, 186]]], ["Both viral and host factors may play a role.", [["viral", "OBSERVATION", 5, 10], ["host factors", "OBSERVATION", 15, 27]]], ["HBV is a highly variable virus and is classified into at least eight genotypes (A-H) that may vary in geographical distribution, viral characteristics, and relationship to clinical outcomes [4] .", [["HBV", "ORGANISM", 0, 3], ["A-H", "CELL", 80, 83], ["HBV", "SPECIES", 0, 3], ["HBV", "PROBLEM", 0, 3], ["a highly variable virus", "PROBLEM", 7, 30], ["highly variable", "OBSERVATION_MODIFIER", 9, 24], ["virus", "OBSERVATION", 25, 30], ["viral characteristics", "OBSERVATION", 129, 150]]], ["HBV mutations in basal core promoter (BCP) and precore (PC) regions have attracted special attention because the BCP mutation may enhance HBV replication in vitro and the PC mutation abrogates translation of the HBe antigen (HBeAg) which is considered to be a tolerant protein to buffer immune attack of the infected hepatocytes [5] [6] [7] .", [["basal core", "ANATOMY", 17, 27], ["hepatocytes", "ANATOMY", 317, 328], ["HBeAg", "CHEMICAL", 225, 230], ["HBV", "ORGANISM", 0, 3], ["basal core promoter (BCP)", "GENE_OR_GENE_PRODUCT", 17, 42], ["BCP", "GENE_OR_GENE_PRODUCT", 113, 116], ["HBV", "ORGANISM", 138, 141], ["PC", "CANCER", 171, 173], ["HBe antigen", "GENE_OR_GENE_PRODUCT", 212, 223], ["HBeAg", "GENE_OR_GENE_PRODUCT", 225, 230], ["hepatocytes", "CELL", 317, 328], ["basal core promoter", "DNA", 17, 36], ["BCP", "DNA", 38, 41], ["precore (PC) regions", "DNA", 47, 67], ["HBe antigen", "PROTEIN", 212, 223], ["HBeAg", "PROTEIN", 225, 230], ["HBV", "SPECIES", 0, 3], ["HBV", "SPECIES", 138, 141], ["HBV mutations", "PROBLEM", 0, 13], ["basal core promoter (BCP) and precore (PC) regions", "TREATMENT", 17, 67], ["the BCP mutation", "PROBLEM", 109, 125], ["HBV replication", "TREATMENT", 138, 153], ["the PC mutation", "TEST", 167, 182], ["the HBe antigen", "TEST", 208, 223], ["a tolerant protein", "PROBLEM", 258, 276], ["the infected hepatocytes", "PROBLEM", 304, 328], ["infected", "OBSERVATION", 308, 316]]], ["Studies have been performed to clarify these virologic features in patients with acute liver failure (ALF) who developed fulminant hepatitis from acute HBV infection.", [["liver", "ANATOMY", 87, 92], ["acute liver failure", "DISEASE", 81, 100], ["ALF", "DISEASE", 102, 105], ["hepatitis", "DISEASE", 131, 140], ["HBV infection", "DISEASE", 152, 165], ["patients", "ORGANISM", 67, 75], ["liver", "ORGAN", 87, 92], ["HBV", "ORGANISM", 152, 155], ["patients", "SPECIES", 67, 75], ["HBV", "SPECIES", 152, 155], ["Studies", "TEST", 0, 7], ["these virologic features", "PROBLEM", 39, 63], ["acute liver failure", "PROBLEM", 81, 100], ["fulminant hepatitis", "PROBLEM", 121, 140], ["acute HBV infection", "PROBLEM", 146, 165], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["liver", "ANATOMY", 87, 92], ["failure", "OBSERVATION", 93, 100], ["fulminant", "OBSERVATION_MODIFIER", 121, 130], ["hepatitis", "OBSERVATION", 131, 140], ["acute", "OBSERVATION_MODIFIER", 146, 151], ["HBV", "OBSERVATION_MODIFIER", 152, 155], ["infection", "OBSERVATION", 156, 165]]], ["The occurrence of the BCP double mutation A1762T/G1764A and the PC mutation G1896A has been documented to be higher in ALF patients than in those with acute hepatitis B [8] [9] [10] [11] [12] [13] [14] .", [["ALF", "DISEASE", 119, 122], ["acute hepatitis B", "DISEASE", 151, 168], ["ALF", "CHEMICAL", 119, 122], ["BCP", "GENE_OR_GENE_PRODUCT", 22, 25], ["patients", "ORGANISM", 123, 131], ["8] [9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 170, 201], ["patients", "SPECIES", 123, 131], ["the BCP double mutation", "TEST", 18, 41], ["the PC mutation", "TEST", 60, 75], ["acute hepatitis B", "PROBLEM", 151, 168], ["higher", "OBSERVATION_MODIFIER", 109, 115], ["hepatitis", "OBSERVATION", 157, 166]]], ["A few other BCP/PC mutations have also been reported to be associated with increased HBV replication capacity and/or reduced HBeAg expression in vitro and, in some cases, also associated with ALF occurrence [15] [16] [17] [18] .", [["HBeAg", "CHEMICAL", 125, 130], ["ALF", "DISEASE", 192, 195], ["ALF", "CHEMICAL", 192, 195], ["BCP", "GENE_OR_GENE_PRODUCT", 12, 15], ["PC", "GENE_OR_GENE_PRODUCT", 16, 18], ["HBV", "ORGANISM", 85, 88], ["HBeAg", "GENE_OR_GENE_PRODUCT", 125, 130], ["HBV", "SPECIES", 85, 88], ["A few other BCP/PC mutations", "PROBLEM", 0, 28], ["increased HBV replication capacity", "PROBLEM", 75, 109], ["reduced HBeAg expression", "PROBLEM", 117, 141], ["ALF occurrence", "PROBLEM", 192, 206], ["few", "OBSERVATION_MODIFIER", 2, 5], ["PC mutations", "OBSERVATION", 16, 28], ["HBV", "OBSERVATION", 85, 88]]], ["However, the findings have been inconsistent, and to date no obvious link has been identified between HBV BCP/PC mutations and ALF or fulminant hepatitis development [19] [20] [21] [22] .", [["ALF", "DISEASE", 127, 130], ["fulminant hepatitis", "DISEASE", 134, 153], ["HBV", "ORGANISM", 102, 105], ["PC", "CANCER", 110, 112], ["HBV", "SPECIES", 102, 105], ["obvious link", "PROBLEM", 61, 73], ["HBV BCP/PC mutations", "PROBLEM", 102, 122], ["ALF", "PROBLEM", 127, 130], ["fulminant hepatitis development", "PROBLEM", 134, 165], ["fulminant", "OBSERVATION_MODIFIER", 134, 143], ["hepatitis", "OBSERVATION", 144, 153]]], ["Such clinical results may be partly due to inadequate sample sizes and the interference of viral genotypes.IntroductionThere is still a paucity of data on the association of HBV BCP/PC mutations and genotypes with ACLF occurrence.", [["sample", "ANATOMY", 54, 60], ["ACLF", "DISEASE", 214, 218], ["HBV", "ORGANISM", 174, 177], ["BCP", "GENE_OR_GENE_PRODUCT", 178, 181], ["PC", "GENE_OR_GENE_PRODUCT", 182, 184], ["ACLF", "CANCER", 214, 218], ["HBV", "SPECIES", 174, 177], ["inadequate sample sizes", "PROBLEM", 43, 66], ["viral genotypes", "PROBLEM", 91, 106], ["HBV BCP/PC mutations", "TREATMENT", 174, 194], ["ACLF occurrence", "PROBLEM", 214, 229], ["viral genotypes", "OBSERVATION", 91, 106], ["ACLF", "OBSERVATION", 214, 218]]], ["Liu et al. [23] reported that these virologic features seemed not to be associated with the fulminant and subfulminant exacerbation of CHB, but their sample size was small.", [["CHB", "DISEASE", 135, 138], ["these virologic features", "PROBLEM", 30, 54], ["the fulminant and subfulminant exacerbation of CHB", "PROBLEM", 88, 138], ["fulminant", "OBSERVATION", 92, 101], ["subfulminant", "OBSERVATION_MODIFIER", 106, 118], ["exacerbation", "OBSERVATION", 119, 131], ["CHB", "OBSERVATION", 135, 138], ["size", "OBSERVATION_MODIFIER", 157, 161], ["small", "OBSERVATION_MODIFIER", 166, 171]]], ["The severity of chronic HBV infection may exhibit a progressive process, i.e., from CHB-M to CHB-S and then to ACLF in many cases.", [["HBV infection", "DISEASE", 24, 37], ["CHB", "DISEASE", 93, 96], ["ACLF", "DISEASE", 111, 115], ["HBV", "ORGANISM", 24, 27], ["ACLF", "CANCER", 111, 115], ["HBV", "SPECIES", 24, 27], ["chronic HBV infection", "PROBLEM", 16, 37], ["a progressive process", "PROBLEM", 50, 71], ["CHB", "PROBLEM", 84, 87], ["CHB", "TREATMENT", 93, 96], ["ACLF", "PROBLEM", 111, 115], ["chronic", "OBSERVATION_MODIFIER", 16, 23], ["HBV", "OBSERVATION", 24, 27], ["infection", "OBSERVATION", 28, 37], ["progressive", "OBSERVATION_MODIFIER", 52, 63], ["process", "OBSERVATION", 64, 71]]], ["In the study reported here, we investigated the features of HBV BCP/PC mutations and genotypes in a large number of CHB-M, CHB-S, and ACLF patients and analyzed the clinical implications of the virologic features.Patients and samplesSera of 793 patients who were admitted to or visited Beijing 302 Hospital from January 2005 to December 2008 were collected and successfully amplified for the HBV BCP/PC and a 1,225-bp-long S/Pol (nt 54-1278) gene regions.", [["CHB", "DISEASE", 116, 119], ["CHB-S", "DISEASE", 123, 128], ["ACLF", "DISEASE", 134, 138], ["HBV", "ORGANISM", 60, 63], ["PC", "CANCER", 68, 70], ["CHB-S", "CELL", 123, 128], ["patients", "ORGANISM", 139, 147], ["Patients", "ORGANISM", 213, 221], ["patients", "ORGANISM", 245, 253], ["HBV", "ORGANISM", 392, 395], ["PC", "CANCER", 400, 402], ["HBV BCP/PC and a 1,225-bp-long S/Pol (nt 54-1278) gene regions", "DNA", 392, 454], ["patients", "SPECIES", 139, 147], ["Patients", "SPECIES", 213, 221], ["patients", "SPECIES", 245, 253], ["HBV", "SPECIES", 60, 63], ["HBV", "SPECIES", 392, 395], ["the study", "TEST", 3, 12], ["HBV BCP/PC mutations", "TREATMENT", 60, 80], ["genotypes", "PROBLEM", 85, 94], ["CHB", "TEST", 116, 119], ["CHB", "TEST", 123, 126], ["ACLF patients", "PROBLEM", 134, 147], ["the virologic features", "PROBLEM", 190, 212], ["bp", "TEST", 415, 417], ["large", "OBSERVATION_MODIFIER", 100, 105], ["CHB", "ANATOMY", 116, 119], ["CHB", "ANATOMY", 123, 126]]], ["The patient cohort comprised 325 CHB-M, 170 CHB-S, and 298 ACLF patients.", [["CHB-S", "DISEASE", 44, 49], ["ACLF", "DISEASE", 59, 63], ["patient", "ORGANISM", 4, 11], ["patients", "ORGANISM", 64, 72], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 64, 72], ["CHB", "TEST", 33, 36], ["CHB", "TEST", 44, 47], ["ACLF", "OBSERVATION", 59, 63]]], ["The patients came from various areas of China, but mainly from the north of the country.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["The diagnostic criteria were based on the Management Scheme of Diagnostic and Therapy Criteria of Viral Hepatitis [24] and Diagnostic and Treatment Guidelines for Liver Failure [25] , issued by the Chinese Society of Infectious Diseases and Parasitology and the Chinese Society of Hepatology, respectively, and have been described in our previous studies [26, 27] .", [["Liver", "ANATOMY", 163, 168], ["Viral Hepatitis", "DISEASE", 98, 113], ["Liver Failure", "DISEASE", 163, 176], ["Infectious Diseases", "DISEASE", 217, 236], ["Liver", "ORGAN", 163, 168], ["Diagnostic and Therapy", "TREATMENT", 63, 85], ["Viral Hepatitis", "PROBLEM", 98, 113], ["Treatment Guidelines", "TREATMENT", 138, 158], ["Liver Failure", "PROBLEM", 163, 176], ["Liver", "ANATOMY", 163, 168], ["Failure", "OBSERVATION", 169, 176], ["Infectious", "OBSERVATION", 217, 227]]], ["Briefly, all patients had persistent seropositivity of HBsAg for at least 6 months before enrollment.", [["HBsAg", "CHEMICAL", 55, 60], ["patients", "ORGANISM", 13, 21], ["HBsAg", "GENE_OR_GENE_PRODUCT", 55, 60], ["HBsAg", "PROTEIN", 55, 60], ["patients", "SPECIES", 13, 21], ["persistent seropositivity of HBsAg", "PROBLEM", 26, 60]]], ["CHB-M patients met the following criteria: a history of chronic hepatitis based on a histopathological diagnosis and/or compatible laboratory data and ultrasonographic findings, with mild to moderate liver disease activities that did not reach the criteria of CHB-S.", [["liver", "ANATOMY", 200, 205], ["chronic hepatitis", "DISEASE", 56, 73], ["liver disease", "DISEASE", 200, 213], ["patients", "ORGANISM", 6, 14], ["liver", "ORGAN", 200, 205], ["patients", "SPECIES", 6, 14], ["chronic hepatitis", "PROBLEM", 56, 73], ["ultrasonographic findings", "TEST", 151, 176], ["mild to moderate liver disease activities", "PROBLEM", 183, 224], ["CHB", "PROBLEM", 260, 263], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["hepatitis", "OBSERVATION", 64, 73], ["mild", "OBSERVATION_MODIFIER", 183, 187], ["moderate", "OBSERVATION_MODIFIER", 191, 199], ["liver", "ANATOMY", 200, 205], ["disease", "OBSERVATION", 206, 213]]], ["CHB-S patients had severe liver disease symptoms, including obvious clinical manifestations and significant alterations in their biochemical parameters, such as significant serum alanine aminotransferase (ALT) elevation.", [["liver", "ANATOMY", 26, 31], ["serum", "ANATOMY", 173, 178], ["liver disease symptoms", "DISEASE", 26, 48], ["alanine", "CHEMICAL", 179, 186], ["alanine", "CHEMICAL", 179, 186], ["patients", "ORGANISM", 6, 14], ["liver", "ORGAN", 26, 31], ["serum", "ORGANISM_SUBSTANCE", 173, 178], ["alanine", "AMINO_ACID", 179, 186], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 187, 203], ["ALT", "SIMPLE_CHEMICAL", 205, 208], ["serum alanine aminotransferase", "PROTEIN", 173, 203], ["ALT", "PROTEIN", 205, 208], ["patients", "SPECIES", 6, 14], ["CHB", "PROBLEM", 0, 3], ["severe liver disease symptoms", "PROBLEM", 19, 48], ["obvious clinical manifestations", "PROBLEM", 60, 91], ["significant alterations in their biochemical parameters", "PROBLEM", 96, 151], ["significant serum alanine aminotransferase (ALT) elevation", "PROBLEM", 161, 219], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["liver", "ANATOMY", 26, 31], ["disease", "OBSERVATION", 32, 39], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["alterations", "OBSERVATION", 108, 119]]], ["Based on the biochemical parameters, the diagnosis of CHB-S had to meet at least one of the following criteria: (1) serum albumin level B32 g/L; (2) serum total bilirubin (TBIL) [85.5 lmol/L; (3) plasma prothrombin activity (PTA) was 60-40%; (4) serum cholinesterase ,500 IU/L. ACLF patients met the following criteria: recent development of increasing jaundice (TBIL [171.0 lmol/L or rapid increase to [17.1 lmol/L/day) and decreasing PTA (0%), with a recent development of complications, such as hepatic encephalopathy (Cgrade 2), or an abrupt and obvious increase of ascites or spontaneous bacterial peritonitis or hepatorenal syndrome.", [["serum", "ANATOMY", 116, 121], ["serum", "ANATOMY", 149, 154], ["plasma", "ANATOMY", 196, 202], ["serum", "ANATOMY", 246, 251], ["hepatic", "ANATOMY", 498, 505], ["ascites", "ANATOMY", 570, 577], ["CHB", "DISEASE", 54, 57], ["bilirubin", "CHEMICAL", 161, 170], ["ACLF", "DISEASE", 278, 282], ["jaundice", "DISEASE", 353, 361], ["TBIL", "DISEASE", 363, 367], ["hepatic encephalopathy", "DISEASE", 498, 520], ["ascites", "DISEASE", 570, 577], ["bacterial peritonitis", "DISEASE", 593, 614], ["hepatorenal syndrome", "DISEASE", 618, 638], ["bilirubin", "CHEMICAL", 161, 170], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["albumin", "GENE_OR_GENE_PRODUCT", 122, 129], ["serum", "ORGANISM_SUBSTANCE", 149, 154], ["bilirubin", "SIMPLE_CHEMICAL", 161, 170], ["TBIL", "SIMPLE_CHEMICAL", 172, 176], ["plasma", "ORGANISM_SUBSTANCE", 196, 202], ["prothrombin", "GENE_OR_GENE_PRODUCT", 203, 214], ["serum", "ORGANISM_SUBSTANCE", 246, 251], ["cholinesterase", "SIMPLE_CHEMICAL", 252, 266], ["patients", "ORGANISM", 283, 291], ["hepatic", "ORGAN", 498, 505], ["serum total bilirubin", "PROTEIN", 149, 170], ["prothrombin", "PROTEIN", 203, 214], ["serum cholinesterase", "PROTEIN", 246, 266], ["patients", "SPECIES", 283, 291], ["the biochemical parameters", "TEST", 9, 35], ["CHB", "PROBLEM", 54, 57], ["serum albumin level", "TEST", 116, 135], ["g/L", "TEST", 140, 143], ["serum total bilirubin", "TEST", 149, 170], ["TBIL", "TEST", 172, 176], ["lmol", "TEST", 184, 188], ["plasma prothrombin activity", "TEST", 196, 223], ["PTA", "TEST", 225, 228], ["serum cholinesterase", "TEST", 246, 266], ["increasing jaundice", "PROBLEM", 342, 361], ["TBIL", "TEST", 363, 367], ["lmol", "TEST", 375, 379], ["rapid increase", "PROBLEM", 385, 399], ["decreasing PTA", "PROBLEM", 425, 439], ["complications", "PROBLEM", 475, 488], ["hepatic encephalopathy", "PROBLEM", 498, 520], ["an abrupt", "PROBLEM", 536, 545], ["ascites", "PROBLEM", 570, 577], ["spontaneous bacterial peritonitis", "PROBLEM", 581, 614], ["hepatorenal syndrome", "PROBLEM", 618, 638], ["increasing", "OBSERVATION_MODIFIER", 342, 352], ["jaundice", "OBSERVATION", 353, 361], ["complications", "OBSERVATION", 475, 488], ["hepatic", "ANATOMY", 498, 505], ["encephalopathy", "OBSERVATION", 506, 520], ["abrupt", "OBSERVATION_MODIFIER", 539, 545], ["obvious", "OBSERVATION_MODIFIER", 550, 557], ["increase", "OBSERVATION_MODIFIER", 558, 566], ["ascites", "OBSERVATION", 570, 577], ["spontaneous", "OBSERVATION_MODIFIER", 581, 592], ["bacterial", "OBSERVATION_MODIFIER", 593, 602], ["peritonitis", "OBSERVATION", 603, 614], ["hepatorenal syndrome", "OBSERVATION", 618, 638]]], ["The criteria for ACLF have been widely used in China and are similar (but not exactly identical) with the newly issued Asian Pacific Association for the Study of the Liver (APASL) criteria [28] .", [["Liver", "ANATOMY", 166, 171], ["ACLF", "CANCER", 17, 21], ["Liver", "ORGAN", 166, 171], ["ACLF", "PROBLEM", 17, 21], ["the Study", "TEST", 149, 158], ["ACLF", "OBSERVATION", 17, 21], ["widely", "OBSERVATION_MODIFIER", 32, 38], ["Liver", "ANATOMY", 166, 171]]], ["For all patients, there was no evidence of HCC or other metastatic liver disease; no evidence for concomitant hepatitis C/D virus (HCV/HDV) or human immunodeficiency virus (HIV) infection or autoimmune liver disease.", [["HCC", "ANATOMY", 43, 46], ["metastatic liver", "ANATOMY", 56, 72], ["liver", "ANATOMY", 202, 207], ["HCC", "DISEASE", 43, 46], ["liver disease", "DISEASE", 67, 80], ["hepatitis C", "DISEASE", 110, 121], ["HCV/HDV) or human immunodeficiency virus (HIV) infection", "DISEASE", 131, 187], ["autoimmune liver disease", "DISEASE", 191, 215], ["patients", "ORGANISM", 8, 16], ["HCC", "CANCER", 43, 46], ["liver", "ORGAN", 67, 72], ["hepatitis C/D virus", "ORGANISM", 110, 129], ["HCV/HDV", "ORGANISM", 131, 138], ["human immunodeficiency virus", "ORGANISM", 143, 171], ["liver", "ORGAN", 202, 207], ["patients", "SPECIES", 8, 16], ["D virus", "SPECIES", 122, 129], ["human", "SPECIES", 143, 148], ["immunodeficiency virus (HIV", "SPECIES", 149, 176], ["hepatitis C/D virus", "SPECIES", 110, 129], ["HCV", "SPECIES", 131, 134], ["HDV", "SPECIES", 135, 138], ["human immunodeficiency virus", "SPECIES", 143, 171], ["HIV", "SPECIES", 173, 176], ["HCC", "PROBLEM", 43, 46], ["other metastatic liver disease", "PROBLEM", 50, 80], ["concomitant hepatitis C", "PROBLEM", 98, 121], ["D virus", "PROBLEM", 122, 129], ["HCV", "PROBLEM", 131, 134], ["HDV", "PROBLEM", 135, 138], ["human immunodeficiency virus", "PROBLEM", 143, 171], ["HIV) infection", "PROBLEM", 173, 187], ["autoimmune liver disease", "PROBLEM", 191, 215], ["no evidence of", "UNCERTAINTY", 28, 42], ["HCC", "OBSERVATION", 43, 46], ["metastatic", "OBSERVATION_MODIFIER", 56, 66], ["liver", "ANATOMY", 67, 72], ["disease", "OBSERVATION", 73, 80], ["no evidence for", "UNCERTAINTY", 82, 97], ["concomitant", "OBSERVATION_MODIFIER", 98, 109], ["hepatitis", "OBSERVATION", 110, 119], ["HDV", "OBSERVATION", 135, 138], ["liver", "ANATOMY", 202, 207]]], ["The study was approved by the Ethics Committee of Beijing 302 Hospital.Serological markers and quantitation of HBV DNAThe detection of biochemical and serological parameters and HBV DNA level were routinely performed in the Central Clinical Laboratory of Beijing 302 Hospital.", [["HBV", "ORGANISM", 111, 114], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["HBV", "ORGANISM", 178, 181], ["DNA", "CELLULAR_COMPONENT", 182, 185], ["HBV", "SPECIES", 111, 114], ["HBV", "SPECIES", 178, 181], ["The study", "TEST", 0, 9], ["Serological markers", "TEST", 71, 90], ["HBV DNA", "PROBLEM", 111, 118], ["The detection", "TEST", 118, 131], ["biochemical and serological parameters", "TEST", 135, 173], ["HBV DNA level", "TEST", 178, 191]]], ["The lower limit of HBV DNA detection is 500 copies/mL (equivalent to 100 IU/mL).Serological markers and quantitation of HBV DNADetection of the BCP/PC mutations Viral DNA was extracted and subjected to a nested PCR as described elsewhere [29] .", [["HBV", "ORGANISM", 19, 22], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["HBV", "ORGANISM", 120, 123], ["Viral", "ORGANISM", 161, 166], ["DNA", "CELLULAR_COMPONENT", 167, 170], ["BCP/PC mutations", "DNA", 144, 160], ["HBV", "SPECIES", 19, 22], ["HBV", "SPECIES", 120, 123], ["HBV DNA detection", "TEST", 19, 36], ["Serological markers", "TEST", 80, 99], ["quantitation", "TEST", 104, 116], ["HBV DNADetection", "TREATMENT", 120, 136], ["the BCP/PC mutations", "TREATMENT", 140, 160], ["Viral DNA", "PROBLEM", 161, 170], ["a nested PCR", "TEST", 202, 214], ["lower limit", "OBSERVATION_MODIFIER", 4, 15], ["HBV", "OBSERVATION", 19, 22]]], ["The primers were 5 0 -GAC GTC CTT TGT YTA CGT CC-3 0 (sense, nt 1413-1432) and 5 0 -TCT GCG ACG CGG CGA TTG AG-3 0 (antisense, nt 2403-2422) for the first-round PCR and 5 0 -ACT TCG CTT CAC CTC TGC AC-3 0 (sense, nt 1583-1602) and 5 0 -ATC CAC ACT CCA AAA GAY ACC-3 0 (antisense, nt 2257-2277) for the second-round PCR.", [["TGT YTA CGT CC-3 0", "DNA", 34, 52], ["nt 1413-1432", "DNA", 61, 73], ["TTG AG-3 0", "DNA", 104, 114], ["antisense, nt 2403-2422", "DNA", 116, 139], ["5 0 -ACT TCG CTT CAC CTC TGC AC-3 0", "DNA", 169, 204], ["5 0 -ATC CAC ACT CCA AAA GAY ACC-3 0", "DNA", 231, 267], ["antisense, nt 2257-2277", "DNA", 269, 292], ["The primers", "TEST", 0, 11], ["GAC GTC", "TEST", 22, 29], ["CGT", "TEST", 42, 45], ["CC", "TEST", 46, 48], ["nt", "TEST", 61, 63], ["ACG", "TEST", 92, 95], ["CGG", "TEST", 96, 99], ["CGA", "TEST", 100, 103], ["TTG", "TEST", 104, 107], ["AG", "TEST", 108, 110], ["antisense", "TEST", 116, 125], ["nt", "TEST", 127, 129], ["PCR", "TEST", 161, 164], ["TCG", "TEST", 178, 181], ["CTT", "TEST", 182, 185], ["CAC", "TEST", 186, 189], ["CTC", "TEST", 190, 193], ["TGC", "TEST", 194, 197], ["AC", "TEST", 198, 200], ["nt", "TEST", 213, 215], ["AAA GAY", "TEST", 252, 259], ["ACC", "TEST", 260, 263], ["nt", "TEST", 280, 282], ["the second-round PCR", "TEST", 298, 318]]], ["The first-round PCR consisted of equilibrating at 94\u00b0C for 3 min, followed by 10Typing of HBV genotypes/subgenotypesThe genotypes/subgenotypes were determined based on complete genomic sequence or on analysis of the 1225-bplong S/Pol-gene sequence, which was amplified by an inhouse nested PCR assay [29] .", [["HBV", "ORGANISM", 90, 93], ["Pol", "GENE_OR_GENE_PRODUCT", 230, 233], ["1225-bplong S/Pol-gene sequence", "DNA", 216, 247], ["HBV", "SPECIES", 90, 93], ["round PCR", "TEST", 10, 19], ["HBV genotypes/subgenotypes", "PROBLEM", 90, 116], ["The genotypes/subgenotypes", "PROBLEM", 116, 142], ["analysis", "TEST", 200, 208], ["an inhouse nested PCR assay", "TEST", 272, 299]]], ["A total of 380 HBV complete genomic sequences from individual patients were used for HBV genotyping, including 115 sequences from CHB-M patients (GenBank accession no.: FJ386574-386689 except for FJ386590), 120 sequences from CHB-S patients (FJ562218-562340 except for FJ562263, 562306, and 562338), and 145 sequences from ACLF patients (EU939536-939681 except for EU939680).", [["HBV", "ORGANISM", 15, 18], ["patients", "ORGANISM", 62, 70], ["HBV", "ORGANISM", 85, 88], ["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 232, 240], ["patients", "ORGANISM", 328, 336], ["HBV complete genomic sequences", "DNA", 15, 45], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 232, 240], ["patients", "SPECIES", 328, 336], ["HBV", "SPECIES", 15, 18], ["HBV", "SPECIES", 85, 88], ["CHB-M", "SPECIES", 130, 135], ["HBV complete genomic sequences", "TEST", 15, 45], ["HBV genotyping", "TEST", 85, 99], ["CHB", "TEST", 226, 229], ["FJ562263", "TEST", 269, 277]]], ["HBV genotyping was performed by direct PCR sequencing followed by molecular evolutionary analysis of the viral sequences using MEGA 4 software.", [["HBV", "ORGANISM", 0, 3], ["viral sequences", "DNA", 105, 120], ["HBV", "SPECIES", 0, 3], ["HBV genotyping", "TEST", 0, 14], ["direct PCR sequencing", "TEST", 32, 53], ["the viral sequences", "TEST", 101, 120]]], ["Standard reference sequences were acquired from the online Hepatitis Virus Database (http://www.ncbi.nlm.nih. gov/projects/genotyping/formpage.cgi).Statistical analysisContinuous variables were expressed as mean \u00b1 standard deviation (SD) or median.", [["Hepatitis Virus", "DISEASE", 59, 74], ["Standard reference sequences", "TEST", 0, 28], ["projects/genotyping/formpage.cgi", "TREATMENT", 114, 146], ["Statistical analysisContinuous variables", "PROBLEM", 148, 188]]], ["Differences in continuous data were evaluated using Student's t test, analysis of variance (ANOVA), or nonparametric Wilcoxon signed-ranked test, where appropriate, and categorical data were analyzed using the chi-square test and Fisher's exact test.", [["Student's t test", "TEST", 52, 68], ["the chi-square test", "TEST", 206, 225], ["Fisher's exact test", "TEST", 230, 249]]], ["Multivariate analyses with logistic regression were used to determine independent factors.", [["Multivariate analyses", "TEST", 0, 21], ["logistic regression", "PROBLEM", 27, 46]]], ["Statistical analysis was carried out in SPSS ver.", [["Statistical analysis", "TEST", 0, 20]]], ["16 .0 software (SPSS, Chicago, IL).", [["SPSS", "TEST", 16, 20]]], ["A P value of .05 (two-sided) was considered to be statistically significant.ResultsClinical background, HBV genotype, and BCP/PC mutation profiles of the patients Table 1 summarizes the clinical background, HBV genotypes, and BCP/PC mutations in the three groups of patients.", [["HBV", "ORGANISM", 104, 107], ["patients", "ORGANISM", 154, 162], ["HBV", "ORGANISM", 207, 210], ["patients", "ORGANISM", 266, 274], ["patients", "SPECIES", 154, 162], ["patients", "SPECIES", 266, 274], ["HBV", "SPECIES", 104, 107], ["HBV", "SPECIES", 207, 210], ["A P value", "TEST", 0, 9], ["ResultsClinical background", "TEST", 76, 102], ["HBV genotype", "TEST", 104, 116], ["BCP/PC mutation profiles", "TEST", 122, 146], ["HBV genotypes", "PROBLEM", 207, 220], ["BCP/PC mutations", "TREATMENT", 226, 242], ["significant", "OBSERVATION", 64, 75]]], ["HBV genotypes C and B were detected in the samples of 648 and 145 patients, respectively.", [["samples", "ANATOMY", 43, 50], ["HBV", "ORGANISM", 0, 3], ["B", "GENE_OR_GENE_PRODUCT", 20, 21], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["HBV", "SPECIES", 0, 3], ["HBV genotypes C and B", "PROBLEM", 0, 21]]], ["HBV/C2 and HBV/B2 were the dominant subgenotypes and found in 96% and 92% individual genotypes, respectively.", [["HBV/C2", "ORGANISM", 0, 6], ["HBV/B2", "ORGANISM", 11, 17], ["HBV", "SPECIES", 0, 3], ["HBV/B2", "SPECIES", 11, 17], ["HBV/C2", "TEST", 0, 6], ["HBV/B2", "TEST", 11, 17], ["C2", "ANATOMY", 4, 6], ["HBV", "OBSERVATION", 11, 14], ["B2", "ANATOMY", 15, 17], ["dominant", "OBSERVATION_MODIFIER", 27, 35], ["subgenotypes", "OBSERVATION", 36, 48]]], ["The HBV genotyping based on the 1225-bp-long gene fragment had 100% (380/380) concordance for the classification of genotypes B and C and 98.7% concordance for the classification of subgenotypes B2 and C2 (B2 100%, C2 98.3%) in comparison with the genotyping based on complete HBV genomes.", [["HBV", "ORGANISM", 4, 7], ["HBV", "ORGANISM", 277, 280], ["1225-bp-long gene fragment", "DNA", 32, 58], ["B2", "DNA", 195, 197], ["C2", "DNA", 202, 204], ["B2", "DNA", 206, 208], ["HBV genomes", "DNA", 277, 288], ["HBV", "SPECIES", 4, 7], ["HBV", "SPECIES", 277, 280], ["The HBV genotyping", "TEST", 0, 18], ["bp", "TEST", 37, 39], ["long gene fragment", "PROBLEM", 40, 58], ["genotypes B", "TEST", 116, 127], ["C", "TEST", 132, 133], ["B2", "TEST", 206, 208], ["C2", "TEST", 215, 217], ["the genotyping", "TEST", 244, 258], ["complete HBV genomes", "PROBLEM", 268, 288], ["HBV", "OBSERVATION", 4, 7], ["C2", "ANATOMY", 202, 204], ["HBV genomes", "OBSERVATION", 277, 288]]], ["A slightly higher ratio of genotype B to C was found in ACLF patients than in CHB patients.", [["ACLF", "ANATOMY", 56, 60], ["CHB", "DISEASE", 78, 81], ["B", "GENE_OR_GENE_PRODUCT", 36, 37], ["C", "GENE_OR_GENE_PRODUCT", 41, 42], ["ACLF", "CANCER", 56, 60], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 82, 90], ["A slightly higher ratio of genotype B to C", "PROBLEM", 0, 42], ["slightly", "OBSERVATION_MODIFIER", 2, 10], ["higher", "OBSERVATION_MODIFIER", 11, 17], ["ACLF", "OBSERVATION", 56, 60]]], ["Compared to CHB patients, ACLF patients had significantly higher mutation incidences at eight of the ten sites of interest, including T1753V (C/A/G), A1762T, G1764A, C1766T, and T1768A in the BCP region and G1862T, G1896A, and G1899A in the PC region.", [["PC region", "ANATOMY", 241, 250], ["CHB", "DISEASE", 12, 15], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 31, 39], ["C/A/G)", "GENE_OR_GENE_PRODUCT", 142, 148], ["T1768A", "GENE_OR_GENE_PRODUCT", 178, 184], ["BCP region", "DNA", 192, 202], ["PC region", "DNA", 241, 250], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 31, 39], ["significantly higher mutation incidences", "PROBLEM", 44, 84], ["C1766T", "TEST", 166, 172], ["PC", "ANATOMY", 241, 243], ["region", "ANATOMY_MODIFIER", 244, 250]]], ["Notably, the frequencies of A1762T, G1764A, and G1896A hotspot mutations and the average substitution number at the ten sites of interest of the viral sequences increased in a stepwise manner in the three groups of patients, namely, CHB-M \u00a0CHB-S \u00a0ACLF patients.", [["CHB-S \u00a0ACLF", "DISEASE", 240, 251], ["A1762T", "GENE_OR_GENE_PRODUCT", 28, 34], ["G1896A", "GENE_OR_GENE_PRODUCT", 48, 54], ["patients", "ORGANISM", 215, 223], ["patients", "ORGANISM", 252, 260], ["viral sequences", "DNA", 145, 160], ["patients", "SPECIES", 215, 223], ["patients", "SPECIES", 252, 260], ["G1896A hotspot mutations", "PROBLEM", 48, 72], ["the viral sequences", "PROBLEM", 141, 160]]], ["Correspondingly, the incidence of the BCP/PC wild-type sequence decreased in the same order.", [["BCP/PC wild-type sequence", "DNA", 38, 63], ["the BCP/PC wild", "TREATMENT", 34, 49]]], ["In addition, two interesting triple BCP mutations, T1753V/A1762T/G1764A and A1762T/ G1764A/C1766T/T1768A-triplet (with any three substitutions at the four sites), were more frequently detected in ACLF patients than in CHB patients.", [["ACLF", "ANATOMY", 196, 200], ["ACLF", "DISEASE", 196, 200], ["CHB", "DISEASE", 218, 221], ["BCP", "GENE_OR_GENE_PRODUCT", 36, 39], ["ACLF", "CANCER", 196, 200], ["patients", "ORGANISM", 201, 209], ["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 222, 230], ["two interesting triple BCP mutations", "PROBLEM", 13, 49], ["A1762T", "TEST", 76, 82], ["BCP mutations", "OBSERVATION", 36, 49]]], ["The frequencies of former triple mutations were 15.7, 15.3, and 29.2% for CHB-M, CHB-S, and ACLF patients, respectively (P \u00a00.01).", [["ACLF", "DISEASE", 92, 96], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["former triple mutations", "TEST", 19, 42], ["CHB", "TEST", 74, 77], ["CHB", "TEST", 81, 84], ["CHB", "ANATOMY", 81, 84]]], ["The frequencies of latter triple mutations were 3.4, 4.7, and 12.8% for CHB-M, CHB-S, and ACLF patients, respectively (P \u00a00.01).", [["ACLF", "DISEASE", 90, 94], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["latter triple mutations", "TEST", 19, 42], ["CHB", "TEST", 72, 75], ["CHB", "TEST", 79, 82], ["CHB", "ANATOMY", 79, 82], ["ACLF", "ANATOMY", 90, 94]]], ["The quadruple mutation A1762T/G1764A/C1766T/T1768A was detected in four ACLF cases only.ResultsTo exclude the potential influence on the results brought by age differences among patient groups, patients aged from 25 to 38 and 39 to 52 years were analyzed as independent two subsets.", [["ACLF", "DISEASE", 72, 76], ["ACLF", "CANCER", 72, 76], ["patient", "ORGANISM", 178, 185], ["patients", "ORGANISM", 194, 202], ["patient", "SPECIES", 178, 185], ["patients", "SPECIES", 194, 202], ["The quadruple mutation", "TEST", 0, 22]]], ["As shown in Table 2 , patients in different illness categories had a similar age within each subset; the frequencies of A1762T, G1764A, G1896A and the average substitution number remained significantly different among the three illness groups as did the stepwise increase in the order of CHB-M[CHB-S[ACLF patients.ResultsIn addition to the ten interested sites, significant difference in variant frequencies among the three illness categories was also found at A1846T (CHB-M 8.3%, CHB-S 36.5%, ACLF 37.5%, P \u00a00.01).Individual profiles of BCP/PC mutations in patients infected with the genotypes B and C virusesBecause HBV genotype influences BCP/PC mutational rates, we analyzed the BCP and PC mutations in genotype B and C viruses individually.", [["illness", "DISEASE", 228, 235], ["illness", "DISEASE", 424, 431], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 305, 313], ["BCP", "GENE_OR_GENE_PRODUCT", 538, 541], ["PC", "GENE_OR_GENE_PRODUCT", 542, 544], ["patients", "ORGANISM", 558, 566], ["genotypes B and C viruses", "ORGANISM", 585, 610], ["HBV", "ORGANISM", 618, 621], ["PC", "CANCER", 646, 648], ["PC", "CANCER", 691, 693], ["C viruses", "ORGANISM", 722, 731], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 305, 313], ["patients", "SPECIES", 558, 566], ["HBV", "SPECIES", 618, 621], ["CHB", "PROBLEM", 288, 291], ["CHB", "PROBLEM", 294, 297], ["ACLF patients", "TREATMENT", 300, 313], ["significant difference in variant frequencies", "PROBLEM", 362, 407], ["CHB", "TEST", 469, 472], ["CHB", "TEST", 481, 484], ["S", "TEST", 485, 486], ["ACLF", "TEST", 494, 498], ["P", "TEST", 506, 507], ["BCP/PC mutations", "PROBLEM", 538, 554], ["the genotypes B and C viruses", "PROBLEM", 581, 610], ["HBV genotype influences", "PROBLEM", 618, 641], ["PC mutational rates", "TREATMENT", 646, 665], ["the BCP", "TREATMENT", 679, 686], ["PC mutations", "TREATMENT", 691, 703], ["genotype B and C viruses", "PROBLEM", 707, 731], ["significant", "OBSERVATION_MODIFIER", 362, 373], ["difference", "OBSERVATION_MODIFIER", 374, 384]]], ["Table 3 summarizes the profiles of the BCP/PC mutations in patients infected with genotypes B or C virus, respectively.", [["BCP", "GENE_OR_GENE_PRODUCT", 39, 42], ["PC", "CANCER", 43, 45], ["patients", "ORGANISM", 59, 67], ["genotypes B or C virus", "ORGANISM", 82, 104], ["patients", "SPECIES", 59, 67], ["the BCP/PC mutations", "TREATMENT", 35, 55], ["genotypes B or C virus", "PROBLEM", 82, 104]]], ["In patients infected with genotype B virus, a statistical difference in the occurrence of mutations among the three groups of patients was only observed at A1762T and G1764A, whereas in those infected with genotype C virus, there was a significant difference for four mutations among the groups, i.e., T1753V, G1862T, G1896A, and G1899A.", [["patients", "ORGANISM", 3, 11], ["genotype B virus", "ORGANISM", 26, 42], ["patients", "ORGANISM", 126, 134], ["genotype C virus", "ORGANISM", 206, 222], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 126, 134], ["B virus", "SPECIES", 35, 42], ["C virus", "SPECIES", 215, 222], ["genotype B virus", "PROBLEM", 26, 42], ["mutations", "PROBLEM", 90, 99], ["genotype C virus", "PROBLEM", 206, 222], ["infected", "OBSERVATION", 12, 20], ["significant", "OBSERVATION_MODIFIER", 236, 247]]], ["The average substitution number/ sample clearly increased in a stepwise manner in the order of CHB-S-Mpatients for both genotypes B and C virus infection.", [["CHB-S-", "CHEMICAL", 95, 101], ["infection", "DISEASE", 144, 153], ["B and C virus", "ORGANISM", 130, 143], ["C virus", "SPECIES", 136, 143], ["The average substitution number/ sample", "TREATMENT", 0, 39], ["CHB", "TREATMENT", 95, 98], ["both genotypes B and C virus infection", "PROBLEM", 115, 153], ["average", "OBSERVATION_MODIFIER", 4, 11], ["substitution", "OBSERVATION_MODIFIER", 12, 24], ["increased", "OBSERVATION_MODIFIER", 48, 57]]], ["The triple mutational pattern Table 1 Clinical features, HBV genotype, and BCP/PC mutation profile of the 793 patients enrolled in the study The clinical and virologic characteristics in relation to mortality of ACLF patients Of the 298 patients with ACLF, 184 patients had a fatal outcome and 90 patients survived[6 months after the onset of liver failure.", [["liver", "ANATOMY", 343, 348], ["ACLF", "DISEASE", 212, 216], ["ACLF", "DISEASE", 251, 255], ["liver failure", "DISEASE", 343, 356], ["HBV", "ORGANISM", 57, 60], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 217, 225], ["patients", "ORGANISM", 237, 245], ["ACLF", "CANCER", 251, 255], ["patients", "ORGANISM", 261, 269], ["patients", "ORGANISM", 297, 305], ["liver", "ORGAN", 343, 348], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 217, 225], ["patients", "SPECIES", 237, 245], ["patients", "SPECIES", 261, 269], ["patients", "SPECIES", 297, 305], ["HBV", "SPECIES", 57, 60], ["The triple mutational pattern Table", "TEST", 0, 35], ["Clinical features", "TEST", 38, 55], ["HBV genotype", "TEST", 57, 69], ["BCP/PC mutation profile", "TEST", 75, 98], ["the study", "TEST", 131, 140], ["ACLF", "PROBLEM", 251, 255], ["liver failure", "PROBLEM", 343, 356], ["ACLF", "OBSERVATION", 212, 216], ["liver", "ANATOMY", 343, 348], ["failure", "OBSERVATION", 349, 356]]], ["Older age (C40 years), higher TBIL level (C408 lmol/L), lower PTA (B24%), higher ALT level (C311 IU/mL), and the HBV PC mutation were detected as independent risk factors of death ( Table 5 ).", [["death", "DISEASE", 174, 179], ["TBIL", "GENE_OR_GENE_PRODUCT", 30, 34], ["ALT", "GENE_OR_GENE_PRODUCT", 81, 84], ["HBV", "ORGANISM", 113, 116], ["PC", "GENE_OR_GENE_PRODUCT", 117, 119], ["TBIL", "PROTEIN", 30, 34], ["ALT", "PROTEIN", 81, 84], ["HBV", "SPECIES", 113, 116], ["higher TBIL level", "PROBLEM", 23, 40], ["lower PTA", "PROBLEM", 56, 65], ["higher ALT level", "PROBLEM", 74, 90], ["the HBV PC mutation", "PROBLEM", 109, 128]]], ["The cutoff values were the median for biochemical parameters.", [["The cutoff values", "TEST", 0, 17], ["biochemical parameters", "TEST", 38, 60]]], ["A age of 40 years, 10 5 copies/mL for HBV DNA, and 3 for the substitution number/sample were selected as cutoff values because they were the integral values closest to the median.DiscussionThe outcome of HBV infection depends on the interplay between the virus, the hepatocytes, and the host's immune response.", [["hepatocytes", "ANATOMY", 266, 277], ["HBV infection", "DISEASE", 204, 217], ["HBV", "ORGANISM", 38, 41], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["HBV", "ORGANISM", 204, 207], ["hepatocytes", "CELL", 266, 277], ["HBV DNA", "DNA", 38, 45], ["hepatocytes", "CELL_TYPE", 266, 277], ["HBV", "SPECIES", 38, 41], ["HBV", "SPECIES", 204, 207], ["HBV DNA", "PROBLEM", 38, 45], ["the substitution number/sample", "TEST", 57, 87], ["cutoff values", "TEST", 105, 118], ["HBV infection", "PROBLEM", 204, 217], ["the virus", "PROBLEM", 251, 260], ["infection", "OBSERVATION", 208, 217], ["hepatocytes", "ANATOMY", 266, 277]]], ["HBV BCP/PC mutations are considered to be likely involved in the driving factors of disease progression of HBV infection because BCP/PC mutations affect viral replication and/or HBeAg expression, which may in turn impact on immune responses to the virus.", [["HBV infection", "DISEASE", 107, 120], ["HBeAg", "CHEMICAL", 178, 183], ["HBV", "ORGANISM", 0, 3], ["PC", "GENE_OR_GENE_PRODUCT", 8, 10], ["HBV", "ORGANISM", 107, 110], ["BCP", "GENE_OR_GENE_PRODUCT", 129, 132], ["PC", "GENE_OR_GENE_PRODUCT", 133, 135], ["HBeAg", "GENE_OR_GENE_PRODUCT", 178, 183], ["HBV", "SPECIES", 0, 3], ["HBV", "SPECIES", 107, 110], ["HBV BCP/PC mutations", "PROBLEM", 0, 20], ["disease progression", "PROBLEM", 84, 103], ["HBV infection", "PROBLEM", 107, 120], ["BCP/PC mutations", "TREATMENT", 129, 145], ["viral replication", "PROBLEM", 153, 170], ["HBeAg expression", "PROBLEM", 178, 194], ["the virus", "PROBLEM", 244, 253], ["HBV", "OBSERVATION", 107, 110]]], ["For example, it has been proposed that expression of HBeAg during perinatal infection, the major mode of HBV transmission in Asia, induces immune tolerance.", [["HBeAg", "CHEMICAL", 53, 58], ["perinatal infection", "DISEASE", 66, 85], ["HBeAg", "GENE_OR_GENE_PRODUCT", 53, 58], ["HBV", "ORGANISM", 105, 108], ["HBV", "SPECIES", 105, 108], ["HBeAg during perinatal infection", "PROBLEM", 53, 85], ["HBV transmission", "TREATMENT", 105, 121], ["HBeAg", "OBSERVATION", 53, 58], ["infection", "OBSERVATION", 76, 85], ["HBV", "OBSERVATION", 105, 108], ["immune tolerance", "OBSERVATION", 139, 155]]], ["Another potential role of HBeAg in promoting persistent infection is to mimic CP so as to buffer the immune attack of the infected hepatocytes by the anti-HBc antibodies [5] .", [["hepatocytes", "ANATOMY", 131, 142], ["HBeAg", "CHEMICAL", 26, 31], ["infection", "DISEASE", 56, 65], ["HBeAg", "GENE_OR_GENE_PRODUCT", 26, 31], ["hepatocytes", "CELL", 131, 142], ["infected hepatocytes", "CELL_TYPE", 122, 142], ["anti-HBc antibodies", "PROTEIN", 150, 169], ["HBeAg", "TREATMENT", 26, 31], ["persistent infection", "PROBLEM", 45, 65], ["CP", "PROBLEM", 78, 80], ["the infected hepatocytes", "PROBLEM", 118, 142], ["the anti-HBc antibodies", "TEST", 146, 169], ["HBeAg", "OBSERVATION", 26, 31], ["persistent", "OBSERVATION_MODIFIER", 45, 55], ["infection", "OBSERVATION", 56, 65], ["infected", "OBSERVATION", 122, 130], ["hepatocytes", "ANATOMY", 131, 142]]], ["When the balance is disrupted by the emergence of HBV mutants with different phenotypes, the altered virus-cell relationship might trigger robust immune responses of the host in some instances, causing extensive hepatocyte necrosis [30] .", [["cell", "ANATOMY", 107, 111], ["hepatocyte", "ANATOMY", 212, 222], ["necrosis", "DISEASE", 223, 231], ["HBV", "ORGANISM", 50, 53], ["cell", "CELL", 107, 111], ["hepatocyte", "CELL", 212, 222], ["HBV", "SPECIES", 50, 53], ["HBV mutants", "PROBLEM", 50, 61], ["different phenotypes", "PROBLEM", 67, 87], ["the altered virus-cell relationship", "PROBLEM", 89, 124], ["extensive hepatocyte necrosis", "PROBLEM", 202, 231], ["extensive", "OBSERVATION_MODIFIER", 202, 211], ["hepatocyte", "ANATOMY", 212, 222], ["necrosis", "OBSERVATION", 223, 231]]], ["Thus, the investigation of virologic features may shed light on the pathogenesis and identify predictors of ACLF development.", [["ACLF", "ANATOMY", 108, 112], ["ACLF", "DISEASE", 108, 112], ["ACLF", "CANCER", 108, 112], ["virologic features", "PROBLEM", 27, 45], ["ACLF development", "PROBLEM", 108, 124], ["ACLF", "OBSERVATION", 108, 112]]], ["However, the development of ACLF is related to multiple factors, all of which need to be studied extensively.", [["ACLF", "DISEASE", 28, 32], ["ACLF", "CANCER", 28, 32], ["ACLF", "PROBLEM", 28, 32], ["multiple factors", "PROBLEM", 47, 63], ["ACLF", "OBSERVATION", 28, 32], ["multiple", "OBSERVATION_MODIFIER", 47, 55], ["factors", "OBSERVATION", 56, 63]]], ["Clinical manifestations of ACLF are different from those of fulminant hepatitis on the basis of acute HBV infection.", [["ACLF", "ANATOMY", 27, 31], ["ACLF", "DISEASE", 27, 31], ["hepatitis", "DISEASE", 70, 79], ["HBV infection", "DISEASE", 102, 115], ["ACLF", "CANCER", 27, 31], ["HBV", "ORGANISM", 102, 105], ["HBV", "SPECIES", 102, 105], ["ACLF", "PROBLEM", 27, 31], ["fulminant hepatitis", "PROBLEM", 60, 79], ["acute HBV infection", "PROBLEM", 96, 115], ["ACLF", "OBSERVATION", 27, 31], ["different", "OBSERVATION_MODIFIER", 36, 45], ["fulminant", "OBSERVATION_MODIFIER", 60, 69], ["hepatitis", "OBSERVATION", 70, 79], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["HBV", "OBSERVATION", 102, 105], ["infection", "OBSERVATION", 106, 115]]], ["ACLF manifestation also differs from the acute exacerbation of CHB, which is defined as clinical symptoms along with an abrupt rise in serum ALT ([200 IU/L [31] or [500 IU/L [32] ).", [["serum", "ANATOMY", 135, 140], ["ACLF", "DISEASE", 0, 4], ["CHB", "DISEASE", 63, 66], ["serum", "ORGANISM_SUBSTANCE", 135, 140], ["ALT", "SIMPLE_CHEMICAL", 141, 144], ["ACLF manifestation", "PROBLEM", 0, 18], ["the acute exacerbation", "PROBLEM", 37, 59], ["CHB", "PROBLEM", 63, 66], ["clinical symptoms", "PROBLEM", 88, 105], ["an abrupt rise", "PROBLEM", 117, 131], ["serum ALT", "TEST", 135, 144], ["IU/L", "TEST", 151, 155], ["IU/L", "TEST", 169, 173], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["exacerbation", "OBSERVATION", 47, 59], ["CHB", "OBSERVATION", 63, 66], ["abrupt", "OBSERVATION_MODIFIER", 120, 126], ["rise", "OBSERVATION_MODIFIER", 127, 131]]], ["ACLF patients are relatively rare compared to the large population of CHB patients.", [["ACLF", "DISEASE", 0, 4], ["CHB", "DISEASE", 70, 73], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 74, 82], ["large", "OBSERVATION_MODIFIER", 50, 55], ["population", "OBSERVATION", 56, 66], ["CHB", "ANATOMY", 70, 73]]], ["The Beijing 302 Hospital is one of the largest hospitals for infectious and liver diseases in China and is well known for its management of hepatitis B. Patients from various areas of China come to the hospital seeking treatment, and this has allowed us to collect a larger sample of ACLF patients.DiscussionThe efficiency of PCR amplification of HBV BCP/PC regions is greatly reduced by the nick-gap structure encompassed in the regions.", [["liver", "ANATOMY", 76, 81], ["infectious and liver diseases", "DISEASE", 61, 90], ["hepatitis B.", "DISEASE", 140, 152], ["ACLF", "DISEASE", 284, 288], ["liver", "ORGAN", 76, 81], ["hepatitis B.", "ORGANISM", 140, 152], ["Patients", "ORGANISM", 153, 161], ["ACLF", "CANCER", 284, 288], ["patients", "ORGANISM", 289, 297], ["HBV", "ORGANISM", 347, 350], ["HBV BCP/PC regions", "DNA", 347, 365], ["Patients", "SPECIES", 153, 161], ["patients", "SPECIES", 289, 297], ["HBV", "SPECIES", 347, 350], ["infectious and liver diseases", "PROBLEM", 61, 90], ["hepatitis B.", "PROBLEM", 140, 152], ["treatment", "TREATMENT", 219, 228], ["ACLF patients", "TREATMENT", 284, 297], ["PCR amplification", "TEST", 326, 343], ["HBV BCP/PC regions", "TREATMENT", 347, 365], ["infectious", "OBSERVATION", 61, 71], ["liver", "ANATOMY", 76, 81], ["diseases", "OBSERVATION", 82, 90], ["hepatitis", "OBSERVATION", 140, 149], ["PC", "ANATOMY", 355, 357], ["regions", "ANATOMY_MODIFIER", 358, 365], ["greatly", "OBSERVATION_MODIFIER", 369, 376], ["reduced", "OBSERVATION_MODIFIER", 377, 384], ["gap structure", "OBSERVATION", 397, 410], ["regions", "ANATOMY_MODIFIER", 430, 437]]], ["A sensitive nested PCR assay with a lower limit of detection of 2000 copies/mL was developed to overcome this obstacle.", [["A sensitive nested PCR assay", "TEST", 0, 28]]], ["The technique allowed us to analyze samples of quite low viral load, as in our previous severe acute respiratory syndrome (SARS)coronavirus studies [33, 34] .", [["samples", "ANATOMY", 36, 43], ["acute respiratory syndrome (SARS)coronavirus", "DISEASE", 95, 139], ["quite low viral load", "PROBLEM", 47, 67], ["our previous severe acute respiratory syndrome", "PROBLEM", 75, 121], ["coronavirus studies", "TEST", 128, 147], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["respiratory syndrome", "OBSERVATION", 101, 121]]], ["A significantly higher incidence of the BCP/PC mutations at eight of the ten sites of interest was found in ACLF patients than in CHB patients.", [["ACLF", "ANATOMY", 108, 112], ["ACLF", "DISEASE", 108, 112], ["CHB", "DISEASE", 130, 133], ["BCP", "GENE_OR_GENE_PRODUCT", 40, 43], ["PC", "CANCER", 44, 46], ["ACLF", "CANCER", 108, 112], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 134, 142], ["the BCP/PC mutations", "TREATMENT", 36, 56], ["significantly", "OBSERVATION_MODIFIER", 2, 15], ["higher", "OBSERVATION_MODIFIER", 16, 22], ["PC mutations", "OBSERVATION", 44, 56], ["ACLF", "OBSERVATION", 108, 112]]], ["In particular, the occurrence of three hotspot BCP/PC mutations and average substitution number in the ten sites of interest increased with the severity of illness in a stepwise fashion ( Table 1 ), suggesting that the accumulation of the BCP/PC mutations could be one of the driving factors of illness severity.", [["illness", "DISEASE", 156, 163], ["illness", "DISEASE", 295, 302], ["BCP", "GENE_OR_GENE_PRODUCT", 239, 242], ["PC", "GENE_OR_GENE_PRODUCT", 243, 245], ["BCP/PC mutations", "TREATMENT", 47, 63], ["average substitution number", "PROBLEM", 68, 95], ["the accumulation of the BCP/PC mutations", "PROBLEM", 215, 255], ["illness severity", "PROBLEM", 295, 311], ["PC mutations", "OBSERVATION", 51, 63], ["substitution", "OBSERVATION_MODIFIER", 76, 88], ["number", "OBSERVATION_MODIFIER", 89, 95], ["PC mutations", "OBSERVATION", 243, 255]]], ["Taking into account that a longer duration of infection may increase the incidence of HBV BCP/PC mutation, we particularly compared different illness groups of comparable ages to minimize this factor.", [["infection", "DISEASE", 46, 55], ["HBV", "ORGANISM", 86, 89], ["HBV", "SPECIES", 86, 89], ["infection", "PROBLEM", 46, 55], ["HBV BCP/PC mutation", "TREATMENT", 86, 105], ["this factor", "PROBLEM", 188, 199], ["infection", "OBSERVATION", 46, 55]]], ["The results showed that the increasing trend of the three hotspot mutations (A1762T, G1764A, and G1896A) with disease severity remained unchanged in age-matched patients ( Table 2 ).", [["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["disease severity", "PROBLEM", 110, 126], ["increasing", "OBSERVATION_MODIFIER", 28, 38], ["trend", "OBSERVATION_MODIFIER", 39, 44], ["unchanged", "OBSERVATION_MODIFIER", 136, 145]]], ["In addition to variants at the ten sites of interest, the frequency of A1846T was found to increase in CHB-S and ACLF patients compared to CHB-M patients, suggesting that this variant may also be associated with disease severity.", [["CHB-S and ACLF", "DISEASE", 103, 117], ["A1846T", "GENE_OR_GENE_PRODUCT", 71, 77], ["ACLF", "CANCER", 113, 117], ["patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 145, 153], ["CHB", "TEST", 103, 106], ["ACLF", "PROBLEM", 113, 117], ["this variant", "PROBLEM", 171, 183], ["disease severity", "PROBLEM", 212, 228], ["increase", "OBSERVATION_MODIFIER", 91, 99], ["CHB", "OBSERVATION", 103, 106], ["may also be associated with", "UNCERTAINTY", 184, 211], ["disease", "OBSERVATION", 212, 219]]], ["A1846T has been reported to be more frequently detected in HBeAg-negative HBV infection than in HBeAg-positive HBV infection [35] , but the mechanism needs further clarification.", [["A1846T", "CHEMICAL", 0, 6], ["HBeAg", "CHEMICAL", 59, 64], ["HBV infection", "DISEASE", 74, 87], ["HBeAg", "CHEMICAL", 96, 101], ["HBV infection", "DISEASE", 111, 124], ["HBeAg", "GENE_OR_GENE_PRODUCT", 59, 64], ["HBV", "ORGANISM", 74, 77], ["HBeAg-positive HBV", "ORGANISM", 96, 114], ["A1846T", "PROTEIN", 0, 6], ["HBV", "SPECIES", 74, 77], ["HBV", "SPECIES", 111, 114], ["HBeAg", "TEST", 59, 64], ["HBV infection", "PROBLEM", 74, 87], ["HBeAg", "TEST", 96, 101], ["positive HBV infection", "PROBLEM", 102, 124], ["HBV", "OBSERVATION_MODIFIER", 74, 77], ["infection", "OBSERVATION", 78, 87], ["HBV", "OBSERVATION_MODIFIER", 111, 114], ["infection", "OBSERVATION", 115, 124]]], ["More frequent BCP mutations and less frequent PC mutations were detected in genotype C virus than in genotype B virus which confirmed previous results [36, 37] .", [["BCP", "GENE_OR_GENE_PRODUCT", 14, 17], ["PC", "CANCER", 46, 48], ["genotype C virus", "ORGANISM", 76, 92], ["genotype B virus", "ORGANISM", 101, 117], ["C virus", "SPECIES", 85, 92], ["B virus", "SPECIES", 110, 117], ["More frequent BCP mutations", "PROBLEM", 0, 27], ["less frequent PC mutations", "PROBLEM", 32, 58], ["genotype C virus", "PROBLEM", 76, 92], ["genotype B virus", "PROBLEM", 101, 117], ["BCP mutations", "OBSERVATION", 14, 27]]], ["Interestingly, T1754G was an exceptional case which was more often seen in genotype B virus infection.", [["infection", "DISEASE", 92, 101], ["genotype B virus", "ORGANISM", 75, 91], ["B virus", "SPECIES", 84, 91], ["genotype B virus infection", "PROBLEM", 75, 101], ["virus infection", "OBSERVATION", 86, 101]]], ["The influence of HBV genotypes on the severity of HBV infection is still uncertain.", [["HBV infection", "DISEASE", 50, 63], ["HBV", "ORGANISM", 17, 20], ["HBV", "ORGANISM", 50, 53], ["HBV", "SPECIES", 17, 20], ["HBV", "SPECIES", 50, 53], ["HBV genotypes", "PROBLEM", 17, 30], ["HBV infection", "PROBLEM", 50, 63], ["HBV", "OBSERVATION", 17, 20], ["HBV", "OBSERVATION_MODIFIER", 50, 53], ["infection", "OBSERVATION", 54, 63]]], ["As genotype B and C viruses have different BCP/PC mutational features, their influence on clinical outcome may be associated with the BCP/PC mutation.", [["B", "GENE_OR_GENE_PRODUCT", 12, 13], ["C viruses", "ORGANISM", 18, 27], ["PC", "CANCER", 47, 49], ["BCP", "GENE_OR_GENE_PRODUCT", 134, 137], ["genotype B and C viruses", "PROBLEM", 3, 27], ["different BCP/PC mutational features", "PROBLEM", 33, 69], ["the BCP/PC mutation", "PROBLEM", 130, 149]]], ["Nevertheless, the average substitution number per sample in BCP/PC regions clearly increased with the severity of the illness categories in both genotype B and C, suggesting that the accumulation of the BCP/PC mutations increased the risk of ACLF occurrence regardless of the HBV genotypes.DiscussionIt has been reported that the co-existence of A1762T/ G1764A with T1753V, C1766T, and T1768A may enhance viral replication in vitro and is associated with ALF and advanced liver disease [38] [39] [40] .", [["liver", "ANATOMY", 472, 477], ["illness", "DISEASE", 118, 125], ["ACLF", "DISEASE", 242, 246], ["ALF", "DISEASE", 455, 458], ["liver disease", "DISEASE", 472, 485], ["BCP", "GENE_OR_GENE_PRODUCT", 203, 206], ["PC", "GENE_OR_GENE_PRODUCT", 207, 209], ["ACLF", "CANCER", 242, 246], ["HBV", "ORGANISM", 276, 279], ["A1762T", "GENE_OR_GENE_PRODUCT", 346, 352], ["liver", "ORGAN", 472, 477], ["BCP/PC regions", "DNA", 60, 74], ["HBV", "SPECIES", 276, 279], ["BCP/PC regions", "TREATMENT", 60, 74], ["the illness categories", "PROBLEM", 114, 136], ["the accumulation of the BCP/PC mutations", "PROBLEM", 179, 219], ["ACLF occurrence", "PROBLEM", 242, 257], ["the HBV genotypes", "PROBLEM", 272, 289], ["viral replication", "PROBLEM", 405, 422], ["ALF", "PROBLEM", 455, 458], ["advanced liver disease", "PROBLEM", 463, 485], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["ACLF", "OBSERVATION", 242, 246], ["HBV", "OBSERVATION", 276, 279], ["liver", "ANATOMY", 472, 477]]], ["We found that T1753V-, C1766T-, and/or T1768A-containing triple mutations were more frequent in ACLF patients than in CHB patients, suggesting highly replicative strains with T1753C, C1766T, and T1768A BCP mutations were also most likely to be associated with ACLF development.", [["ACLF", "ANATOMY", 96, 100], ["ACLF", "ANATOMY", 260, 264], ["ACLF", "DISEASE", 96, 100], ["CHB", "DISEASE", 118, 121], ["ACLF", "DISEASE", 260, 264], ["T1753V", "GENE_OR_GENE_PRODUCT", 14, 20], ["C1766T", "GENE_OR_GENE_PRODUCT", 23, 29], ["T1768A", "GENE_OR_GENE_PRODUCT", 39, 45], ["ACLF", "CANCER", 96, 100], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 122, 130], ["T1753C", "GENE_OR_GENE_PRODUCT", 175, 181], ["T1768A", "GENE_OR_GENE_PRODUCT", 195, 201], ["ACLF", "CANCER", 260, 264], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 122, 130], ["T1753V", "TEST", 14, 20], ["C1766T", "TEST", 23, 29], ["T1768A", "TEST", 39, 45], ["triple mutations", "PROBLEM", 57, 73], ["highly replicative strains", "PROBLEM", 143, 169], ["T1768A BCP mutations", "PROBLEM", 195, 215], ["ACLF development", "PROBLEM", 260, 276], ["replicative strains", "OBSERVATION", 150, 169], ["ACLF", "OBSERVATION", 260, 264]]], ["Among the 57 cases with triplet B patterns, 30 (52.6%) were A1762T/ G1764A/C1766T, nine (15.8%) were A1762T/G1764A/ T1768A, and 18 (31.6%) were G1764A/C1766T/T1768A.", [["triplet B patterns", "TEST", 24, 42], ["G1764A", "TEST", 108, 114]]], ["Noticeably, the last pattern has not been documented earlier and mainly occurred in ACLF patients.", [["ACLF", "ANATOMY", 84, 88], ["ACLF", "DISEASE", 84, 88], ["ACLF", "CANCER", 84, 88], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97]]], ["In the luciferase reporter system, the natural G1764A/C1766T/T1768A mutant sequences have been proven to have a 1.8-fold higher transcriptional regulation activity on average than the wild-type sequences generated by reverse site-directed mutagenesis (data not shown).DiscussionIt has been suggested that the BCP mutations frequently emerge at the late HBeAg phase of infection, whereas the PC mutations usually emerge later, at the height of the anti-HBe immune response [15] .", [["HBeAg", "CHEMICAL", 353, 358], ["infection", "DISEASE", 368, 377], ["luciferase", "GENE_OR_GENE_PRODUCT", 7, 17], ["G1764A", "GENE_OR_GENE_PRODUCT", 47, 53], ["C1766T", "GENE_OR_GENE_PRODUCT", 54, 60], ["BCP", "GENE_OR_GENE_PRODUCT", 309, 312], ["PC", "GENE_OR_GENE_PRODUCT", 391, 393], ["natural G1764A/C1766T/T1768A mutant sequences", "DNA", 39, 84], ["wild-type sequences", "DNA", 184, 203], ["reverse site", "DNA", 217, 229], ["the natural G1764A", "TEST", 35, 53], ["a 1.8-fold higher transcriptional regulation activity", "PROBLEM", 110, 163], ["the BCP mutations", "PROBLEM", 305, 322], ["infection", "PROBLEM", 368, 377], ["the PC mutations", "PROBLEM", 387, 403], ["activity", "OBSERVATION_MODIFIER", 155, 163], ["infection", "OBSERVATION", 368, 377]]], ["Therefore, we classified three BCP/PC mutation statuses as BCP-/PC-, BCP?/PCand BCP\u00b1/PC? and analyzed their implications.", [["PC", "CANCER", 35, 37], ["PC", "CANCER", 85, 87], ["BCP/PC mutation statuses", "TEST", 31, 55], ["BCP", "TEST", 59, 62], ["PC", "TEST", 64, 66], ["BCP", "TEST", 69, 72], ["PC", "TREATMENT", 85, 87]]], ["The results showed that CHB-M patients infected with BCP/PC mutants exhibited more enhanced inflammatory responses (significant increase in TBIL and ALT levels and a slight decrease of viral load) than those with the BCP/PC wildtype virus, whereas CHB-S and ACLF patients did not.", [["patients", "ORGANISM", 30, 38], ["BCP/PC", "ORGANISM", 53, 59], ["TBIL", "GENE_OR_GENE_PRODUCT", 140, 144], ["ALT", "SIMPLE_CHEMICAL", 149, 152], ["BCP/PC wildtype virus", "ORGANISM", 217, 238], ["ACLF", "ORGANISM", 258, 262], ["patients", "ORGANISM", 263, 271], ["TBIL", "PROTEIN", 140, 144], ["ALT", "PROTEIN", 149, 152], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 263, 271], ["CHB", "PROBLEM", 24, 27], ["BCP/PC mutants", "PROBLEM", 53, 67], ["enhanced inflammatory responses", "PROBLEM", 83, 114], ["significant increase in TBIL", "PROBLEM", 116, 144], ["ALT levels", "TEST", 149, 159], ["a slight decrease of viral load)", "PROBLEM", 164, 196], ["the BCP/PC wildtype virus", "PROBLEM", 213, 238], ["CHB", "TEST", 248, 251], ["ACLF", "PROBLEM", 258, 262], ["enhanced", "OBSERVATION_MODIFIER", 83, 91], ["inflammatory", "OBSERVATION", 92, 104], ["significant", "OBSERVATION_MODIFIER", 116, 127], ["increase", "OBSERVATION_MODIFIER", 128, 136], ["slight", "OBSERVATION_MODIFIER", 166, 172], ["decrease", "OBSERVATION_MODIFIER", 173, 181], ["viral load", "OBSERVATION", 185, 195]]], ["In contrast, CHB-S patients infected with BCP/PC mutants had lower TBIL and HBV DNA levels than those with the wild-type virus.", [["patients", "ORGANISM", 19, 27], ["BCP/PC", "ORGANISM", 42, 48], ["TBIL", "GENE_OR_GENE_PRODUCT", 67, 71], ["HBV", "ORGANISM", 76, 79], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["wild-type virus", "ORGANISM", 111, 126], ["patients", "SPECIES", 19, 27], ["HBV", "SPECIES", 76, 79], ["CHB", "TEST", 13, 16], ["BCP/PC mutants", "TREATMENT", 42, 56], ["lower TBIL", "PROBLEM", 61, 71], ["HBV DNA levels", "PROBLEM", 76, 90], ["type virus", "PROBLEM", 116, 126], ["CHB", "ANATOMY", 13, 16]]], ["To date, few studies have been able to show an association between these clinical parameters and HBV BCP/PC mutations.", [["HBV", "ORGANISM", 97, 100], ["HBV", "SPECIES", 97, 100], ["few studies", "TEST", 9, 20], ["these clinical parameters", "TEST", 67, 92], ["HBV BCP/PC mutations", "TREATMENT", 97, 117]]], ["BCP mutants have been shown to be positively correlated with increased ALT levels in chronic HBV carriers and CHB patients [41] , and reduced viremia associated with BCP/PC mutants was explained by the fact that enhanced HBV replication of the mutants would efficiently stimulate immune reactions, leading to the enhanced destruction of viral particles [13, 15] .", [["CHB", "DISEASE", 110, 113], ["viremia", "DISEASE", 142, 149], ["BCP", "GENE_OR_GENE_PRODUCT", 0, 3], ["ALT", "SIMPLE_CHEMICAL", 71, 74], ["HBV", "ORGANISM", 93, 96], ["patients", "ORGANISM", 114, 122], ["BCP/PC", "GENE_OR_GENE_PRODUCT", 166, 172], ["HBV", "ORGANISM", 221, 224], ["BCP mutants", "PROTEIN", 0, 11], ["ALT", "PROTEIN", 71, 74], ["patients", "SPECIES", 114, 122], ["HBV", "SPECIES", 93, 96], ["HBV", "SPECIES", 221, 224], ["BCP mutants", "PROBLEM", 0, 11], ["increased ALT levels", "PROBLEM", 61, 81], ["chronic HBV carriers", "PROBLEM", 85, 105], ["CHB patients", "PROBLEM", 110, 122], ["reduced viremia", "PROBLEM", 134, 149], ["BCP/PC mutants", "PROBLEM", 166, 180], ["enhanced HBV replication", "PROBLEM", 212, 236], ["the mutants", "PROBLEM", 240, 251], ["immune reactions", "PROBLEM", 280, 296], ["the enhanced destruction of viral particles", "PROBLEM", 309, 352], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["HBV", "OBSERVATION", 93, 96], ["viremia", "OBSERVATION", 142, 149], ["HBV", "OBSERVATION", 221, 224], ["destruction", "OBSERVATION", 322, 333], ["viral particles", "OBSERVATION", 337, 352]]], ["The alternation of ALT and HBV DNA levels may be influenced by the use of antiviral treatment; furthermore, a blood test at a single time point may bias the evaluation of disease activity for some CHB patients with fluctuating ALT and HBV DNA levels, although these influences were relatively proportionate in large-size samples in this study.", [["blood", "ANATOMY", 110, 115], ["samples", "ANATOMY", 321, 328], ["CHB", "DISEASE", 197, 200], ["ALT", "GENE_OR_GENE_PRODUCT", 19, 22], ["HBV", "ORGANISM", 27, 30], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["patients", "ORGANISM", 201, 209], ["ALT", "SIMPLE_CHEMICAL", 227, 230], ["HBV", "ORGANISM", 235, 238], ["DNA", "CELLULAR_COMPONENT", 239, 242], ["ALT", "PROTEIN", 19, 22], ["patients", "SPECIES", 201, 209], ["HBV", "SPECIES", 27, 30], ["HBV", "SPECIES", 235, 238], ["ALT", "TEST", 19, 22], ["HBV DNA levels", "TEST", 27, 41], ["antiviral treatment", "TREATMENT", 74, 93], ["a blood test", "TEST", 108, 120], ["the evaluation", "TEST", 153, 167], ["disease activity", "PROBLEM", 171, 187], ["some CHB patients", "PROBLEM", 192, 209], ["fluctuating ALT", "TEST", 215, 230], ["HBV DNA levels", "TEST", 235, 249], ["this study", "TEST", 332, 342], ["large", "OBSERVATION_MODIFIER", 310, 315], ["size", "OBSERVATION_MODIFIER", 316, 320]]], ["Further genotypic and phenotypic studies need to be performed to make a clearer outline.DiscussionThe rates of HBeAg loss and anti-HBe positivity increased in a stepwise manner along with the emergence of BCP mutation and PC mutation in CHB-M patients.", [["HBeAg", "CHEMICAL", 111, 116], ["HBeAg", "GENE_OR_GENE_PRODUCT", 111, 116], ["HBe", "GENE_OR_GENE_PRODUCT", 131, 134], ["BCP", "GENE_OR_GENE_PRODUCT", 205, 208], ["PC", "CANCER", 222, 224], ["patients", "ORGANISM", 243, 251], ["HBe", "PROTEIN", 131, 134], ["patients", "SPECIES", 243, 251], ["phenotypic studies", "TEST", 22, 40], ["HBeAg loss", "PROBLEM", 111, 121], ["anti-HBe positivity", "PROBLEM", 126, 145], ["BCP mutation", "PROBLEM", 205, 217], ["PC mutation", "PROBLEM", 222, 233]]], ["In CHB-S and ACLF patients, BCP mutation alone did not significantly increase HBeAg-negative/anti-HBe-positive rates, suggesting that BCP mutations may have diverse influence on HBeAg seroconversion in different illness categories.", [["ACLF", "DISEASE", 13, 17], ["HBeAg", "CHEMICAL", 78, 83], ["HBeAg", "CHEMICAL", 178, 183], ["illness", "DISEASE", 212, 219], ["ACLF", "CANCER", 13, 17], ["patients", "ORGANISM", 18, 26], ["BCP", "GENE_OR_GENE_PRODUCT", 28, 31], ["HBeAg", "GENE_OR_GENE_PRODUCT", 78, 83], ["HBe", "GENE_OR_GENE_PRODUCT", 98, 101], ["BCP", "GENE_OR_GENE_PRODUCT", 134, 137], ["HBeAg", "GENE_OR_GENE_PRODUCT", 178, 183], ["patients", "SPECIES", 18, 26], ["CHB", "TEST", 3, 6], ["BCP mutation", "TEST", 28, 40], ["HBeAg", "TEST", 78, 83], ["anti", "TEST", 93, 97], ["HBe", "TEST", 98, 101], ["positive rates", "PROBLEM", 102, 116], ["BCP mutations", "PROBLEM", 134, 147], ["HBeAg seroconversion", "PROBLEM", 178, 198], ["CHB", "ANATOMY", 3, 6]]], ["There have been reports of the BCP double mutations being associated with lower viral loads in HBeAg-positive individuals [42] and the PC mutation being correlated with high levels of HBV DNA in HBeAgnegative CHB patients [43] .", [["HBeAg", "CHEMICAL", 95, 100], ["CHB", "DISEASE", 209, 212], ["BCP", "GENE_OR_GENE_PRODUCT", 31, 34], ["HBeAg", "GENE_OR_GENE_PRODUCT", 95, 100], ["PC", "CANCER", 135, 137], ["HBV", "ORGANISM", 184, 187], ["DNA", "CELLULAR_COMPONENT", 188, 191], ["patients", "ORGANISM", 213, 221], ["HBV DNA", "DNA", 184, 191], ["patients", "SPECIES", 213, 221], ["HBV", "SPECIES", 184, 187], ["the BCP double mutations", "PROBLEM", 27, 51], ["lower viral loads", "PROBLEM", 74, 91], ["HBeAg", "TEST", 95, 100], ["positive individuals", "PROBLEM", 101, 121], ["the PC mutation", "PROBLEM", 131, 146], ["HBV DNA", "PROBLEM", 184, 191]]], ["However, these associations were not observed in our study (data not shown).", [["our study", "TEST", 49, 58]]], ["Mutant viruses frequently coexist with wild-type viruses, and subpopulations comprising 0% of the total HBV population may be missed by direct sequencing techniques [44] .", [["HBV", "ORGANISM", 104, 107], ["HBV", "SPECIES", 104, 107], ["Mutant viruses", "PROBLEM", 0, 14], ["type viruses", "PROBLEM", 44, 56], ["the total HBV population", "TREATMENT", 94, 118], ["viruses", "OBSERVATION", 7, 14], ["type viruses", "OBSERVATION_MODIFIER", 44, 56], ["subpopulations", "OBSERVATION_MODIFIER", 62, 76], ["HBV", "OBSERVATION", 104, 107]]], ["This may account for the detection of G1896A mutants in some HBeAg-positive patients.DiscussionInterestingly, we found that ACLF patients infected with PC mutants had a significantly higher mortality than those with PC wild-type HBV, indicating that the HBV PC mutation could serve as a predictive indicator for ACLF outcome.", [["ACLF", "ANATOMY", 312, 316], ["HBeAg", "CHEMICAL", 61, 66], ["ACLF", "DISEASE", 312, 316], ["G1896A", "GENE_OR_GENE_PRODUCT", 38, 44], ["HBeAg", "GENE_OR_GENE_PRODUCT", 61, 66], ["patients", "ORGANISM", 76, 84], ["ACLF", "ORGANISM", 124, 128], ["patients", "ORGANISM", 129, 137], ["PC wild-type HBV", "ORGANISM", 216, 232], ["HBV", "ORGANISM", 254, 257], ["PC", "CANCER", 258, 260], ["ACLF", "CANCER", 312, 316], ["G1896A mutants", "PROTEIN", 38, 52], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 129, 137], ["HBV", "SPECIES", 229, 232], ["HBV", "SPECIES", 254, 257], ["the detection", "TEST", 21, 34], ["some HBeAg", "TEST", 56, 66], ["ACLF", "PROBLEM", 124, 128], ["PC mutants", "PROBLEM", 152, 162], ["type HBV", "PROBLEM", 224, 232], ["the HBV PC mutation", "PROBLEM", 250, 269], ["ACLF outcome", "PROBLEM", 312, 324], ["may account for", "UNCERTAINTY", 5, 20]]], ["In summary, our findings suggest that CHB patients infected with BCP/PC mutant virus are more susceptible to severe hepatitis and ACLF than those with the BCP/PC wild-type virus and that ACLF patients with PC mutant virus have an increased risk of death.", [["CHB", "CHEMICAL", 38, 41], ["hepatitis", "DISEASE", 116, 125], ["ACLF", "DISEASE", 130, 134], ["death", "DISEASE", 248, 253], ["CHB", "ORGANISM", 38, 41], ["patients", "ORGANISM", 42, 50], ["BCP/PC mutant virus", "ORGANISM", 65, 84], ["ACLF", "CANCER", 130, 134], ["BCP/PC wild-type virus", "ORGANISM", 155, 177], ["ACLF", "ORGANISM", 187, 191], ["patients", "ORGANISM", 192, 200], ["PC mutant virus", "ORGANISM", 206, 221], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 192, 200], ["CHB", "PROBLEM", 38, 41], ["BCP/PC mutant virus", "PROBLEM", 65, 84], ["severe hepatitis", "PROBLEM", 109, 125], ["ACLF", "PROBLEM", 130, 134], ["the BCP", "TEST", 151, 158], ["type virus", "PROBLEM", 167, 177], ["PC mutant virus", "PROBLEM", 206, 221], ["death", "PROBLEM", 248, 253], ["CHB", "OBSERVATION", 38, 41], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["hepatitis", "OBSERVATION", 116, 125], ["ACLF", "OBSERVATION", 130, 134], ["increased", "OBSERVATION_MODIFIER", 230, 239]]], ["The results of this study further our knowledge of the virologic factors that are associated with the severity of chronic HBV infection.", [["HBV infection", "DISEASE", 122, 135], ["HBV", "ORGANISM", 122, 125], ["virologic factors", "PROTEIN", 55, 72], ["HBV", "SPECIES", 122, 125], ["this study", "TEST", 15, 25], ["the virologic factors", "PROBLEM", 51, 72], ["chronic HBV infection", "PROBLEM", 114, 135], ["chronic", "OBSERVATION_MODIFIER", 114, 121], ["HBV", "OBSERVATION", 122, 125], ["infection", "OBSERVATION", 126, 135]]]], "a02c29e3bb9d5d57824e8b619970bc8156694c0c": [["Biological contextThe SARS coronavirus (SARS-CoV) is the etiological agent of the severe acute respiratory syndrome (SARS), a type of pneumonia with a high mortality rate (Peiris et al. 2003) .", [["SARS coronavirus", "DISEASE", 22, 38], ["SARS-CoV)", "DISEASE", 40, 49], ["acute respiratory syndrome", "DISEASE", 89, 115], ["SARS", "DISEASE", 117, 121], ["pneumonia", "DISEASE", 134, 143], ["SARS coronavirus", "ORGANISM", 22, 38], ["SARS-CoV", "ORGANISM", 40, 48], ["SARS coronavirus", "SPECIES", 22, 38], ["SARS-CoV", "SPECIES", 40, 48], ["The SARS coronavirus", "PROBLEM", 18, 38], ["the severe acute respiratory syndrome", "PROBLEM", 78, 115], ["SARS", "PROBLEM", 117, 121], ["pneumonia", "PROBLEM", 134, 143], ["a high mortality rate", "PROBLEM", 149, 170], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["respiratory syndrome", "OBSERVATION", 95, 115], ["pneumonia", "OBSERVATION", 134, 143], ["high", "OBSERVATION_MODIFIER", 151, 155]]], ["To date there is no vaccine or effective treatment for SARS, and intense ongoing work is focused on the structural and functional characterization of the proteins encoded by the SARS-CoV genome (Bartlam et al. 2005; Chen et al. 2006) .", [["SARS", "DISEASE", 55, 59], ["SARS-CoV", "ORGANISM", 178, 186], ["SARS-CoV genome", "DNA", 178, 193], ["SARS-CoV", "SPECIES", 178, 186], ["vaccine", "TREATMENT", 20, 27], ["effective treatment", "TREATMENT", 31, 50], ["SARS", "PROBLEM", 55, 59], ["no", "UNCERTAINTY", 17, 19]]], ["The viral RNA genome is translated into polyproteins, which are long polypeptide chains that are subsequently processed by virus-encoded proteases to produce a manifold of functional proteins important for the life-cycle of the virus (Prentice et al. 2004; Schiller et al. 1998) .", [["viral RNA genome", "DNA", 4, 20], ["virus-encoded proteases", "PROTEIN", 123, 146], ["functional proteins", "PROTEIN", 172, 191], ["The viral RNA genome", "PROBLEM", 0, 20], ["polyproteins", "PROBLEM", 40, 52], ["long polypeptide chains", "PROBLEM", 64, 87], ["the virus", "PROBLEM", 224, 233], ["viral RNA genome", "OBSERVATION", 4, 20]]], ["One of these is the nonstructural protein nsp3, which is thought to be involved in RNA replication and processing, and which has been predicted to consist of multiple domains .", [["nsp3", "GENE_OR_GENE_PRODUCT", 42, 46], ["nonstructural protein", "PROTEIN", 20, 41], ["nsp3", "PROTEIN", 42, 46], ["the nonstructural protein nsp3", "PROBLEM", 16, 46], ["RNA replication", "TREATMENT", 83, 98], ["nonstructural protein nsp3", "OBSERVATION", 20, 46], ["thought to be", "UNCERTAINTY", 57, 70], ["RNA replication", "OBSERVATION", 83, 98], ["multiple", "OBSERVATION_MODIFIER", 158, 166], ["domains", "OBSERVATION", 167, 174]]], ["We identified a construct of residues 513-651 that has long-term stability in aqueous solution.", [["residues 513-651", "CHEMICAL", 29, 45], ["aqueous", "ORGANISM_SUBSTANCE", 78, 85], ["aqueous solution", "TREATMENT", 78, 94], ["long-term stability", "OBSERVATION_MODIFIER", 55, 74]]], ["It is part of the domain nsp3c, which extends from residues 366-722 and is apparently unique to the SARS-CoV ('SARS-unique domain'; Snijder et al. 2003) .", [["residues 366-722", "CHEMICAL", 51, 67], ["SARS", "DISEASE", 100, 104], ["nsp3c", "GENE_OR_GENE_PRODUCT", 25, 30], ["-722", "AMINO_ACID", 63, 67], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 100, 108], ["nsp3c", "PROTEIN", 25, 30], ["SARS-CoV", "SPECIES", 100, 108], ["the domain nsp3c", "PROBLEM", 14, 30]]], ["As the physiological role of nsp3 is still poorly understood, a complete characterization of each of its domains is essential for deciphering its physiological function.", [["nsp3", "GENE_OR_GENE_PRODUCT", 29, 33], ["nsp3", "PROTEIN", 29, 33], ["a complete characterization", "TEST", 62, 89]]], ["To establish a basis for structural and functional studies by NMR spectroscopy, we report here the sequence-specific resonance assignment of the 139-residue independently folded polypeptide nsp3(513-651).Methods and experimentsThe starting construct nsp3(451-651) was obtained from the cloning and expression pipeline of the FSPS consortium (http://www.visp.scripps.edu/SARS/default.aspx).", [["nsp3", "PROTEIN", 190, 194], ["nsp3", "DNA", 250, 254], ["FSPS consortium", "DNA", 325, 340], ["NMR spectroscopy", "TEST", 62, 78], ["The starting construct nsp3", "TEST", 227, 254]]], ["1D 1 H NMR spectroscopy showed that this 22 kD construct contained a globular domain, but the protein was chemically unstable, being subject to proteolytic degradation after purification from either the soluble or the insoluble fraction of the bacterial cell lysate by Ni 2+ affinity and size-exclusion chromatography.", [["cell lysate", "ANATOMY", 254, 265], ["Ni", "CHEMICAL", 269, 271], ["1 H", "CHEMICAL", 3, 6], ["Ni 2+", "CHEMICAL", 269, 274], ["Ni 2+", "SIMPLE_CHEMICAL", 269, 274], ["22 kD construct", "DNA", 41, 56], ["globular domain", "PROTEIN", 69, 84], ["NMR spectroscopy", "TEST", 7, 23], ["this 22 kD construct", "PROBLEM", 36, 56], ["a globular domain", "PROBLEM", 67, 84], ["the protein", "TEST", 90, 101], ["chemically unstable", "PROBLEM", 106, 125], ["proteolytic degradation", "PROBLEM", 144, 167], ["purification", "TREATMENT", 174, 186], ["the bacterial cell lysate", "TEST", 240, 265], ["size", "TEST", 288, 292], ["exclusion chromatography", "TEST", 293, 317], ["globular domain", "OBSERVATION", 69, 84], ["bacterial cell lysate", "OBSERVATION", 244, 265], ["size", "OBSERVATION_MODIFIER", 288, 292]]], ["This proteolytic degradation could not be suppressed by the addition of protease inhibitors, and it persisted also after additional purification steps.", [["This proteolytic degradation", "PROBLEM", 0, 28], ["protease inhibitors", "TREATMENT", 72, 91]]], ["We then noticed that proteolysis assays consistently yielded a fragment of about 15.5 kD.", [["proteolysis assays", "PROBLEM", 21, 39]]], ["Edman degradation of this fragment identified a single cleavage site between residues 512 and 513.", [["Edman degradation", "PROBLEM", 0, 17], ["this fragment", "PROBLEM", 21, 34], ["a single cleavage site", "PROBLEM", 46, 68], ["fragment", "OBSERVATION", 26, 34]]], ["We subsequently cloned and expressed nsp3(513-651) and found it to be chemically stable, while still containing the globular domain.Methods and experimentsTo prepare the protein for the NMR structure determination, the construct encoding nsp3(513-651) was expressed in the E. coli strain BL21(DE3) (Stratagene), using the vector pET-28b, which encodes an N-terminal 6\u00b7His tag followed by a thrombin cleavage site.", [["pET-28b", "CHEMICAL", 329, 336], ["N-", "CHEMICAL", 355, 357], ["His", "CHEMICAL", 368, 371], ["nsp3", "GENE_OR_GENE_PRODUCT", 238, 242], ["E. coli", "ORGANISM", 273, 280], ["strain BL21", "ORGANISM", 281, 292], ["DE3", "GENE_OR_GENE_PRODUCT", 293, 296], ["pET-28b", "GENE_OR_GENE_PRODUCT", 329, 336], ["thrombin", "GENE_OR_GENE_PRODUCT", 390, 398], ["nsp3(513-651", "PROTEIN", 37, 49], ["globular domain", "PROTEIN", 116, 131], ["nsp3", "PROTEIN", 238, 242], ["513-651", "PROTEIN", 243, 250], ["vector pET-28b", "DNA", 322, 336], ["N-terminal 6\u00b7His tag", "PROTEIN", 355, 375], ["thrombin", "PROTEIN", 390, 398], ["E. coli", "SPECIES", 273, 280], ["E. coli strain BL21", "SPECIES", 273, 292], ["the NMR structure determination", "TEST", 182, 213], ["the E. coli strain BL21(DE3) (Stratagene)", "TREATMENT", 269, 310], ["the vector pET", "TEST", 318, 332], ["His tag", "TREATMENT", 368, 375], ["a thrombin cleavage site", "TREATMENT", 388, 412], ["chemically", "OBSERVATION_MODIFIER", 70, 80], ["stable", "OBSERVATION", 81, 87], ["globular domain", "OBSERVATION", 116, 131], ["thrombin", "OBSERVATION", 390, 398]]], ["Thrombin cleavage leaves a tag-related N-terminal tetrapeptide segment, GSHM.", [["N", "CHEMICAL", 39, 40], ["tetrapeptide", "CHEMICAL", 50, 62], ["Thrombin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Thrombin", "PROTEIN", 0, 8], ["N-terminal tetrapeptide segment", "PROTEIN", 39, 70], ["GSHM", "PROTEIN", 72, 76], ["Thrombin cleavage", "TREATMENT", 0, 17], ["a tag", "TREATMENT", 25, 30], ["N-terminal tetrapeptide segment", "TREATMENT", 39, 70], ["terminal", "ANATOMY_MODIFIER", 41, 49], ["tetrapeptide segment", "OBSERVATION", 50, 70]]], ["Cells were grown at 37\u00b0C, induced with 1 mM isopropyl b-D-thiogalactoside (IPTG) at an OD 600 of 0.7, and then grown for another 20 h at 18\u00b0C. For the protein purification, the cells were disrupted by sonication in 25 mM phosphate buffer, pH 6.5, with 250 mM NaCl, 2 mM DTT, 5% Triton X-100 and Complete protease inhibitor tablets (Roche).", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 177, 182], ["isopropyl b-D-thiogalactoside", "CHEMICAL", 44, 73], ["IPTG", "CHEMICAL", 75, 79], ["phosphate", "CHEMICAL", 221, 230], ["NaCl", "CHEMICAL", 259, 263], ["Triton X-100", "CHEMICAL", 278, 290], ["isopropyl b-D-thiogalactoside", "CHEMICAL", 44, 73], ["IPTG", "CHEMICAL", 75, 79], ["phosphate", "CHEMICAL", 221, 230], ["NaCl", "CHEMICAL", 259, 263], ["DTT", "CHEMICAL", 270, 273], ["Cells", "CELL", 0, 5], ["isopropyl b-D-thiogalactoside", "SIMPLE_CHEMICAL", 44, 73], ["IPTG", "SIMPLE_CHEMICAL", 75, 79], ["cells", "CELL", 177, 182], ["DTT", "SIMPLE_CHEMICAL", 270, 273], ["Triton X-100", "SIMPLE_CHEMICAL", 278, 290], ["Cells", "TEST", 0, 5], ["thiogalactoside (IPTG", "TREATMENT", 58, 79], ["the protein purification", "TREATMENT", 147, 171], ["25 mM phosphate buffer", "TREATMENT", 215, 237], ["pH", "TEST", 239, 241], ["250 mM NaCl", "TREATMENT", 252, 263], ["DTT", "TEST", 270, 273], ["Complete protease inhibitor tablets", "TREATMENT", 295, 330]]], ["The solution was then centrifuged (18,000g, 4\u00b0C, 30 min) and the supernatant was applied to a 5 ml His-Trap HP column (Amersham) equilibrated with 25 mM phosphate buffer (pH 6.5, 250 mM NaCl, 2 mM DTT), using a flow rate of 1 ml/min.", [["supernatant", "ANATOMY", 65, 76], ["phosphate", "CHEMICAL", 153, 162], ["NaCl", "CHEMICAL", 186, 190], ["phosphate", "CHEMICAL", 153, 162], ["NaCl", "CHEMICAL", 186, 190], ["DTT", "CHEMICAL", 197, 200], ["The solution", "TREATMENT", 0, 12], ["the supernatant", "TREATMENT", 61, 76], ["His-Trap HP column", "TREATMENT", 99, 117], ["25 mM phosphate buffer", "TREATMENT", 147, 169], ["pH", "TEST", 171, 173], ["NaCl", "TEST", 186, 190], ["a flow rate", "TEST", 209, 220]]], ["The bound proteins were eluted with a linear imidazole gradient (5-500 mM) at 8.25 mM/min.", [["imidazole", "CHEMICAL", 45, 54], ["imidazole", "CHEMICAL", 45, 54], ["imidazole", "SIMPLE_CHEMICAL", 45, 54], ["The bound proteins", "TEST", 0, 18], ["a linear imidazole gradient", "TEST", 36, 63]]], ["The eluted proteins were fractionated and monitored at wavelengths of 280 and 254 nm.", [["eluted proteins", "PROTEIN", 4, 19], ["The eluted proteins", "TEST", 0, 19]]], ["Fractions containing the protein nsp3(513-651) were pooled and exchanged with 25 mM phosphate buffer, pH 6.5, containing 150 mM NaCl and 2 mM DTT, to remove imidazole.", [["513-651", "CHEMICAL", 38, 45], ["phosphate", "CHEMICAL", 84, 93], ["NaCl", "CHEMICAL", 128, 132], ["imidazole", "CHEMICAL", 157, 166], ["phosphate", "CHEMICAL", 84, 93], ["NaCl", "CHEMICAL", 128, 132], ["DTT", "CHEMICAL", 142, 145], ["imidazole", "CHEMICAL", 157, 166], ["DTT", "SIMPLE_CHEMICAL", 142, 145], ["imidazole", "SIMPLE_CHEMICAL", 157, 166], ["protein nsp3", "PROTEIN", 25, 37], ["the protein nsp3", "TEST", 21, 37], ["25 mM phosphate buffer", "TREATMENT", 78, 100], ["pH", "TEST", 102, 104], ["150 mM NaCl", "TREATMENT", 121, 132], ["2 mM DTT", "TREATMENT", 137, 145], ["imidazole", "TREATMENT", 157, 166], ["protein nsp3", "OBSERVATION", 25, 37]]], ["The histidine tag was then removed from the protein by digestion during 15 min at room temperature with 50 units of thrombin (Enzyme Research Laboratories, USA) per 10 ml of protein solution.", [["histidine", "CHEMICAL", 4, 13], ["histidine", "CHEMICAL", 4, 13], ["histidine", "AMINO_ACID", 4, 13], ["thrombin", "GENE_OR_GENE_PRODUCT", 116, 124], ["histidine tag", "PROTEIN", 4, 17], ["thrombin", "PROTEIN", 116, 124], ["The histidine tag", "TREATMENT", 0, 17], ["thrombin", "TREATMENT", 116, 124], ["protein solution", "TREATMENT", 174, 190]]], ["After the cleavage, the protein was passed through a size-exclusion Superdex 75 column (Amersham).", [["the cleavage", "TREATMENT", 6, 18], ["the protein", "TEST", 20, 31], ["a size-exclusion Superdex", "TREATMENT", 51, 76]]], ["The fractions containing the protein (as determined by SDS-PAGE) were pooled, exchanged with 25 mM phosphate buffer, pH 6.5, containing 150 mM NaCl and 2 mM NaN 3 , and concentrated to a volume of 500 ll using Vivaspin 15 R centrifugal devices (Vivascience) and supplemented with 10% D 2 O. Isotope labeling was accomplished by growing cultures in minimal medium containing either 1 g/l of 15 NH 4 Cl as the sole nitrogen source, yielding the uniformly 15 N-labeled protein, or 1 g/l of 15 NH 4 Cl and 4 g/l of [ 13 C 6 ]-D-glucose (Cambridge Isotope Laboratories), yielding uniformly [ 13 C, 15 N]-labeled nsp3(513-651).", [["phosphate", "CHEMICAL", 99, 108], ["NaCl", "CHEMICAL", 143, 147], ["NH 4 Cl", "CHEMICAL", 393, 400], ["NH 4 Cl", "CHEMICAL", 490, 497], ["[ 13 C 6 ]-D-glucose", "CHEMICAL", 511, 531], ["phosphate", "CHEMICAL", 99, 108], ["NaCl", "CHEMICAL", 143, 147], ["NaN 3", "CHEMICAL", 157, 162], ["NH", "CHEMICAL", 393, 395], ["Cl", "CHEMICAL", 398, 400], ["nitrogen", "CHEMICAL", 413, 421], ["NH", "CHEMICAL", 490, 492], ["Cl", "CHEMICAL", 495, 497], ["[ 13 C 6 ]-D-glucose", "CHEMICAL", 511, 531], ["[ 13 C, 15 N]-labeled nsp3", "CHEMICAL", 585, 611], ["NH 4 Cl", "SIMPLE_CHEMICAL", 393, 400], ["[ 13 C 6 ]-D-glucose", "SIMPLE_CHEMICAL", 511, 531], ["[ 13 C, 15 N]-labeled nsp3", "SIMPLE_CHEMICAL", 585, 611], ["25 mM phosphate buffer", "TREATMENT", 93, 115], ["pH", "TEST", 117, 119], ["150 mM NaCl", "TREATMENT", 136, 147], ["2 mM NaN", "TREATMENT", 152, 160], ["Vivaspin 15 R centrifugal devices (Vivascience)", "TREATMENT", 210, 257], ["Isotope labeling", "TREATMENT", 291, 307], ["growing cultures", "TEST", 328, 344], ["the sole nitrogen source", "TEST", 404, 428], ["protein", "TEST", 466, 473], ["NH", "TEST", 490, 492], ["Cl", "TEST", 495, 497], ["D-glucose", "TEST", 522, 531], ["Cambridge Isotope Laboratories", "TEST", 533, 563], ["labeled nsp3", "TEST", 599, 611]]], ["Growth in M9 minimal medium yielded about 15 mg of pure protein from 1 l of culture.", [["culture", "TEST", 76, 83]]], ["In the 550 ll NMR samples, the protein concentration was adjusted to 1.2 mM, since higher concentrations led to precipitation.Methods and experimentsNMR experiments were recorded at 298 K on Bruker Avance 600 and Avance 800 spectrometers equipped with TXI HCN z-or xyz-gradient probes.", [["TXI HCN z-or xyz-gradient probes", "DNA", 252, 284], ["the protein concentration", "TEST", 27, 52], ["higher concentrations", "PROBLEM", 83, 104], ["precipitation", "PROBLEM", 112, 125], ["NMR experiments", "TEST", 149, 164], ["Avance", "TREATMENT", 213, 219], ["TXI HCN z", "TREATMENT", 252, 261], ["xyz-gradient probes", "TREATMENT", 265, 284], ["precipitation", "OBSERVATION_MODIFIER", 112, 125]]], ["The sequence-specific H N , 15 N, C a and C 0 backbone assignments were based on the following experiments (Sattler et al. 1999 (Muhandiram et al. 1993; W\u00fcthrich 1986 ) and 2D [ 13 C, 1 H]-HSQC experiments.", [["H N", "CHEMICAL", 22, 25], ["[ 13 C", "CHEMICAL", 176, 182], ["H N", "SIMPLE_CHEMICAL", 22, 25], ["C", "SIMPLE_CHEMICAL", 34, 35], ["The sequence", "TEST", 0, 12], ["2D", "TEST", 173, 175], ["HSQC experiments", "TEST", 189, 205]]], ["Internal 2,2dimethyl-2-silapentane-5-sulfonate (DSS) was used as a chemical shift reference for 1 H, and 15 N and 13 C shifts were referenced indirectly using the absolute frequency ratios (Wishart et al. 1995) .Assignments and data depositionThe protein nsp3(513-651) has the following amino acid sequence:Assignments and data depositionThe residue numbering above the sequence refers to the fulllength nsp3 protein, and the tag-related N-terminal tetrapeptide segment extends from positions -4 to -1.", [["2,2dimethyl-2-silapentane-5-sulfonate", "CHEMICAL", 9, 46], ["DSS", "CHEMICAL", 48, 51], ["amino acid", "CHEMICAL", 287, 297], ["2,2dimethyl-2-silapentane-5-sulfonate", "CHEMICAL", 9, 46], ["DSS", "CHEMICAL", 48, 51], ["H", "CHEMICAL", 98, 99], ["amino acid", "CHEMICAL", 287, 297], ["N", "CHEMICAL", 438, 439], ["tetrapeptide", "CHEMICAL", 449, 461], ["Internal 2,2dimethyl-2-silapentane-5-sulfonate", "SIMPLE_CHEMICAL", 0, 46], ["DSS", "SIMPLE_CHEMICAL", 48, 51], ["nsp3", "GENE_OR_GENE_PRODUCT", 255, 259], ["amino acid", "AMINO_ACID", 287, 297], ["nsp3", "GENE_OR_GENE_PRODUCT", 404, 408], ["tag", "GENE_OR_GENE_PRODUCT", 426, 429], ["-1", "GENE_OR_GENE_PRODUCT", 499, 501], ["protein nsp3", "PROTEIN", 247, 259], ["513-651", "PROTEIN", 260, 267], ["fulllength nsp3 protein", "PROTEIN", 393, 416], ["tag", "PROTEIN", 426, 429], ["N-terminal tetrapeptide segment", "PROTEIN", 438, 469], ["positions -4 to -1", "DNA", 483, 501], ["Internal 2,2dimethyl", "TREATMENT", 0, 20], ["silapentane-5-sulfonate (DSS)", "TREATMENT", 23, 52], ["data deposition", "TEST", 228, 243], ["The protein nsp3", "TEST", 243, 259], ["data deposition", "TEST", 323, 338], ["The residue numbering", "PROBLEM", 338, 359], ["the fulllength nsp3 protein", "TEST", 389, 416], ["the tag", "TEST", 422, 429], ["N-terminal tetrapeptide segment", "TREATMENT", 438, 469], ["terminal", "ANATOMY_MODIFIER", 440, 448], ["tetrapeptide segment", "OBSERVATION", 449, 469]]], ["Below the sequence, the residues in the presently studied construct are numbered consecutively from 1 to 143, so that the segment Val 5-Ser 143 corresponds to the segment Val 513-Ser 651 of nsp3 (used in Fig. 1) .", [["Val 5-Ser", "CHEMICAL", 130, 139], ["Val 513-Ser", "CHEMICAL", 171, 182], ["Val", "CHEMICAL", 130, 133], ["Ser", "CHEMICAL", 136, 139], ["Val", "CHEMICAL", 171, 174], ["Ser", "CHEMICAL", 179, 182], ["Ser 143", "AMINO_ACID", 136, 143], ["Ser 651", "AMINO_ACID", 179, 186], ["nsp3", "GENE_OR_GENE_PRODUCT", 190, 194], ["nsp3", "PROTEIN", 190, 194], ["the segment Val", "TEST", 159, 174], ["nsp3", "TREATMENT", 190, 194], ["segment", "ANATOMY_MODIFIER", 122, 129], ["segment", "ANATOMY_MODIFIER", 163, 170]]], ["High-quality NMR data for the protein nsp3(513-651) were obtained, as illustrated by the [ 15 N, 1 H]-HSQC spectrum shown in Fig. 1 .", [["[ 15 N, 1 H]-HSQC", "CHEMICAL", 89, 106], ["protein nsp3", "PROTEIN", 30, 42], ["513-651", "PROTEIN", 43, 50], ["the protein nsp3", "TEST", 26, 42], ["HSQC spectrum", "TEST", 102, 115]]], ["Assignments are complete, with the sole exceptions of the backbone 13 C 0 of Leu 514, Ala 518, Met 547, Glu 587, Glu 601, Met 606, Lys 628 and Ser 637 (these residues precede Pro residues), cCH 3 of Val 513 and fCH of Phe 581 (could not be assigned due to spectral overlap).", [["Leu 514", "CHEMICAL", 77, 84], ["Ala 518, Met 547, Glu 587, Glu 601, Met 606, Lys 628", "CHEMICAL", 86, 138], ["Phe 581", "CHEMICAL", 218, 225], ["Leu", "CHEMICAL", 77, 80], ["Ala", "CHEMICAL", 86, 89], ["Met", "CHEMICAL", 95, 98], ["Glu", "CHEMICAL", 104, 107], ["Glu", "CHEMICAL", 113, 116], ["Met", "CHEMICAL", 122, 125], ["Lys", "CHEMICAL", 131, 134], ["Ser", "CHEMICAL", 143, 146], ["Pro", "CHEMICAL", 175, 178], ["Val", "CHEMICAL", 199, 202], ["Phe", "CHEMICAL", 218, 221], ["Leu 514", "AMINO_ACID", 77, 84], ["Ala 518", "AMINO_ACID", 86, 93], ["Met 547", "AMINO_ACID", 95, 102], ["Glu 587", "AMINO_ACID", 104, 111], ["Glu 601", "AMINO_ACID", 113, 120], ["Met 606", "AMINO_ACID", 122, 129], ["Lys 628", "AMINO_ACID", 131, 138], ["Ser 637", "AMINO_ACID", 143, 150], ["Phe 581", "AMINO_ACID", 218, 225], ["Leu", "TEST", 77, 80], ["Ala", "TEST", 86, 89], ["Met", "TEST", 95, 98], ["Glu", "TEST", 104, 107], ["Glu", "TEST", 113, 116], ["Met", "TEST", 122, 125], ["Lys", "TEST", 131, 134], ["Ser", "TEST", 143, 146], ["Pro residues", "TEST", 175, 187], ["cCH", "TEST", 190, 193], ["Val", "TEST", 199, 202], ["fCH", "TEST", 211, 214], ["Phe", "TEST", 218, 221]]], ["The side chain amide groups of all eight Asn and Gln were also assigned.", [["Asn", "CHEMICAL", 41, 44], ["Gln", "CHEMICAL", 49, 52], ["amide", "CHEMICAL", 15, 20], ["Asn", "CHEMICAL", 41, 44], ["Gln", "CHEMICAL", 49, 52], ["Asn", "AMINO_ACID", 41, 44], ["Gln", "AMINO_ACID", 49, 52], ["The side chain amide groups", "TREATMENT", 0, 27], ["all eight Asn and Gln", "TREATMENT", 31, 52]]], ["The chemical shifts have been deposited in the BioMagResBank (http://www.bmrb.wisc.edu) under the accession number 15469.Identification of regular secondary structures from 13 C chemical shiftsHere we use well-established empirical relations between 13 C chemical shifts and regular polypeptide secondary structures (Saito 1986; Pastore and Saudek 1990; Spera and Bax 1991; Wishart et al. 1994; Luginb\u00fchl et al. 1995) to identify polypeptide segments that form a-helices and b-strands.", [["a-helices", "GENE_OR_GENE_PRODUCT", 461, 470], ["polypeptide segments", "PROTEIN", 430, 450], ["a-helices", "PROTEIN", 461, 470], ["b-strands", "PROTEIN", 475, 484], ["regular secondary structures", "PROBLEM", 139, 167], ["chemical shifts", "OBSERVATION", 4, 19], ["deposited", "OBSERVATION_MODIFIER", 30, 39], ["secondary", "OBSERVATION_MODIFIER", 147, 156]]], ["Specifically we usedIdentification of regular secondary structures from 13 C chemical shiftsDdC is the deviation of the experimentally observed 13 C chemical shift from the corresponding random coil value (Metzler et al. 1993) .", [["C", "CHEMICAL", 75, 76], ["C", "CHEMICAL", 147, 148]]], ["In a plot of Dd i versus the amino acid sequence (Fig. 2) , a positive value for Dd i indicates that residue i is located in a regular helical structure, while a negative value indicates its location in an extended b-strand.", [["amino acid", "CHEMICAL", 29, 39], ["amino acid", "CHEMICAL", 29, 39], ["Dd i", "GENE_OR_GENE_PRODUCT", 13, 17], ["amino acid", "AMINO_ACID", 29, 39], ["Dd i", "GENE_OR_GENE_PRODUCT", 81, 85], ["Dd i", "PROTEIN", 13, 17], ["amino acid sequence", "PROTEIN", 29, 48], ["Dd", "PROTEIN", 81, 83], ["regular helical structure", "PROTEIN", 127, 152], ["the amino acid sequence", "TEST", 25, 48], ["residue i", "PROBLEM", 101, 110], ["residue", "OBSERVATION", 101, 108]]], ["(Herrmann et al. 2002a, b) by subtracting the random coil shifts from the experimentally determined chemical shifts.", [["the random coil shifts", "TREATMENT", 42, 64], ["chemical shifts", "OBSERVATION", 100, 115]]], ["The Dd i value for a residue i represents a three-point average over the three consecutive residues i -1, i and i + 1, calculated as Dd i = (DdC a i\u00c01 \u00fe Dd C a i \u00fe DdC a i\u00fe1 \u00c0 DdC b i\u00c01 \u00c0DdC b i \u00c0 DdC b i\u00fe1 )/3 (Metzler et al. 1993) .", [["i + 1", "GENE_OR_GENE_PRODUCT", 112, 117], ["DdC", "PROTEIN", 141, 144], ["i\u00c01", "PROTEIN", 147, 150], ["Dd C", "PROTEIN", 153, 157], ["DdC", "PROTEIN", 164, 167], ["i\u00fe1", "PROTEIN", 170, 173], ["DdC b", "PROTEIN", 176, 181], ["i\u00c01", "PROTEIN", 182, 185], ["\u00c0DdC b", "PROTEIN", 186, 192], ["DdC", "PROTEIN", 197, 200], ["i\u00fe1", "PROTEIN", 203, 206], ["a residue", "PROBLEM", 19, 28], ["DdC", "TEST", 141, 144], ["DdC", "TEST", 164, 167], ["DdC", "TEST", 176, 179], ["b", "TEST", 180, 181], ["\u00c0DdC", "TEST", 186, 190], ["DdC", "TEST", 197, 200]]], ["A positive value for Dd i indicates that residue i is located in a regular helical structure, while a negative value indicates its location in a regular b-strand.", [["Dd i", "GENE_OR_GENE_PRODUCT", 21, 25], ["Dd", "PROTEIN", 21, 23], ["residue i", "PROBLEM", 41, 50], ["residue", "OBSERVATION", 41, 48]]], ["Tentative positions for regular secondary structures indicated at the top of the figure, were obtained with the criterion that |Dd i | \u2021 1 for three or more contiguous residues", [["regular secondary structures", "PROBLEM", 24, 52]]]], "PMC7335224": [["IntroductionThe high prevalence of obesity among non-Hispanic Black Americans (38.3%), aged 18 years and older in 2018, as compared with 31.1% for the general US population, remains an important public health problem [1].", [["obesity", "DISEASE", 35, 42], ["obesity", "PROBLEM", 35, 42], ["high prevalence", "OBSERVATION_MODIFIER", 16, 31], ["obesity", "OBSERVATION", 35, 42]]], ["Obesity has a broad range of health consequences, and its higher prevalence among non-Hispanic Blacks puts them at increased risk for type 2 diabetes (Blacks = 13.0%, Whites = 8.0%), coronary heart disease (Black women = 5.2%, White women = 3.9%), asthma (Blacks = 9.2%, Whites = 8.0%), and stroke (Blacks = 4.0%, Whites = 2.7%) [1].IntroductionThe important role of socioeconomic position (SEP) in the obesity epidemic has long been a focus of research [2\u20135].", [["coronary", "ANATOMY", 183, 191], ["heart", "ANATOMY", 192, 197], ["Obesity", "DISEASE", 0, 7], ["type 2 diabetes", "DISEASE", 134, 149], ["coronary heart disease", "DISEASE", 183, 205], ["asthma", "DISEASE", 248, 254], ["stroke", "DISEASE", 291, 297], ["obesity", "DISEASE", 403, 410], ["heart", "ORGAN", 192, 197], ["women", "SPECIES", 213, 218], ["women", "SPECIES", 233, 238], ["Obesity", "PROBLEM", 0, 7], ["type 2 diabetes", "PROBLEM", 134, 149], ["Blacks", "TEST", 151, 157], ["Whites", "TEST", 167, 173], ["coronary heart disease", "PROBLEM", 183, 205], ["Black women", "TEST", 207, 218], ["White women", "TEST", 227, 238], ["asthma", "PROBLEM", 248, 254], ["Blacks", "TEST", 256, 262], ["Whites", "TEST", 271, 277], ["stroke", "PROBLEM", 291, 297], ["Blacks", "TEST", 299, 305], ["Whites", "TEST", 314, 320], ["socioeconomic position (SEP)", "TREATMENT", 367, 395], ["broad range", "OBSERVATION_MODIFIER", 14, 25], ["coronary heart", "ANATOMY", 183, 197], ["disease", "OBSERVATION", 198, 205], ["asthma", "OBSERVATION", 248, 254], ["stroke", "OBSERVATION", 291, 297], ["obesity", "OBSERVATION", 403, 410]]], ["Prior research has documented correlations between lower rates of obesity and residence in communities with beneficial structural characteristics of neighborhood SEP, including the presence of neighborhood parks and supermarkets [9\u201311].IntroductionResearch findings on the relationship between obesity and individual and household measures of SEP, however, have been more mixed.", [["obesity", "DISEASE", 66, 73], ["obesity", "DISEASE", 294, 301], ["obesity", "PROBLEM", 66, 73], ["obesity", "PROBLEM", 294, 301], ["obesity", "OBSERVATION", 66, 73], ["obesity", "OBSERVATION", 294, 301], ["more mixed", "OBSERVATION_MODIFIER", 367, 377]]], ["For example, some studies have revealed a weakening of the protective effect of increasing education on obesity over the past 30 years, a consequence of the increase in obesity among the most educated [12].", [["obesity", "DISEASE", 104, 111], ["obesity", "DISEASE", 169, 176], ["some studies", "TEST", 13, 25], ["obesity", "PROBLEM", 104, 111], ["the increase in obesity", "PROBLEM", 153, 176], ["weakening", "OBSERVATION_MODIFIER", 42, 51], ["protective effect", "OBSERVATION_MODIFIER", 59, 76], ["increasing", "OBSERVATION_MODIFIER", 80, 90], ["obesity", "OBSERVATION", 104, 111], ["increase", "OBSERVATION_MODIFIER", 157, 165], ["obesity", "OBSERVATION", 169, 176]]], ["The inverse association between SEP and body mass index (BMI) and obesity is stronger among women compared with men [2, 13\u201317].", [["body", "ANATOMY", 40, 44], ["obesity", "DISEASE", 66, 73], ["body", "ORGANISM_SUBDIVISION", 40, 44], ["women", "ORGANISM", 92, 97], ["men", "ORGANISM", 112, 115], ["women", "SPECIES", 92, 97], ["men", "SPECIES", 112, 115], ["The inverse association between SEP and body mass index", "PROBLEM", 0, 55], ["obesity", "PROBLEM", 66, 73], ["body", "ANATOMY", 40, 44], ["mass", "OBSERVATION", 45, 49], ["obesity", "OBSERVATION", 66, 73]]], ["Some studies, in fact, reported a reversal of the expected inverse SEP-obesity association among men; i.e., men of high SEP were more likely to have increased BMI and be overweight or obese than men of low SEP [14\u201316, 18].", [["obesity", "DISEASE", 71, 78], ["overweight or obese", "DISEASE", 170, 189], ["men", "ORGANISM", 97, 100], ["men", "ORGANISM", 108, 111], ["men", "ORGANISM", 195, 198], ["men", "SPECIES", 97, 100], ["men", "SPECIES", 108, 111], ["men", "SPECIES", 195, 198], ["Some studies", "TEST", 0, 12], ["the expected inverse SEP", "PROBLEM", 46, 70], ["high SEP", "PROBLEM", 115, 123], ["increased BMI", "PROBLEM", 149, 162], ["obese", "PROBLEM", 184, 189], ["low SEP", "PROBLEM", 202, 209], ["obesity", "OBSERVATION", 71, 78]]], ["Furthermore, nativity status (foreign-born vs. US-born) differentials in the association of an individual-level measure of SEP on obesity have been reported among Black Americans, with native-born Blacks being at higher risk [19].IntroductionFew studies, however, have examined sex-specific associations between obesity and multilevel measures of SEP within an ethnically diverse group of Black Americans.", [["obesity", "DISEASE", 130, 137], ["obesity", "DISEASE", 312, 319], ["SEP on obesity", "PROBLEM", 123, 137], ["Few studies", "TEST", 242, 253], ["obesity", "PROBLEM", 312, 319], ["multilevel measures of SEP", "PROBLEM", 324, 350], ["obesity", "OBSERVATION", 130, 137], ["obesity", "OBSERVATION", 312, 319], ["multilevel", "OBSERVATION_MODIFIER", 324, 334]]], ["Hence, the present study investigates the potential differential associations between obesity and individual, household, and neighborhood-level SEP indicators among Black American men and women (African-Americans) and Blacks with Caribbean ethnicity (Caribbean-Blacks).", [["obesity", "DISEASE", 86, 93], ["men", "ORGANISM", 180, 183], ["women", "ORGANISM", 188, 193], ["men", "SPECIES", 180, 183], ["women", "SPECIES", 188, 193], ["the present study", "TEST", 7, 24], ["obesity", "PROBLEM", 86, 93], ["obesity", "OBSERVATION", 86, 93]]], ["Elucidation of the differential patterning of multidimensional measures of SEP on obesity among African-American and Caribbean-Black men and women would be beneficial for developing effective interventions to reduce obesity and obesity-related diseases within an increasingly heterogeneous US Black population.Methods and ProceduresThis cross-sectional study utilizes data from the National Survey of American Life (NSAL).", [["obesity", "DISEASE", 82, 89], ["obesity", "DISEASE", 216, 223], ["obesity", "DISEASE", 228, 235], ["men", "ORGANISM", 133, 136], ["women", "ORGANISM", 141, 146], ["men", "SPECIES", 133, 136], ["women", "SPECIES", 141, 146], ["SEP", "PROBLEM", 75, 78], ["obesity", "PROBLEM", 82, 89], ["effective interventions", "TREATMENT", 182, 205], ["obesity", "PROBLEM", 216, 223], ["obesity", "PROBLEM", 228, 235], ["related diseases", "PROBLEM", 236, 252], ["This cross-sectional study", "TEST", 332, 358], ["differential", "OBSERVATION_MODIFIER", 19, 31], ["patterning", "OBSERVATION_MODIFIER", 32, 42], ["obesity", "OBSERVATION", 82, 89], ["obesity", "OBSERVATION", 216, 223], ["obesity", "OBSERVATION", 228, 235], ["increasingly", "OBSERVATION_MODIFIER", 263, 275], ["heterogeneous", "OBSERVATION_MODIFIER", 276, 289], ["Black population", "OBSERVATION", 293, 309]]], ["All procedures involving human subjects, including oral and written consent from all participants 18 years of age and older, were approved by the Institutional Review Board at the University of Michigan [21].", [["oral", "ANATOMY", 51, 55], ["human", "ORGANISM", 25, 30], ["oral", "ORGANISM_SUBDIVISION", 51, 55], ["human", "SPECIES", 25, 30], ["participants", "SPECIES", 85, 97], ["human", "SPECIES", 25, 30]]], ["The NSAL includes a sample of 891 non-Hispanic Whites, 3570 African-Americans, persons who identified as Black but did not have ancestral ties to the Caribbean (including 67 foreign-born Blacks), and 1621 Caribbean-Blacks, persons who identified as Black and who either were born in Caribbean area countries (73% of the Caribbean-Black sample), had parents or grandparents who were born in the Caribbean, or had indicated that they were of Caribbean ethnicity.", [["persons", "ORGANISM", 79, 86], ["persons", "ORGANISM", 223, 230], ["persons", "SPECIES", 79, 86], ["persons", "SPECIES", 223, 230]]], ["The NSAL survey data includes assessments of mental, emotional, and physical health and residential, environmental, and socioeconomic characteristics.", [["The NSAL survey data", "TEST", 0, 20]]], ["Data were collected between February 2001 and June 2003 with response rates of 70.7% for African-Americans, 77.7% for Caribbean-Blacks, and 72.3% for Whites.", [["response rates", "TEST", 61, 75], ["Caribbean", "TEST", 118, 127], ["Blacks", "TEST", 128, 134]]], ["This paper capitalizes on the growing heterogeneity of the US Black population as reflected in the NSAL sample and reports findings for African-American and Caribbean-Black men and women, aged 18 years and older within the NSAL sample.Methods and ProceduresThe study outcome is obesity, characterized as having a body mass index (BMI, weight (kg)/height (m)2) 30 or higher [22].", [["body", "ANATOMY", 313, 317], ["obesity", "DISEASE", 278, 285], ["men", "ORGANISM", 173, 176], ["women", "ORGANISM", 181, 186], ["body", "ORGANISM_SUBDIVISION", 313, 317], ["men", "SPECIES", 173, 176], ["women", "SPECIES", 181, 186], ["Black population", "PROBLEM", 62, 78], ["obesity", "PROBLEM", 278, 285], ["a body mass index", "TEST", 311, 328], ["BMI", "TEST", 330, 333], ["weight", "TEST", 335, 341], ["height", "TEST", 347, 353], ["growing", "OBSERVATION_MODIFIER", 30, 37], ["heterogeneity", "OBSERVATION_MODIFIER", 38, 51], ["Black", "OBSERVATION_MODIFIER", 62, 67], ["population", "OBSERVATION", 68, 78], ["obesity", "OBSERVATION", 278, 285]]], ["BMI is calculated within the NSAL based on self-reported weight and height.", [["BMI", "TEST", 0, 3]]], ["SEP indicators at the individual level include current education specified as < high school (HS), HS and > HS, and respondent\u2019s main occupation categorized into professional/managerial, sales/administrative, skilled blue collar, unskilled blue collar, and service.", [["SEP indicators", "PROBLEM", 0, 14], ["skilled blue collar", "TREATMENT", 208, 227], ["unskilled blue collar", "TREATMENT", 229, 250], ["blue collar", "OBSERVATION", 239, 250]]], ["Finally, SEP measures assessed at the neighborhood level include self-reported measures previously found to be associated with obesity within African-Americans and Caribbean-Blacks\u2014having a supermarket within one\u2019s neighborhood (yes vs. no) and having a park within one\u2019s neighborhood (yes vs. no) [23].Methods and ProceduresCovariates utilized for statistical adjustment due to their known associations with SEP and obesity include demographic variables such as age [5], categorized into less than or equal to 29 years, 30\u201344 years, 45\u201359 years, and 60 or more years; marital status, [24] characterized as (1) married or living with a partner, (2) separated, divorced or widowed, and (3) never married; and three measures of health behaviors, (1) physical activity [22], a continuous measure based on how often the study participants worked in the garden or yard, engaged in active sports or exercise, and walked, (2) smoking status [25], specified as the participant never having smoked more than 100 cigarettes in his/her lifetime or \u201cnever smoker,\u201d having smoked more than 100 cigarettes in the past or \u201cpast smoker,\u201d and \u201ccurrent smoker,\u201d and (3) current alcohol consumption [22], categorized for analytical purposes into consuming no alcoholic drinks within the past year or \u201cnone,\u201d having consumed less than 12 drinks within the past year, or \u201cinfrequent drinker,\u201d and moderate-to-heavy drinkers having consumed 12 or more drinks within the past year or \u201cregular drinker.\u201dMethods and ProceduresTo minimize bias due to differentially distributed missing data on measures of SEP and BMI by ethnicity (African-American and Caribbean-Black) and sex, multiple imputation was performed prior to statistical analysis within the statistical software package IVEware [26].", [["obesity", "DISEASE", 127, 134], ["obesity", "DISEASE", 417, 424], ["alcohol", "CHEMICAL", 1160, 1167], ["alcohol", "CHEMICAL", 1160, 1167], ["alcohol", "SIMPLE_CHEMICAL", 1160, 1167], ["participants", "SPECIES", 822, 834], ["participant", "SPECIES", 957, 968], ["SEP measures", "TEST", 9, 21], ["obesity", "PROBLEM", 127, 134], ["statistical adjustment", "TREATMENT", 349, 371], ["obesity", "PROBLEM", 417, 424], ["Methods", "TREATMENT", 1479, 1486], ["SEP", "PROBLEM", 1580, 1583], ["multiple imputation", "TEST", 1653, 1672], ["statistical analysis", "TEST", 1696, 1716], ["obesity", "OBSERVATION", 127, 134]]], ["IVEware uses a sequential regression imputation method to impute values for each individual, conditional on all other values observed for that individual, consequently producing complete datasets for unbiased analyses [27].", [["a sequential regression imputation method", "TREATMENT", 13, 54], ["unbiased analyses", "TEST", 200, 217]]], ["Chi-square tests were performed to examine group differences in categorical variables, whereas the global F test within an unadjusted linear regression model was utilized to calculate ethnicity and sex differences in physical activity.", [["Chi-square tests", "TEST", 0, 16], ["the global F test", "TEST", 95, 112]]], ["Since previous studies reveal differential SEP patterning of obesity by both sex and ethnicity [4, 19], three-way interactions between measures of SEP, ethnicity, and sex were tested.", [["obesity", "DISEASE", 61, 68], ["previous studies", "TEST", 6, 22], ["obesity", "PROBLEM", 61, 68], ["differential", "OBSERVATION_MODIFIER", 30, 42], ["SEP", "OBSERVATION_MODIFIER", 43, 46], ["patterning", "OBSERVATION_MODIFIER", 47, 57], ["obesity", "OBSERVATION", 61, 68]]], ["Statistically significant three-way interactions were found for five out of the eight SEP indicators, p values ranging from 0.008 to 0.024.", [["significant", "OBSERVATION_MODIFIER", 14, 25]]], ["Therefore, all nested multivariate logistic regression models assessing the strength of the independent associations between multilevel measures of SEP and obesity after covariate adjustment are presented stratified by ethnicity and sex.", [["obesity", "DISEASE", 156, 163], ["all nested multivariate logistic regression models", "TREATMENT", 11, 61], ["SEP", "PROBLEM", 148, 151], ["obesity", "PROBLEM", 156, 163], ["covariate adjustment", "TREATMENT", 170, 190], ["obesity", "OBSERVATION", 156, 163]]], ["Specifically, the following five models were fitted for each SEP indicator: (1) odds ratios (ORs) adjusted for age; (2) ORs additionally adjusted for individual-level SEP, i.e., education, occupation, as well as for marital status; (3) ORs additionally adjusted for family-level SEP, i.e., public support, house value, and family income; (4) ORs additionally adjusted for neighborhood-level SEP, i.e., neighborhood supermarket and neighborhood park; and (5) ORs additionally adjusted for health behaviors, i.e., physical activity, alcohol intake, and smoking.Methods and ProceduresData management was conducted using SAS Version 9, [28] and all statistical analyses were performed using SUDAAN [29] to account for the multiple imputation and the complex sample design of the NSAL in calculating unbiased effect estimates and standard errors.", [["alcohol", "CHEMICAL", 531, 538], ["smoking", "CHEMICAL", 551, 558], ["alcohol", "CHEMICAL", 531, 538], ["alcohol", "SIMPLE_CHEMICAL", 531, 538], ["SAS Version", "TEST", 617, 628], ["all statistical analyses", "TEST", 641, 665], ["the multiple imputation", "PROBLEM", 714, 737]]], ["Sample sizes presented within tables are un-weighted; however, all other estimates, means proportions, and standard errors, as well as ORs and 95% confidence intervals (CIs), are weighted.ResultsTable 1 describes the general characteristics of African-American and Caribbean-Black men and women in the NSAL sample.", [["men", "ORGANISM", 281, 284], ["women", "ORGANISM", 289, 294], ["men", "SPECIES", 281, 284], ["women", "SPECIES", 289, 294], ["Sample sizes", "TEST", 0, 12], ["sizes", "OBSERVATION_MODIFIER", 7, 12]]], ["African-American women had the highest prevalence of obesity at 41.2% followed by Caribbean-Black women at 31.1% and African-American men at 29.9%.", [["obesity", "DISEASE", 53, 60], ["African-American", "ORGANISM", 0, 16], ["women", "ORGANISM", 17, 22], ["women", "ORGANISM", 98, 103], ["men", "ORGANISM", 134, 137], ["women", "SPECIES", 17, 22], ["women", "SPECIES", 98, 103], ["men", "SPECIES", 134, 137], ["obesity", "PROBLEM", 53, 60], ["obesity", "OBSERVATION", 53, 60]]], ["Caribbean-Black men had the lowest prevalence of obesity at 21.6%.", [["obesity", "DISEASE", 49, 56], ["men", "ORGANISM", 16, 19], ["men", "SPECIES", 16, 19], ["obesity", "PROBLEM", 49, 56], ["obesity", "OBSERVATION", 49, 56]]], ["Caribbean-Black men and women were also younger than African-American men and women with 64.9% and 66.2% of Caribbean-Black men and women being under the age of 45 as compared with 61.0% and 58.8% of African-American men and women, respectively.ResultsCaribbean-Black men and women had greater educational attainment than African-American men and women, with 49.4% of Caribbean-Black men and 48.8% of Caribbean-Black women and 37.3% of African-American men and 38.4% of African-American women having > HS education.", [["men", "ORGANISM", 16, 19], ["women", "ORGANISM", 24, 29], ["men", "ORGANISM", 70, 73], ["women", "ORGANISM", 78, 83], ["men", "ORGANISM", 124, 127], ["women", "ORGANISM", 132, 137], ["men", "ORGANISM", 217, 220], ["women", "ORGANISM", 225, 230], ["men", "ORGANISM", 268, 271], ["women", "ORGANISM", 276, 281], ["men", "ORGANISM", 339, 342], ["women", "ORGANISM", 347, 352], ["men", "ORGANISM", 384, 387], ["women", "ORGANISM", 417, 422], ["men", "ORGANISM", 453, 456], ["women", "ORGANISM", 487, 492], ["men", "SPECIES", 16, 19], ["women", "SPECIES", 24, 29], ["men", "SPECIES", 70, 73], ["women", "SPECIES", 78, 83], ["men", "SPECIES", 124, 127], ["women", "SPECIES", 132, 137], ["men", "SPECIES", 217, 220], ["women", "SPECIES", 225, 230], ["men", "SPECIES", 268, 271], ["women", "SPECIES", 276, 281], ["men", "SPECIES", 339, 342], ["women", "SPECIES", 347, 352], ["men", "SPECIES", 384, 387], ["women", "SPECIES", 417, 422], ["men", "SPECIES", 453, 456], ["women", "SPECIES", 487, 492]]], ["Men were more likely to be married or living with a partner than women; Caribbean-Black men had the highest prevalence at 59.9%, while African-American women had the lowest at 35.6%.", [["Men", "ORGANISM", 0, 3], ["women", "ORGANISM", 65, 70], ["men", "ORGANISM", 88, 91], ["women", "ORGANISM", 152, 157], ["Men", "SPECIES", 0, 3], ["women", "SPECIES", 65, 70], ["men", "SPECIES", 88, 91], ["women", "SPECIES", 152, 157]]], ["In addition, men were more likely than women to be employed in the skilled and unskilled blue collar professions; unskilled blue collar employment was highest for African-American men at 33.2%.", [["men", "ORGANISM", 13, 16], ["women", "ORGANISM", 39, 44], ["men", "ORGANISM", 180, 183], ["men", "SPECIES", 13, 16], ["women", "SPECIES", 39, 44], ["men", "SPECIES", 180, 183], ["unskilled blue collar professions", "TREATMENT", 79, 112], ["unskilled blue collar employment", "TREATMENT", 114, 146]]], ["Women were more likely than men to be employed in service professions.", [["Women", "ORGANISM", 0, 5], ["men", "ORGANISM", 28, 31], ["Women", "SPECIES", 0, 5], ["men", "SPECIES", 28, 31]]], ["Moreover, Caribbean-Black men and women, at 23.0% and 23.3%, respectively, were more likely to work in professional/managerial positions compared with African-American men and women at 15.4% and 17.9%, respectively.ResultsAfrican-American women were the most likely to receive public support, and accordingly, most likely to have had the lowest family income compared with all other ethnic/sex groups.", [["men", "ORGANISM", 26, 29], ["women", "ORGANISM", 34, 39], ["men", "ORGANISM", 168, 171], ["women", "ORGANISM", 176, 181], ["women", "ORGANISM", 239, 244], ["men", "SPECIES", 26, 29], ["women", "SPECIES", 34, 39], ["men", "SPECIES", 168, 171], ["women", "SPECIES", 176, 181], ["women", "SPECIES", 239, 244], ["public support", "TREATMENT", 277, 291], ["most likely", "UNCERTAINTY", 310, 321]]], ["Caribbean-Black men were least likely to receive public support and to have had the highest family income.", [["men", "ORGANISM", 16, 19], ["men", "SPECIES", 16, 19], ["public support", "TREATMENT", 49, 63]]], ["African-American men were most likely to be homeowners relative to all other ethnic/sex groups, whereas Caribbean-Black women were least likely to be homeowners.ResultsCaribbean-Black men and women were more likely than African-American men and women to live in neighborhoods that had a supermarket or a park.", [["African-American", "ORGANISM", 0, 16], ["men", "ORGANISM", 17, 20], ["women", "ORGANISM", 120, 125], ["men", "ORGANISM", 184, 187], ["women", "ORGANISM", 192, 197], ["men", "ORGANISM", 237, 240], ["women", "ORGANISM", 245, 250], ["men", "SPECIES", 17, 20], ["women", "SPECIES", 120, 125], ["men", "SPECIES", 184, 187], ["women", "SPECIES", 192, 197], ["men", "SPECIES", 237, 240], ["women", "SPECIES", 245, 250]]], ["Caribbean-Black men had the highest prevalence, in that 91% lived in a neighborhood with a supermarket and 88.1% resided in a neighborhood with a park.", [["men", "ORGANISM", 16, 19], ["men", "SPECIES", 16, 19]]], ["African-American women had the lowest prevalence with approximately 71% residing in a neighborhood that had a supermarket or park.ResultsMen reported higher rates of physical activity than women, with Caribbean-Black men having the highest average score (2.95) and African-American women having the lowest (2.56).", [["African-American", "ORGANISM", 0, 16], ["women", "ORGANISM", 17, 22], ["women", "ORGANISM", 189, 194], ["men", "ORGANISM", 217, 220], ["women", "ORGANISM", 282, 287], ["women", "SPECIES", 17, 22], ["women", "SPECIES", 189, 194], ["men", "SPECIES", 217, 220], ["women", "SPECIES", 282, 287]]], ["Seventy-nine percent of Caribbean-Black women never smoked, whereas only 49.4% of African-American men never smoked.", [["women", "ORGANISM", 40, 45], ["men", "ORGANISM", 99, 102], ["women", "SPECIES", 40, 45], ["men", "SPECIES", 99, 102]]], ["Finally, African-American women were least likely to consume alcohol in the past year where 43.5% never drank.", [["alcohol", "CHEMICAL", 61, 68], ["alcohol", "CHEMICAL", 61, 68], ["women", "ORGANISM", 26, 31], ["alcohol", "SIMPLE_CHEMICAL", 61, 68], ["women", "SPECIES", 26, 31]]], ["Caribbean-Black men were most likely to drink alcohol in the past year and 55.7% were regular drinkers.ResultsTables 2, 3, 4, and 5 present the adjusted odds ratios (ORs) and 95% confidence intervals for the associations between obesity and individual-, family-, and neighborhood-level socioeconomic position (SEP) among African-American men, Caribbean-Black men, African-American women, and Caribbean-Black women, respectively.", [["alcohol", "CHEMICAL", 46, 53], ["obesity", "DISEASE", 229, 236], ["alcohol", "CHEMICAL", 46, 53], ["men", "ORGANISM", 16, 19], ["men", "ORGANISM", 338, 341], ["men", "ORGANISM", 359, 362], ["women", "ORGANISM", 381, 386], ["women", "ORGANISM", 408, 413], ["men", "SPECIES", 16, 19], ["men", "SPECIES", 338, 341], ["men", "SPECIES", 359, 362], ["women", "SPECIES", 381, 386], ["women", "SPECIES", 408, 413], ["obesity", "PROBLEM", 229, 236], ["obesity", "OBSERVATION", 229, 236]]], ["Unless otherwise stated, all ORs were determined from the fully adjusted models.ResultsFor African-American men, no significant associations between obesity and any individual-level measure of SEP were observed (Table 2).", [["obesity", "DISEASE", 149, 156], ["men", "ORGANISM", 108, 111], ["men", "SPECIES", 108, 111], ["significant associations between obesity", "PROBLEM", 116, 156], ["SEP", "PROBLEM", 193, 196], ["obesity", "OBSERVATION", 149, 156]]], ["Low SEP at the family level, however, was associated with a lower odds of obesity.", [["obesity", "DISEASE", 74, 81], ["Low SEP", "PROBLEM", 0, 7], ["obesity", "PROBLEM", 74, 81], ["obesity", "OBSERVATION", 74, 81]]], ["Within all adjusted models for African-American men, family income within the lowest quartile was protective against obesity relative to the highest quartile, OR = 0.50, 95% CI (0.27, 0.92).", [["obesity", "DISEASE", 117, 124], ["men", "ORGANISM", 48, 51], ["men", "SPECIES", 48, 51], ["obesity", "PROBLEM", 117, 124], ["CI", "TEST", 174, 176]]], ["Furthermore, African-American male homeowners with housing equity at or below the median had a 43% increased odds of obesity compared with their non-home-owning counterparts, OR = 1.43, 95% CI (1.00, 2.06).", [["obesity", "DISEASE", 117, 124], ["obesity", "PROBLEM", 117, 124], ["CI", "TEST", 190, 192], ["obesity", "OBSERVATION", 117, 124]]], ["Neighborhood-level SEP was also associated with obesity, with all adjusted models showing lower odds of obesity for African-American men residing in neighborhoods that contained a park compared with those who lived in neighborhoods without one (OR = 0.60, 95% CI (0.38, 0.94)).ResultsAs shown in Table 3, none of the individual-level measures of SEP for Caribbean-Black men was significantly associated with obesity, paralleling the findings for African-American men.", [["obesity", "DISEASE", 48, 55], ["obesity", "DISEASE", 104, 111], ["obesity", "DISEASE", 408, 415], ["men", "ORGANISM", 133, 136], ["men", "ORGANISM", 370, 373], ["men", "ORGANISM", 463, 466], ["men", "SPECIES", 133, 136], ["men", "SPECIES", 370, 373], ["men", "SPECIES", 463, 466], ["obesity", "PROBLEM", 48, 55], ["obesity", "PROBLEM", 104, 111], ["CI", "TEST", 260, 262], ["ResultsAs", "TEST", 277, 286], ["obesity", "PROBLEM", 408, 415], ["obesity", "OBSERVATION", 48, 55], ["obesity", "OBSERVATION", 104, 111], ["obesity", "OBSERVATION", 408, 415]]], ["Nevertheless, selected family- and neighborhood-level SEP measures were associated with obesity.", [["obesity", "DISEASE", 88, 95], ["obesity", "PROBLEM", 88, 95], ["obesity", "OBSERVATION", 88, 95]]], ["For example, like African-American men, low family income was protective for Caribbean-Black men within the age-adjusted model; however, this association became non-significant (P > 0.05) with additional covariate adjustment.", [["African-American", "ORGANISM", 18, 34], ["men", "ORGANISM", 35, 38], ["men", "ORGANISM", 93, 96], ["men", "SPECIES", 35, 38], ["men", "SPECIES", 93, 96], ["additional covariate adjustment", "TREATMENT", 193, 224]]], ["Furthermore, Caribbean-Black men who received any public assistance had 3.5 times the odds (95% CI 1.30, 9.42) of obesity compared with their counterparts who did not.", [["obesity", "DISEASE", 114, 121], ["men", "ORGANISM", 29, 32], ["men", "SPECIES", 29, 32], ["CI", "TEST", 96, 98], ["obesity", "PROBLEM", 114, 121], ["obesity", "OBSERVATION", 114, 121]]], ["Finally, Caribbean-Black men residing in a neighborhood containing a supermarket experienced an 86% decreased odds of obesity compared with those in neighborhoods without this amenity, OR = 0.14, 95% CI (0.04, 0.52).ResultsIn contrast to men, Table 4 shows statistically significant associations between measures of individual-level SEP and obesity for African-American women.", [["obesity", "DISEASE", 118, 125], ["obesity", "DISEASE", 341, 348], ["men", "ORGANISM", 25, 28], ["men", "ORGANISM", 238, 241], ["women", "ORGANISM", 370, 375], ["men", "SPECIES", 25, 28], ["men", "SPECIES", 238, 241], ["women", "SPECIES", 370, 375], ["obesity", "PROBLEM", 118, 125], ["CI", "TEST", 200, 202], ["obesity", "PROBLEM", 341, 348], ["obesity", "OBSERVATION", 118, 125], ["obesity", "OBSERVATION", 341, 348]]], ["African-American women with < HS education had 1.47 times the odds (95% CI (1.04, 2.09)) of obesity than those with > HS education.", [["obesity", "DISEASE", 92, 99], ["African-American", "ORGANISM", 0, 16], ["women", "ORGANISM", 17, 22], ["women", "SPECIES", 17, 22], ["obesity", "PROBLEM", 92, 99]]], ["Though only borderline significant in fully adjusted models, African-American women with a HS education had 1.40 times the odds (95% CI (0.96, 2.05)) of obesity compared with those with > HS education.", [["obesity", "DISEASE", 153, 160], ["women", "ORGANISM", 78, 83], ["women", "SPECIES", 78, 83], ["a HS education", "TREATMENT", 89, 103], ["CI", "TEST", 133, 135], ["obesity", "PROBLEM", 153, 160], ["borderline", "OBSERVATION_MODIFIER", 12, 22], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["obesity", "OBSERVATION", 153, 160]]], ["African-American women employed in the sales/administrative occupations had 27% lower odds of obesity compared with African-American women employed in service employment, OR = 0.73, 95% CI (0.57, 0.94).ResultsIn contrast to African-American men, higher family SEP was protective against obesity for African-American women.", [["obesity", "DISEASE", 94, 101], ["obesity", "DISEASE", 287, 294], ["African-American", "ORGANISM", 0, 16], ["women", "ORGANISM", 17, 22], ["women", "ORGANISM", 133, 138], ["men", "ORGANISM", 241, 244], ["women", "ORGANISM", 316, 321], ["women", "SPECIES", 17, 22], ["women", "SPECIES", 133, 138], ["men", "SPECIES", 241, 244], ["women", "SPECIES", 316, 321], ["obesity", "PROBLEM", 94, 101], ["CI", "TEST", 186, 188], ["obesity", "PROBLEM", 287, 294], ["obesity", "OBSERVATION", 94, 101]]], ["Though of borderline significance, African-American women who received public support had a 27% greater odds of obesity compared with those not receiving such support, OR = 1.27, 95% CI (0.98, 1.63).", [["obesity", "DISEASE", 112, 119], ["women", "ORGANISM", 52, 57], ["women", "SPECIES", 52, 57], ["public support", "TREATMENT", 71, 85], ["obesity", "PROBLEM", 112, 119], ["such support", "TREATMENT", 154, 166], ["CI", "TEST", 183, 185], ["obesity", "OBSERVATION", 112, 119]]], ["Though not statistically significant, African-American women with family income in the third quartile were associated with a 35% increased odds of obesity compared with women in the highest quartile, OR = 1.35, 95% CI (0.97, 1.89).", [["obesity", "DISEASE", 147, 154], ["African-American", "ORGANISM", 38, 54], ["women", "ORGANISM", 55, 60], ["women", "ORGANISM", 169, 174], ["women", "SPECIES", 55, 60], ["women", "SPECIES", 169, 174], ["obesity", "PROBLEM", 147, 154], ["CI", "TEST", 215, 217], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["obesity", "OBSERVATION", 147, 154]]], ["African-American females with housing equity above the median had 22% lower odds of obesity compared with their non-home-owning counterparts, though borderline significant, OR = 0.78, 95% CI (0.59, 1.03).", [["obesity", "DISEASE", 84, 91], ["African-American", "ORGANISM", 0, 16], ["obesity", "PROBLEM", 84, 91], ["CI", "TEST", 188, 190], ["obesity", "OBSERVATION", 84, 91]]], ["Finally, at the neighborhood level, African-American women residing in neighborhoods containing a supermarket had a 26% decreased odds of obesity compared with those without this amenity, OR = 0.74, 95% CI (0.56, 0.96).ResultsTable 5 summarizes associations between SEP and obesity among Caribbean-Black women.", [["obesity", "DISEASE", 138, 145], ["obesity", "DISEASE", 274, 281], ["women", "ORGANISM", 53, 58], ["women", "ORGANISM", 304, 309], ["women", "SPECIES", 53, 58], ["women", "SPECIES", 304, 309], ["obesity", "PROBLEM", 138, 145], ["CI", "TEST", 203, 205], ["SEP", "PROBLEM", 266, 269], ["obesity", "PROBLEM", 274, 281], ["obesity", "OBSERVATION", 138, 145], ["obesity", "OBSERVATION", 274, 281]]], ["Occupation is the only individual-level SEP measure that was associated with obesity in this group.", [["obesity", "DISEASE", 77, 84], ["obesity", "PROBLEM", 77, 84], ["obesity", "OBSERVATION", 77, 84]]], ["Being employed within professional/managerial occupations was associated with a decreased odds of obesity compared with employment in service occupations, after adjusting for age, marital status, and other individual-level, family-level, and neighborhood-level SEP measures, OR = 0.55, 95% CI (0.30, 0.99).", [["obesity", "DISEASE", 98, 105], ["obesity", "PROBLEM", 98, 105], ["CI", "TEST", 290, 292], ["obesity", "OBSERVATION", 98, 105]]], ["This association became statistically insignificant, however, after adjusting for physical activity, smoking, and alcohol consumption, OR = 0.61, 95% CI (0.35, 1.07).ResultsSimilar to African-American women, receipt of public assistance increased the odds of obesity for Caribbean-Black women; however, the magnitude of the association was stronger for the latter.", [["smoking", "CHEMICAL", 101, 108], ["alcohol", "CHEMICAL", 114, 121], ["obesity", "DISEASE", 259, 266], ["alcohol", "CHEMICAL", 114, 121], ["alcohol", "SIMPLE_CHEMICAL", 114, 121], ["women", "ORGANISM", 201, 206], ["women", "ORGANISM", 287, 292], ["women", "SPECIES", 201, 206], ["women", "SPECIES", 287, 292], ["obesity", "PROBLEM", 259, 266], ["insignificant", "OBSERVATION", 38, 51], ["obesity", "OBSERVATION", 259, 266]]], ["Caribbean-Black women receiving public support had 1.74 times the odds of obesity compared with Caribbean-Black women not on public assistance, 95% CI (1.08, 2.82).", [["obesity", "DISEASE", 74, 81], ["women", "ORGANISM", 16, 21], ["women", "ORGANISM", 112, 117], ["women", "SPECIES", 16, 21], ["women", "SPECIES", 112, 117], ["public support", "TREATMENT", 32, 46], ["obesity", "PROBLEM", 74, 81], ["obesity", "OBSERVATION", 74, 81]]], ["Yet, unlike African-American women, in age-adjusted and individual-level SEP adjusted models, Caribbean-Black women with family income in the third quartile had a decreased odds of obesity compared with those with family income in the fourth quartile.", [["obesity", "DISEASE", 181, 188], ["African-American women", "ORGANISM", 12, 34], ["women", "ORGANISM", 110, 115], ["women", "SPECIES", 29, 34], ["women", "SPECIES", 110, 115], ["obesity", "PROBLEM", 181, 188], ["obesity", "OBSERVATION", 181, 188]]], ["In fully adjusted models, this relationship became statistically insignificant, OR = 0.56, 95% CI (0.28, 1.14).", [["CI", "TEST", 95, 97]]], ["No association was observed between obesity and neighborhood-level SEP variables for Caribbean-Black women, in contrast to findings for both groups of men.DiscussionThis study of the association between multiple dimensions of SEP (individual, family, and neighborhood) and obesity in a sample of US Blacks found that associations varied by ethnicity and by sex.", [["obesity", "DISEASE", 36, 43], ["obesity", "DISEASE", 273, 280], ["women", "ORGANISM", 101, 106], ["men", "ORGANISM", 151, 154], ["women", "SPECIES", 101, 106], ["men", "SPECIES", 151, 154], ["obesity", "PROBLEM", 36, 43], ["This study", "TEST", 165, 175], ["obesity", "PROBLEM", 273, 280], ["obesity", "OBSERVATION", 273, 280]]], ["Among African-American men, no statistically significant associations between SEP and obesity were observed at the individual level, but a positive relationship was observed for family SEP; namely, African-American men in the bottom quartile of family income and who had no housing equity had the lowest odds of obesity.", [["obesity", "DISEASE", 86, 93], ["obesity", "DISEASE", 312, 319], ["men", "ORGANISM", 23, 26], ["men", "ORGANISM", 215, 218], ["men", "SPECIES", 23, 26], ["men", "SPECIES", 215, 218], ["SEP", "PROBLEM", 78, 81], ["obesity", "PROBLEM", 86, 93], ["obesity", "PROBLEM", 312, 319], ["obesity", "OBSERVATION", 86, 93], ["obesity", "OBSERVATION", 312, 319]]], ["Similar to African-American men, there was no association between adulthood SEP at the individual level among Caribbean-Black men.", [["men", "ORGANISM", 28, 31], ["men", "ORGANISM", 126, 129], ["men", "SPECIES", 28, 31], ["men", "SPECIES", 126, 129], ["adulthood SEP", "PROBLEM", 66, 79], ["no", "UNCERTAINTY", 43, 45]]], ["For Caribbean-Black men, more complex SEP patterns for family income were observed, wherein (1) obesity increased among those receiving public assistance and (2), similar to African-American men, a positive association was observed between family income and obesity.DiscussionThe association between public assistance and the increasing odds of obesity among Caribbean-Black men is consistent with a previous report showing that participation in public assistance programs increased the risk of adult obesity [30].", [["obesity", "DISEASE", 96, 103], ["obesity", "DISEASE", 258, 265], ["obesity", "DISEASE", 345, 352], ["obesity", "DISEASE", 501, 508], ["men", "ORGANISM", 20, 23], ["men", "ORGANISM", 191, 194], ["men", "ORGANISM", 375, 378], ["men", "SPECIES", 20, 23], ["men", "SPECIES", 191, 194], ["men", "SPECIES", 375, 378], ["obesity", "PROBLEM", 96, 103], ["obesity", "PROBLEM", 258, 265], ["public assistance", "TREATMENT", 300, 317], ["obesity", "PROBLEM", 345, 352], ["public assistance programs", "TREATMENT", 446, 472], ["adult obesity", "PROBLEM", 495, 508], ["obesity", "OBSERVATION", 258, 265], ["obesity", "OBSERVATION", 345, 352]]], ["In this particular study, the association was stronger among men than women and was mediated by dietary quality as assessed by higher soda consumption.", [["men", "ORGANISM", 61, 64], ["women", "ORGANISM", 70, 75], ["men", "SPECIES", 61, 64], ["women", "SPECIES", 70, 75], ["this particular study", "TEST", 3, 24]]], ["Moreover, in the current study, our finding of a positive association between obesity and SEP at the family level among Black men is also in line with previous reports [5, 14, 31, 32].", [["obesity", "DISEASE", 78, 85], ["men", "ORGANISM", 126, 129], ["men", "SPECIES", 126, 129], ["the current study", "TEST", 13, 30], ["a positive association between obesity", "PROBLEM", 47, 85], ["obesity", "OBSERVATION", 78, 85]]], ["African-American elementary school boys with low SEP have been reported to engage in more vigorous physical activity than high SEP boys through participation in team sports such as football and basketball [33].", [["African-American", "ORGANISM", 0, 16], ["boys", "SPECIES", 35, 39], ["boys", "SPECIES", 131, 135]]], ["This engagement in vigorous team sports, if it continues throughout adulthood [34], is a possible contributing factor in lowering the risk of obesity among low SEP African-American and Caribbean-Black men.", [["obesity", "DISEASE", 142, 149], ["men", "ORGANISM", 201, 204], ["men", "SPECIES", 201, 204], ["obesity", "PROBLEM", 142, 149], ["obesity", "OBSERVATION", 142, 149]]], ["This is a hypothesis that should be tested in prospective research.", [["a hypothesis", "PROBLEM", 8, 20]]], ["Moreover, the higher obesity rate among high SEP men has been postulated to be due to the positive effect increased body weight has on higher earned income and social prestige among men [35].", [["body", "ANATOMY", 116, 120], ["obesity", "DISEASE", 21, 28], ["men", "ORGANISM", 49, 52], ["body", "ORGANISM_SUBDIVISION", 116, 120], ["men", "ORGANISM", 182, 185], ["men", "SPECIES", 49, 52], ["men", "SPECIES", 182, 185], ["the higher obesity rate", "PROBLEM", 10, 33], ["the positive effect increased body weight", "PROBLEM", 86, 127], ["higher", "OBSERVATION_MODIFIER", 14, 20], ["obesity", "OBSERVATION", 21, 28]]], ["Future longitudinal investigations should determine whether perceived and actual positive economic consequences for increasing body size drive the positive relationship between SEP and obesity among men.DiscussionFor African-American women, the expected inverse relationship between individual-level SEP and obesity was seen for education [15]; however, educational attainment was not associated with obesity among Caribbean-Black women.", [["body", "ANATOMY", 127, 131], ["obesity", "DISEASE", 185, 192], ["obesity", "DISEASE", 308, 315], ["obesity", "DISEASE", 401, 408], ["body", "ORGANISM_SUBDIVISION", 127, 131], ["men", "ORGANISM", 199, 202], ["women", "ORGANISM", 234, 239], ["women", "ORGANISM", 431, 436], ["men", "SPECIES", 199, 202], ["women", "SPECIES", 234, 239], ["women", "SPECIES", 431, 436], ["Future longitudinal investigations", "TEST", 0, 34], ["actual positive economic consequences", "PROBLEM", 74, 111], ["increasing body size", "PROBLEM", 116, 136], ["obesity", "PROBLEM", 185, 192], ["obesity", "PROBLEM", 308, 315], ["obesity", "PROBLEM", 401, 408], ["body size", "OBSERVATION_MODIFIER", 127, 136], ["obesity", "OBSERVATION", 185, 192]]], ["In line with previous research [36], our study also reveals that higher status occupations, i.e., sales and administrative jobs among African-American women and professional and managerial jobs among Caribbean-Black women, are associated with lower odds for obesity than lesser status service professions.", [["obesity", "DISEASE", 258, 265], ["women", "ORGANISM", 151, 156], ["women", "ORGANISM", 216, 221], ["women", "SPECIES", 151, 156], ["women", "SPECIES", 216, 221], ["our study", "TEST", 37, 46], ["obesity", "PROBLEM", 258, 265]]], ["Finally, our results at family-level SEP show that similar to Caribbean-Black men, receipt of public assistance increased odds for obesity among women, with a stronger association for Caribbean-Black women.DiscussionLastly, our results show important ethnic and sex differences in the association between community SEP characteristics and obesity.", [["obesity", "DISEASE", 131, 138], ["obesity", "DISEASE", 339, 346], ["men", "ORGANISM", 78, 81], ["women", "ORGANISM", 145, 150], ["women", "ORGANISM", 200, 205], ["men", "SPECIES", 78, 81], ["women", "SPECIES", 145, 150], ["women", "SPECIES", 200, 205], ["obesity", "PROBLEM", 131, 138], ["obesity", "PROBLEM", 339, 346], ["obesity", "OBSERVATION", 339, 346]]], ["The lower odds of obesity among Caribbean-Black male and African-American female residents in neighborhoods containing a supermarket is consistent with prior research [23, 37].", [["obesity", "DISEASE", 18, 25], ["African-American female", "ORGANISM", 57, 80], ["obesity", "PROBLEM", 18, 25], ["lower", "OBSERVATION_MODIFIER", 4, 9], ["obesity", "OBSERVATION", 18, 25]]], ["In addition, the lower odds of obesity for residence within a neighborhood containing a supermarket found among Caribbean-Black women suggests that this relationship may hold for them as well despite the lack of statistical significance most likely due to low statistical power.", [["obesity", "DISEASE", 31, 38], ["women", "ORGANISM", 128, 133], ["women", "SPECIES", 128, 133], ["obesity", "PROBLEM", 31, 38], ["lower", "OBSERVATION_MODIFIER", 17, 22], ["obesity", "OBSERVATION", 31, 38]]], ["The absence of any relationship between obesity and residence within a neighborhood containing a supermarket among African-American men warrants further investigation.DiscussionIt is important to highlight the substantial decrease in the odds of obesity exclusively among African-American men who live in neighborhoods containing a park.", [["obesity", "DISEASE", 40, 47], ["obesity", "DISEASE", 246, 253], ["men", "ORGANISM", 132, 135], ["men", "ORGANISM", 289, 292], ["men", "SPECIES", 132, 135], ["men", "SPECIES", 289, 292], ["obesity", "PROBLEM", 40, 47], ["further investigation", "TEST", 145, 166], ["obesity", "PROBLEM", 246, 253], ["obesity", "OBSERVATION", 40, 47], ["substantial", "OBSERVATION_MODIFIER", 210, 221], ["decrease", "OBSERVATION_MODIFIER", 222, 230], ["obesity", "OBSERVATION", 246, 253]]], ["Research has shown that increased access to parks is associated with increased moderate-to-vigorous physical activity in boys but not among girls aged 8 to 12 years [38].", [["boys", "SPECIES", 121, 125], ["girls", "SPECIES", 140, 145], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["moderate", "OBSERVATION_MODIFIER", 79, 87]]], ["For many Black men, these childhood patterns of engaging in vigorous competitive team sports (e.g., basketball) in neighborhood parks extend into early adulthood, a pattern not seen historically among Black women [39, 40].", [["men", "ORGANISM", 15, 18], ["women", "ORGANISM", 207, 212], ["men", "SPECIES", 15, 18], ["women", "SPECIES", 207, 212]]], ["Additional research is needed to determine whether elevated energy expenditure due to increased access to recreational parks across the life course explains the lower prevalence of obesity among African-American men living in neighborhoods with community parks.", [["obesity", "DISEASE", 181, 188], ["men", "ORGANISM", 212, 215], ["men", "SPECIES", 212, 215], ["elevated energy expenditure", "PROBLEM", 51, 78], ["obesity", "PROBLEM", 181, 188], ["obesity", "OBSERVATION", 181, 188]]], ["Previous research documenting a lack of association between SEP and exercise frequency in Black women may explain the absence of a relationship between neighborhood parks and obesity among African-American and Caribbean women within our findings [41].", [["obesity", "DISEASE", 175, 182], ["women", "ORGANISM", 96, 101], ["women", "ORGANISM", 220, 225], ["women", "SPECIES", 96, 101], ["women", "SPECIES", 220, 225], ["SEP and exercise frequency", "PROBLEM", 60, 86], ["obesity", "PROBLEM", 175, 182]]], ["Further theoretical and empirical investigations are needed to uncover additional mechanisms through which measures of SEP at the neighborhood level independently operate to increase obesity within the various ethnic and sex groups.DiscussionTo our knowledge, this is the first study to document associations between multilevel and multidimensional measures of SEP and obesity in a sample of US self-identified and Caribbean self-identified Black Americans, while using an intersectionality approach centered on both within-race ethnic and sex differentiation.", [["obesity", "DISEASE", 183, 190], ["obesity", "DISEASE", 369, 376], ["empirical investigations", "TEST", 24, 48], ["SEP", "PROBLEM", 119, 122], ["increase obesity", "PROBLEM", 174, 190], ["the first study", "TEST", 268, 283], ["SEP", "PROBLEM", 361, 364], ["obesity", "PROBLEM", 369, 376], ["US", "TEST", 392, 394], ["an intersectionality approach", "TREATMENT", 470, 499], ["increase", "OBSERVATION_MODIFIER", 174, 182], ["obesity", "OBSERVATION", 183, 190], ["obesity", "OBSERVATION", 369, 376]]], ["This study has several limitations, however.", [["This study", "TEST", 0, 10]]], ["Multiple imputation was not performed on measures with over 40% of missing data, such as individual-level income, and so, this variable was not included within the analysis in order to minimize bias [42, 43].", [["Multiple imputation", "TEST", 0, 19], ["the analysis", "TEST", 160, 172]]], ["Furthermore, the lower sample size of Caribbean-Blacks within the NSAL dataset limited statistical power to examine any additional variation in the SEP-obesity associations by nativity status, i.e., foreign-born vs. US-born.DiscussionThe public-use NSAL questionnaire utilized for analysis included only self-reported measures of neighborhood physical characteristics and did not allow for geocoding addresses to include census tract measures, i.e., percentages of families below the poverty, unemployed and/or low-educated adults, and homeowners within a neighborhood, for multilevel modeling.", [["obesity", "DISEASE", 152, 159], ["tract", "ORGANISM_SUBDIVISION", 428, 433], ["US", "TEST", 216, 218], ["analysis", "TEST", 281, 289], ["census tract measures", "TREATMENT", 421, 442], ["multilevel modeling", "PROBLEM", 574, 593], ["lower", "OBSERVATION_MODIFIER", 17, 22], ["size", "OBSERVATION_MODIFIER", 30, 34], ["obesity", "OBSERVATION", 152, 159]]], ["Although the inability to examine objective assessments of neighborhood SEP within hierarchical models is a disadvantage, perceived measures of neighborhood resources have been found in previous studies to be equally robust correlates of obesity as observed neighborhood indicators [44].DiscussionThe cross-sectional nature of the NSAL study design does not establish a clear, unbiased temporal relationship between multilevel SEP indicators and adult obesity; therefore, neither causality nor direction of the SEP-obesity associations can be ascertained with certainty.", [["obesity", "DISEASE", 238, 245], ["obesity", "DISEASE", 452, 459], ["obesity", "DISEASE", 515, 522], ["objective assessments", "TEST", 34, 55], ["previous studies", "TEST", 186, 202], ["obesity", "PROBLEM", 238, 245], ["the NSAL study", "TEST", 327, 341], ["multilevel SEP indicators", "PROBLEM", 416, 441], ["adult obesity", "PROBLEM", 446, 459], ["obesity", "OBSERVATION", 238, 245], ["obesity", "OBSERVATION", 452, 459], ["obesity", "OBSERVATION", 515, 522]]], ["The NSAL, one of the few studies that allow for an examination of the socioeconomic correlates of cardio-metabolic health by ethnicity and sex within Black Americans, was conducted in 2001\u20132003 and hence is an established dataset.", [["an examination", "TEST", 48, 62], ["cardio", "ANATOMY", 98, 104]]], ["Notwithstanding, the stability of SEP indicators over time for Black Americans, including median income, which was $40,573 in 2003 and $41, 361 in 2018, supports the present-day relevancy of our findings [45].DiscussionThe use of self-reported weight and height to estimate obesity prevalence is also a potential bias.", [["obesity", "DISEASE", 274, 281], ["obesity prevalence", "PROBLEM", 274, 292], ["stability", "OBSERVATION_MODIFIER", 21, 30], ["obesity", "OBSERVATION", 274, 281]]], ["Studies have found that these self-reported measures are reasonably valid and reliable indicators of actual weight and height, although obese individuals tend to underestimate their weight [46\u201348].", [["obese individuals", "PROBLEM", 136, 153]]], ["A dilution rather than an exaggeration of the magnitude of our associations is expected however if a systematic underreporting of weight is similar across SEP categories.", [["A dilution", "TREATMENT", 0, 10], ["dilution", "OBSERVATION", 2, 10]]], ["Statistical adjustment for additional health behaviors related to obesity such as dietary quality could not be made within the analyses since this information is not assessed in the NSAL.", [["obesity", "DISEASE", 66, 73], ["obesity", "PROBLEM", 66, 73], ["obesity", "OBSERVATION", 66, 73]]], ["In addition, physical activity, crudely assessed within the NSAL as a continuous measure of reported leisure time activity, is a less reliable measure of activity level than other methods which directly monitor the intensity of physical activity such as the use of double isotopically labeled water (D2O18) methodology and measurement by a pedometer or tachometer [49].", [["water", "SIMPLE_CHEMICAL", 293, 298], ["D2O18", "SIMPLE_CHEMICAL", 300, 305], ["double isotopically labeled water (D2O18)", "TREATMENT", 265, 306]]], ["The extent to which the inclusion of dietary intake and a more reliable indicator of the intensity of physical activity would explain the associations between multilevel indicators of SEP and obesity cannot be determined.DiscussionOur study findings highlight that adulthood SEP at the individual, family, and neighborhood levels plays an important role in obesity in the US Black population, and this varies by ethnicity and sex.", [["obesity", "DISEASE", 192, 199], ["obesity", "DISEASE", 357, 364], ["SEP", "PROBLEM", 184, 187], ["obesity", "PROBLEM", 192, 199], ["DiscussionOur study", "TEST", 221, 240], ["adulthood SEP", "PROBLEM", 265, 278], ["obesity", "PROBLEM", 357, 364], ["obesity", "OBSERVATION", 192, 199], ["obesity", "OBSERVATION", 357, 364]]], ["The opposite SEP-obesity relationships between Black men and women suggest the need for further empirical investigation into the sex-specific mechanisms of obesity, particularly among low SEP families where the disparity between young adult Black women and men is the largest [50].", [["obesity", "DISEASE", 17, 24], ["obesity", "DISEASE", 156, 163], ["men", "ORGANISM", 53, 56], ["women", "ORGANISM", 61, 66], ["women", "ORGANISM", 247, 252], ["men", "ORGANISM", 257, 260], ["men", "SPECIES", 53, 56], ["women", "SPECIES", 61, 66], ["women", "SPECIES", 247, 252], ["men", "SPECIES", 257, 260], ["further empirical investigation", "TEST", 88, 119], ["obesity", "PROBLEM", 156, 163], ["SEP", "OBSERVATION_MODIFIER", 13, 16], ["obesity", "OBSERVATION", 17, 24], ["obesity", "OBSERVATION", 156, 163], ["largest", "OBSERVATION_MODIFIER", 268, 275]]], ["Moreover, the lower odds of obesity associated with residence in neighborhoods with a supermarket for African-American women and Caribbean-Black men, and with residence in neighborhoods containing a park for African-American men, suggests that continued public policy attention to increasing access to food and recreational facilities within Black American communities, as was undertaken in the national \u201cLet us Move!\u201d comprehensive initiative for preventing childhood obesity [51], is likely to be an important endeavor.", [["obesity", "DISEASE", 28, 35], ["obesity", "DISEASE", 469, 476], ["women", "ORGANISM", 119, 124], ["men", "ORGANISM", 145, 148], ["men", "ORGANISM", 225, 228], ["women", "SPECIES", 119, 124], ["men", "SPECIES", 145, 148], ["men", "SPECIES", 225, 228], ["obesity", "PROBLEM", 28, 35], ["childhood obesity", "PROBLEM", 459, 476], ["obesity", "OBSERVATION", 28, 35], ["likely to be", "UNCERTAINTY", 486, 498]]], ["Evidence from this study also suggests that the development of targeted, multilevel, cultural, and sex-specific societal interventions could be vital to not only curtailing the US obesity epidemic but to reducing racial inequities in survival from emerging infectious diseases such as COVID-19, for which obesity has arisen as a strong risk and prognostic factor in its severity [52\u201354].", [["obesity", "DISEASE", 180, 187], ["infectious diseases", "DISEASE", 257, 276], ["obesity", "DISEASE", 305, 312], ["this study", "TEST", 14, 24], ["targeted, multilevel, cultural", "PROBLEM", 63, 93], ["sex-specific societal interventions", "TREATMENT", 99, 134], ["the US obesity epidemic", "PROBLEM", 173, 196], ["emerging infectious diseases", "PROBLEM", 248, 276], ["COVID", "TEST", 285, 290], ["obesity", "PROBLEM", 305, 312], ["multilevel", "OBSERVATION_MODIFIER", 73, 83], ["obesity", "OBSERVATION", 180, 187]]]], "e3c52fb57d8bb2ff68d0df62d77880531d1c9380": [["Dear Editor,During the first wave of COVID-19 in China, the attack rate of coronavirus disease 2019 in children was much lower than in adults, and most child cases had mild symptoms (Dong et al., 2020) .", [["coronavirus disease", "DISEASE", 75, 94], ["coronavirus", "ORGANISM", 75, 86], ["children", "ORGANISM", 103, 111], ["children", "SPECIES", 103, 111], ["COVID", "TEST", 37, 42], ["coronavirus disease", "PROBLEM", 75, 94], ["mild symptoms", "PROBLEM", 168, 181], ["coronavirus disease", "OBSERVATION", 75, 94]]], ["However, the secondary attack rate of COVID-19 among close contacts was later found similar between children and other age groups (Bi et al., 2020) .", [["COVID-19", "CHEMICAL", 38, 46], ["COVID-19", "GENE_OR_GENE_PRODUCT", 38, 46], ["children", "ORGANISM", 100, 108], ["children", "SPECIES", 100, 108], ["COVID", "TEST", 38, 43], ["secondary", "OBSERVATION_MODIFIER", 13, 22]]], ["The reasons why children were exempted from COVID-19 infection in the early stage remain unclear.", [["COVID-19", "CHEMICAL", 44, 52], ["infection", "DISEASE", 53, 62], ["children", "ORGANISM", 16, 24], ["COVID-19", "ORGANISM", 44, 52], ["children", "SPECIES", 16, 24], ["COVID-19 infection", "PROBLEM", 44, 62], ["infection", "OBSERVATION", 53, 62]]], ["One hypothesis is the potential interference of seasonal influenza peaks with the newly-emerging COVID-19 outbreak among young children.", [["influenza", "DISEASE", 57, 66], ["children", "ORGANISM", 127, 135], ["children", "SPECIES", 127, 135], ["seasonal influenza peaks", "PROBLEM", 48, 72], ["seasonal", "OBSERVATION_MODIFIER", 48, 56], ["influenza", "OBSERVATION", 57, 66]]], ["Liu et al reported that 11% and 1.6% of 366 hospitalized children (\u226416 years of age) were infected by influenza and SARS-CoV-2, respectively, in early January 2020 in Wuhan, China.", [["influenza", "DISEASE", 102, 111], ["SARS", "DISEASE", 116, 120], ["children", "ORGANISM", 57, 65], ["SARS-CoV-2", "ORGANISM", 116, 126], ["children", "SPECIES", 57, 65], ["SARS-CoV", "SPECIES", 116, 124], ["influenza", "PROBLEM", 102, 111]]], ["Kong et al found that the incidence rate of influenza-illness-like (ILI) was substantially higher in the 2019-2020 season than in the previous two years based on the surveillance data in two hospitals in Wuhan, China.", [["influenza-illness", "DISEASE", 44, 61], ["ILI", "DISEASE", 68, 71], ["influenza", "PROBLEM", 44, 53], ["illness", "PROBLEM", 54, 61], ["the surveillance data", "TEST", 162, 183], ["influenza", "OBSERVATION", 44, 53], ["higher", "OBSERVATION_MODIFIER", 91, 97]]], ["The retrospective laboratory tests in the specimens from these ILI patients to January 2020 showed that an outbreak of seasonal influenza attacked the \u226430 age group in October-November 2019, followed by the COVID-19 cases in the >30-years of age group that first emerged in December 2019 to January 2020.", [["specimens", "ANATOMY", 42, 51], ["influenza", "DISEASE", 128, 137], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["The retrospective laboratory tests", "TEST", 0, 34], ["seasonal influenza", "PROBLEM", 119, 137]]], ["Surprisingly, no COVID-19 case was found in the \u226430 age group in their 120 samples (Table 1) .Thus, there is an apparent inconsistency between the studies byKong et al and Liu et al, as one would expect some COVID-19 cases among the young age group of ILI patients by the mid-January in Wuhan, China.Thus, there is an apparent inconsistency between the studies byWe obtained the test results of 194,672 specimens from the Maternal and Child Health Hospital of Hubei Province in Wuhan.Thus, there is an apparent inconsistency between the studies byThese specimens were collected from 1 January 2017 to 20 May 2020, for immunofluorescence tests of influenza type A and B.Thus, there is an apparent inconsistency between the studies byAround 75% of the specimens were taken from the outpatients and inpatients aged \u22646 years old.", [["specimens", "ANATOMY", 403, 412], ["specimens", "ANATOMY", 553, 562], ["specimens", "ANATOMY", 750, 759], ["ILI", "DISEASE", 252, 255], ["influenza type A", "DISEASE", 646, 662], ["patients", "ORGANISM", 256, 264], ["specimens", "CANCER", 750, 759], ["outpatients", "ORGANISM", 780, 791], ["COVID", "DNA", 17, 22], ["patients", "SPECIES", 256, 264], ["outpatients", "SPECIES", 780, 791], ["COVID", "TEST", 17, 22], ["an apparent inconsistency", "PROBLEM", 109, 134], ["the studies", "TEST", 349, 360], ["the test", "TEST", 375, 383], ["an apparent inconsistency", "PROBLEM", 499, 524], ["the studies", "TEST", 533, 544], ["These specimens", "TEST", 547, 562], ["immunofluorescence tests", "TEST", 618, 642], ["influenza type A and B.", "PROBLEM", 646, 669], ["the studies", "TEST", 718, 729], ["no", "UNCERTAINTY", 14, 16], ["inconsistency", "OBSERVATION", 511, 524]]], ["In consistent with the findings by Kong et al, we also found a peak of influenza A in early January, coinciding with the start of the COVID-19 outbreak.", [["influenza A", "DISEASE", 71, 82], ["influenza A", "PROBLEM", 71, 82], ["the COVID", "TEST", 130, 139], ["consistent with", "UNCERTAINTY", 3, 18], ["peak", "OBSERVATION_MODIFIER", 63, 67], ["influenza", "OBSERVATION", 71, 80]]], ["It is interesting to note that the winter peak of seasonal influenza in Wuhan appeared in We observe a sudden drop of influenza A cases in early January 2020, presumably due to social distancing and avoidance of hospital visits immediately after the official report of pneumonia clusters of COVID-19 and closure of the Huanan Seafood market on 31Thus, there is an apparent inconsistency between the studies byDecember 2019 (Figure 1 ).Thus, there is an apparent inconsistency between the studies byInfection risk of COVID-19 was known to increase with age (Sun, Chen, & Viboud, 2020) .", [["influenza", "DISEASE", 59, 68], ["influenza", "DISEASE", 118, 127], ["pneumonia", "DISEASE", 269, 278], ["COVID-19", "CHEMICAL", 291, 299], ["COVID-19", "CHEMICAL", 516, 524], ["seasonal influenza", "PROBLEM", 50, 68], ["influenza", "PROBLEM", 118, 127], ["pneumonia", "PROBLEM", 269, 278], ["COVID", "TEST", 291, 296], ["closure", "TREATMENT", 304, 311], ["an apparent inconsistency", "PROBLEM", 450, 475], ["the studies", "TEST", 484, 495], ["COVID", "TEST", 516, 521], ["pneumonia", "OBSERVATION", 269, 278], ["inconsistency", "OBSERVATION", 462, 475]]], ["If we assume that the ratio of COVID-19 to influenza cases in the <30 age group was not less than that in the <16 age group and similar across different hospitals, we could derive a ratio of 0.136 (1.6%/ 11.80%) based on reference .", [["influenza", "DISEASE", 43, 52], ["the ratio", "TEST", 18, 27], ["COVID", "TEST", 31, 36], ["influenza cases", "TEST", 43, 58], ["a ratio", "TEST", 180, 187]]], ["Given the influenza positive rate of 60% from reference (Kong et al., 2020) , we would expect that around 8% of COVID-19 would have occurred in ILI patients under 30 years old.", [["ILI", "DISEASE", 144, 147], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["the influenza positive rate", "PROBLEM", 6, 33], ["COVID", "TEST", 112, 117]]], ["Hence, the chance of having zero COVID-19 case in the <30 age group of ILI cases, as reported in reference (Kong et al., 2020) , was estimated to be very low ( CoV-2, particularly in children.DH was supported by an Alibaba (China) Co. Ltd.", [["ILI", "DISEASE", 71, 74], ["children", "ORGANISM", 183, 191], ["children", "SPECIES", 183, 191]]], ["All authors critically revised the manuscript, and all authors approved the submission.E TH I C A L A PPROVA L A N D CO N S E NT TO PA RTI CI PATEThe ethical approval has been obtained from the Maternal and ChildE TH I C A L A PPROVA L A N D CO N S E NT TO PA RTI CI PATEHealth Hospital of Hubei Province.", [["N D CO N S E", "CHEMICAL", 113, 125], ["A N D CO", "TEST", 111, 119]]], ["Individual consents were exempted as the aggregated data were used in this study.DATA AVA I L A B I L I T Y S TAT E M E N TAll data used are from public domain.O RCI DLin Yang https://orcid.org/0000-0002-5964-3233O RCI DDaihai He https://orcid.org/0000-0003-3253-654X", [["the aggregated data", "TEST", 37, 56], ["this study", "TEST", 70, 80], ["TAll data", "TEST", 122, 131]]]]}